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ABSTRACT 
SYSTEMS BIOLOGY APPROACH FOR TARGETED THERAPY 
OF LIVER CANCER  
PI3K/AKT/MTOR PATHWAY INHIBITORS: AN ALLY OR RIVAL 
FOR SORAFENIB 
Tülin Erşahin 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Assoc. Prof. Dr. Rengül ÇETİN-ATALAY 
August 2014, 146 Pages 
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-
related mortality worldwide. It is the second most frequent cause of cancer death in 
men, and the sixth in women due to its aggressive behavior and resistance to 
conventional therapies. Sorafenib (Nexavar, BAY43-9006), a multi-kinase inhibitor 
with anti-angiogenic functions, is the only FDA-approved molecular-targeted agent 
for the treatment of patients with advanced HCC. Yet, Sorafenib shows limited 
overall survival benefit associated with resistance and tumor recurrence. Current 
mono-target- or single pathway-centric drug designs are not sufficient for effective 
therapy of advanced HCC. Negative results of clinical trials on targeted therapies for 
advanced HCC are due to clinical heterogeneity, complexity of cirrhotic background 
and interconnected regulation of cancer hallmarks through compensatory signaling 
pathways with redundant functions. Secretion of growth factors, pro-inflammatory 
and immune-suppressive cytokines and chemokines in the tumor microenvironment 
and consequent activation of tumor-promoting signaling cascades confer resistance 
to Sorafenib treatment. RAF/MEK/ERK and PI3K/AKT/mTOR are the major tumor-
promoting signaling pathways with regulatory functions in all hallmarks of HCC. 
They have redundant functions and inhibition of one pathway can stimulate 
compensatory signaling from the other pathway. Since Sorafenib targets angiogenic 
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VEGFR and PDGFR kinases and RAF/MEK/ERK signaling, the primary mechanism 
of resistance to Sorafenib and tumor recurrence in HCC patients emerges to be the 
compensatory signaling from the PI3K/AKT pathway. Therefore, we anticipated that 
combined treatment with Sorafenib and PI3K/AKT inhibitors could reverse drug 
resistance in HCC. 
In this study, we analyzed the synergistic effects of Sorafenib and PI3K/AKT 
inhibitors on HCC cell growth and migration, determined possible mechanisms 
underlying synergistic mechanism of action by transcriptome analysis, and further 
showed that combination therapy leads to tumor regression in PTEN-deficient HCC 
xenografts in vivo. We showed that PTEN-deficient HCC cells with constitutively 
active PI3K/AKT signaling depend on the alpha isoform of PI3K (p110-α) for 
survival and co-targeting these cells with the isoform specific PI3K inhibitor (PI3Ki-
α, PIK-75) overcomes resistance to Sorafenib. Indeed, while dual-targeting of PTEN-
deficient HCC cells with Sorafenib and PI3Ki-α results in synergistic growth 
inhibition, dual-targeting these cells with Sorafenib and a beta isoform specific 
inhibitor of PI3K (PI3Ki-!, TGX-221) leads to an antagonistic increase in tumor 
growth compared to single treatment with Sorafenib, since inhibiting p110-! 
promotes compensatory signaling from p110-α.  
We also investigated the cytotoxic effects of inhibiting Akt kinase by using 
an Akt2 isoform-specific inhibitor (Akti-2) and a general Akt inhibitor targeting both 
isoforms (Akti-1,2). Akti-1,2 and Akti-2 did not induce anti-growth or pro-apoptotic 
mechanisms, but they were highly effective in reducing migration. Akt2 isoform is 
specifically overexpressed in HCC, and is correlated with its progression. Moreover, 
the Akt2 isoform-specific role of Akt kinase on migration has been demonstrated in 
breast cancer, and depletion of AKT2, but not AKT1, was shown to promote 
regression of PTEN-deficient prostate cancer xenografts. Based on these findings, we 
predicted a prominent role of Akt2 in PTEN-deficient HCC cells and examined the 
therapeutic efficacy of combined treatment of Sorafenib and Akti-2 in vivo in 
athymic mice bearing Mahlavu tumor xenografts. After 3 weeks of treatment, tumor 
growth was reduced significantly in all tested groups (Sorafenib, Akti-2 and 
Combination) compared to the control group. Substantial intra-tumoral necrosis 
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produced a temporary increase in tumor size but resulted in significant reduction in 
tumor weight (p<0.001) in combination-treated mice compared to Sorafenib-treated 
mice and further produced tumor regressions. 
 In this study, we showed cytotoxic activity of a new PI3K ! isoform specific 
kinase inhibitor (PI3Ki-! / PIK-75) at 0.1 µM that acts synergistically with Sorafenib 
in vitro, determined the predominant role of PI3K isoform p110α in PTEN-deficient 
HCC cells, and revealed synergistic anti-tumor effect of combining Sorafenib with a 
new Akt isoform 2 specific kinase inhibitor (Akti-2) in vitro and in vivo. 
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 Hepatosellüler kanser (HCC) dünyada kanser nedenli ölümlerin başlıca 
nedenlerindendir. Agresif doğası ve geleneksel terapilere dirençli olması nedeniyle 
erkeklerde ikinci kadınlarda ise altıncı en sık görülen kanser ölümü sebebidir. 
Sorafenib (Nexavar, BAY43-9006), anti-anjiyojenik özelliler taşıyan çoklu-kinaz 
inhibitörü, FDA tarafından ileri düzey HCC hastalarının tedavisi için onaylanan tek 
moleküler-hedefli ajandır. Lakin, Sorafenib sınırlı sağkalım avantajı sağlamakta, 
direnç ve tümör nüksü gözlemlenmektedir. Güncel tek-hedefli veya tek sinyal yolağı 
merkezli ilaç tasarımları ileri düzeydeki HCC tedavisi için yeterli değildir. İleri 
düzeydeki HCC tedavisine yönelik klinik çalışmaların olumsuz sonuçları klinik 
heterojenite, sirozlu doku ve birbirini kompanse edebilen sinyal yolakların kanser 
karakteristik özelliklerini sağlamadaki örtüşen fonksiyonlarıdır. 
 Tümör ortamında salgılanan büyüme faktörleri, pro-inflamatuar ve immün-
baskılayıcı sitokinlerin ve kemokinlerin tümör arttırıcı sinyal yolaklaını aktive etmesi 
Sorafenib tedavisine karşı direnç kazandırır. Raf/MEK/ERK ve PI3K/AKT/mTOR 
başlıca tümör destekleyici sinyal yolaklarıdır ve kanserin karakteristik özelliklerinı 
düzenleyici fonksiyonları vardır. Birbiriyle örtüşen işlevleri vardır ve bir yolun 
inhibisyonu diğer telafi edici yolu uyarabilir. Sorafenib anjiyojenik VEGFR ve 
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PDGFR kinazları ve RAF/MEK/ERK sinyalizasyonunu hedeflediği için, Sorafenib'e 
direncin ve HCC hastalarında tümör nüksünün ana mekanizmasının PI3K/Akt 
yolağının telafi edici etkisi olduğu düşünülmektedir. Bu nedenle, Sorafenib ve 
PI3K/Akt inhibitörleri ile kombine tedavinin HCC`de ilaç direncini önleyebileceğini 
düşünmekteyiz. 
 Bu çalışmada, Sorafenib ve PI3K/Akt inhibitörünün hücre büyümesi ve 
migrasyon üzerindeki sinerjistik etkisini analiz ettik ve sinerjistik etkinin altında 
yatan olası mekanizmaları transkriptom analizi ile belirledik. Ayrıca, bu 
kombinasyon tedavisinin PTEN-eksikli HCC tümör xenograftlarında gerilemeye yol 
açtığını in vivo olarak gösterdik. PTEN-eksikliği nedeniyle sürekli aktif PI3K/Akt 
sinyali olan HCC hücrelerinin hayatta kalmalarının PI3K`in alfa izoformuna bağlı 
olduğunu ve izoforma özel PI3K inhibitörünün (PI3Ki-α, PIK-75) Sorafenib`e olan 
direnci yenebileceğini gösterdik. PTEN-eksikliği olan HCC hücrelerinde Sorafenib 
ve PI3Ki-α uygulaması sinerjistik büyüme inhibisyonuna yol açarken, Sorafenib ve 
PI3K`in beta izoformuna specifik inhibitörü (PI3Ki-β, TGA-221), alfa izoformu 
üzerinden gelen sinyalin artması nedeniyle antagonistik hücre büyümesine neden 
olmuştur. 
 Ayrıca, Akt2 izoformuna spesifik Akt inhibitörü (Akti-2) ve her iki izoformu 
da hedef alan genel Akt inhibitörü (Akti-1, 2) kullanılarak Akt kinazın inhibe 
etmenin sitotoksik etkileri araştırıldı. Akti-1, 2 ve Akti-2 büyüme karşıtı ya da 
apoptoz sağlayıcı mekanizmaları uyarmamış fakat migrasyonu azaltmada oldukça 
etkili olmuştur. Özellikle Akt2 izoformu HCC`de aşırı eksprese edilir ve HCC`nin 
ilerlemesi ile ilişkilidir. Ayrıca, meme kanserinde spesifik olarak Akt2 izoformunun 
migrasyon üzerindeki etkisi gösterilmiş olup, Akt1`in değil ama Akt2`nin 
azalmasının PTEN eksikliği olan prostat kanseri ksenograftlarının gerilemesini teşvik 
ettiği gözlemlenmiştir. 
 Bu bulgulara dayanarak, PTEN eksikliği olan HCC hücrelerinde Akt2`nin 
rolü öngörülerek, Mahlavu tümör ksenograftları taşıyan atimik farede in vivo olarak 
Sorafenib ve Akti-2`nin kombine tedavisinin terapötik etkinliği incelenmiştir.  
3 haftalık tedavinin ardından, test edilen tüm gruplarda (Sorafenib, Akti-2 ve 
kombinasyon) tümör büyümesi kontrol grubuna kıyasla, önemli ölçüde azaltılmıştır.  
İntra-tümör nekrozu tümör boyutunda geçici bir artış yaratsa da Sorafenib ile tedavi 
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edilen fareler ile karşılaştırıldığında kombinasyon ile tedavi edilmiş farelerde tümör 
ağırlığı anlamlı derecede azalırken aynı zamanda tümörde gerileme görüldü (p 
<0.001). 
 Bu çalışmada 0.1 µM dozda sitotoksik aktivitesi olan yeni bir PI3K α 
izoformu spesifik kinaz inhibitörünün (PI3Ki-α / PIK-75) in vitro deneylerde 
Sorafenib ile sinerjistik olarak hareket ettiğini, PTEN eksikliği olan HCC 
hücrelerinde PI3K p110α izoformunun baskın rol aldığını, ve yeni bir Akt 2 
izoformu spesifik kinaz inhibitörünün (Akti-2) Sorafenib ile birlikte kullanıldığında 
Sorafenib`in tekli kullanımına kıyasla anti-tümör etkiyi arttırdığını in vitro ve in vivo 
olarak gösterdik. 
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CHAPTER 1. INTRODUCTION 
1.1. Hepatocellular Carcinoma 
 Primary liver cancer is one of the leading causes of cancer-related mortality 
worldwide (Jemal, Bray, & Ferlay, 2011). 748,300 new liver cancer cases and 
695,900 cancer deaths were reported in 2008 (Ferlay et al., 2010). Hepatocellular 
carcinoma (HCC) is the major histological subtype of primary liver cancers, 
accounting for about 80% of all liver cancer cases (Perz, Armstrong, Farrington, 
Hutin, & Bell, 2006).  
 The major risk factors for HCC are hepatitis B virus (HBV) and hepatitis C 
virus (HCV) infections, alcohol consumption, and aflatoxin B1 exposure. HBV DNA 
integrates into the host genome, while HCV RNA induces oxidative stress and pro-
inflammatory response. Alcohol and aflatoxins also lead to hepatic injury (Aston, 
Watt, Morton, Tanner, & Evans, 2000; Eckers, Reimann, & Klotz, 2009; Jung et al., 
2000; Kedderis, 1996; Ozcelik, Ozaras, Gurel, Uzun, & Aydin, 2003). Development 
of HCC is a multistep process, where hepatic injury first leads to chronic liver 
disease and then continuous inflammation results in cycles of cell death and 
hepatocyte regeneration. The increase in the proliferating fraction of hepatocytes and 
subsequent expansion of dysplastic nodules along with telomerase reactivation, and 
increased genomic instability is followed by malignant transformation (Figure 1.1) 
(Farazi & DePinho, 2006). Acquisition of the malignant phenotype is achieved by 
inactivation of tumor suppressors, activation of oncogenes and an increase in growth 
factor signaling. Tumor-promoting inflammation and metabolic alterations also favor 
the uncontrolled growth of hepatocytes as the cancer advances. The highly malignant 
state associated with stemness markers is maintained by the acquisition of invasive, 
metastatic and angiogenic capabilities. 
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Figure 1.1: Multi-step progression of Hepatocarcinoma. Development of HCC is 
a multistep process, where injured hepatocytes promote chronic inflammation 
leading to hepatocyte death and regeneration. The subsequent expansion of 
dysplastic nodules, telomerase reactivation, increased genomic instability, 
inactivation of tumor suppressors, activation of oncogenes and increase in growth 
factor signaling initiates HCC. Chromosomal instability and somatic mutations that 
favor the uncontrolled growth of HCC cells accumulate as malignancy of carcinoma 
increases. Acquisition of the malignant phenotype is supported by tumor-promoting 
inflammation, capability to evade immune destruction and metabolic alterations that 
allow continued growth and survival of cancer cells. Onset of invasion, metastasis 
and angiogenesis capabilities promotes progression of carcinoma to the highly 
malignant metastatic state associated with stemness markers. Molecular alterations 
throughout the malignant transformation of HCC are regulated both in genetic and 
epigenetic levels.  
 Patients with HCC are often diagnosed at advanced stage, where 
chemotherapy is the only treatment option. Sorafenib (Nexavar, BAY43-9006), a 
multi-kinase inhibitor, is the only FDA-approved molecular-targeted agent for the 
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treatment of patients with advanced HCC (Cheng et al., 2012; Raoul et al., 2012; 
Wilhelm et al., 2006). Sorafenib inhibits Raf, VEGFR, and PDGFR kinases, and 
thereby suppresses cell proliferation and angiogenesis. In phase III randomized 
controlled trials, Sorafenib showed an overall survival benefit of only three months 
(Cheng et al., 2009; Llovet, Di Bisceglie, et al., 2008). Besides, resistance to 
Sorafenib and tumor recurrence occurs at a high rate. The highly heterogenic 
character of HCC necessitates a molecular level classification for effective diagnosis 
and personalized treatment options (El-Serag, 2011; J.-S. Lee, Kim, Park, & Mills, 
2011).  
 Sequencing of the liver cancer genome and comprehensive analyses of large-
scale omics data (genomics, transcriptomics, methylomics, metabolomics) revealed 
multiple critical genes and pathways associated with hepatocarcinogenesis, which 
can be potential therapeutic targets in HCC (Table 1.1) (Fujimoto et al., 2012; Han, 
2012; Nakagawa & Shibata, 2013; Totoki et al., 2011; Woo et al., 2009). 
Table 1.1: Molecular Alterations of Critical Genes in HCC 
Cellular 
Process Molecule 
Alteration  
in HCC 
Acquired Capability 
Growth 
factor 
signaling 
EGF / EGFR Up-regulation Sustaining proliferative signaling 
HGF / MET Up-regulation 
IGF / IGFR Overexpression Resisting cell death 
VEGF / VEGFR Up-regulation 
Inducing angiogenesis PDGF / PDGFR Up-regulation 
FGF / FGFR Up-regulation 
Cell Cycle 
Regulation 
TP53 Inactivating mutation / LOH 
Sustaining proliferative signaling 
Evading growth suppressors 
RB1 Inactivating mutation / LOH 
c-myc Overexpression 
p16 (CDKN2A) 
Inactivating 
mutation / 
Hypermethylati
on 
Cyclin D1 Overexpression 
IRF2 Inactivating mutation 
Ras/RAF 
pathway 
RAS Activating mutation Sustaining proliferative signaling Evading growth suppressors 
Inducing angiogenesis RPS6KA3 Inactivating mutation 
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Activating invasion and metastasis 
PI3K/AKT 
pathway 
PI3K-alpha 
(PIK3CA) 
Activating 
mutation Sustaining proliferative signaling 
Evading growth suppressors 
Inducing angiogenesis 
Activating Invasion and Metastasis  
Reprogramming energy metabolism 
PTEN Inactivating mutation / LOH 
AKT Constitutive activation 
mTORC1 Up-regulation 
JAK/Stat 
pathway 
Stat Constitutive activation Tumor-promoting inflammation 
SOCS1,SOCS3 Down-regulation 
NF-κB 
pathway 
NF-κB Constitutive activation 
Sustaining proliferative signaling 
Resisting cell death 
Tumor-promoting inflammation 
Wnt/훽-
catenin 
pathway 
β-catenin 
(CTNNB1) 
Activating 
mutation / 
Overexpression Sustaining proliferative signaling 
Tumor-promoting inflammation AXIN1, AXIN2 Inactivating mutation / LOH 
APC Inactivating mutation 
Hedgehog 
pathway 
SHH Overexpression 
Reprogramming energy metabolism SMO Overexpression 
HHIP 
LOH, 
hypermethylatio
n 
Histone 
modification 
DNMT1, 3A, 3B Up-regulation 
Sustaining proliferative signaling 
Evading growth suppressors EZH2 Overexpression 
ARID1, ARID2 Inactivating mutation 
Apoptosis 
Fas Down-regulation 
Resisting cell death FasL Up-regulation 
DR5 Down-regulation 
Angiogenesis 
Angiopoietin Up-regulation Inducing angiogenesis 
Tie-2 Up-regulation 
Immunity Glypican-3 Up-regulation 
Evading immune destruction 
 
1.2. Current targeted therapeutics for HCC 
 The multi-kinase inhibitor Sorafenib (Nexavar, BAY43-9006) is the only 
approved systemic therapy for patients with advanced HCC so far (Cheng et al., 
2009; Llovet, Ricci, et al., 2008). Sorafenib targets angiogenesis and proliferation by 
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inhibiting Raf, VEGFR, and PDGFR kinases. However, systematic mechanism of 
action of Sorafenib is still poorly understood due to its capacity to inhibit multiple 
other targets. Limited overall survival benefit, acquired resistance and tumor 
recurrence in HCC patients treated with Sorafenib accelerated research on molecular 
targeted therapies (Table 1.2). 
 Angiogenesis is the most extensively targeted characteristic of HCC. 
Nevertheless, none of the anti-angiogenic tyrosine kinase inhibitors under clinical 
trials showed higher efficacy than Sorafenib so far. Following the failure of 
subsequent clinical trials with anti-angiogenic agents, therapeutic approach for 
advanced HCC shifted towards oncogenic signaling pathways (Bergers & Hanahan, 
2008; He & Goldenberg, 2013). However, agents targeting EGFR, IGFR, MEK, c-
Met, TGF-β, STAT3 and mTOR have not shown improvement in overall survival 
compared to Sorafenib (Y.-C. Shen et al., 2013; Wörns & Galle, 2014). 
 Consequently, new therapeutic designs started to use combinations of 
targeted agents. Ongoing clinical studies mostly involve multi-targeting of a single 
pathway (vertical inhibition) or two alternative pathways (horizontal inhibition) 
alone or in combination with Sorafenib. Compensatory up-regulation of pro-
angiogenic signals upon Sorafenib treatment or continuing signaling from untargeted 
growth/survival pathways can be major mechanisms of acquired resistance to 
Sorafenib and tumor recurrence. Nonetheless, combination of Sorafenib with other 
anti-angiogenic (Brivanib etc.) or anti-proliferative (Erlotinib etc.) agents could not 
provide median survival advantage compared to Sorafenib alone. The failure of 
clinical trials highlights the requirement of new network-based combinational 
therapies. 
 
Table 1.2: Clinical trials of molecular targeted agents for the treatment of 
advanced HCC 
Therapeutic 
agent Target Molecule(s) 
Target 
Cellular 
Process 
Phase Trial Number 
AMG386 Angiopoietin Angiogenesis II 
NCT00872014 
Axitinib VEGFR, PDGFR Angiogenesis II 
NCT01210495 
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Bevacizumab VEGF Angiogenesis II 
NCT00867321 
Brivanib VEGFR, PDGFR, FGFR Angiogenesis III 
NCT00858871  
Dovitinib VEGFR, PDGFR, FGFR Angiogenesis II 
NCT01232296 
Lenvatinib 
VEGFR, PDGFR, FGFR, 
RET, KIT Angiogenesis III 
NCT01761266 
Linifanib VEGFR, PDGFR Angiogenesis III 
NCT01009593  
Nintedanib VEGFR, PDGFR, FGFR Angiogenesis I 
NCT01594125 
Orantinib VEGFR, PDGFR, FGFR Angiogenesis I / II 
NCT00784290 
Ramucirumab VEGFR2 Angiogenesis III 
NCT01140347 
Regorafenib 
VEGFR, RET, KIT, 
PDGFR, RAF-1, BRAF, 
BRAFV600E, FGFR1, 
FGFR2, TIE2, DDR2, 
Trk2A, Eph2A 
Angiogenesis III NCT01774344 
Sunitinib 
VEGFR, PDGFR, KIT, 
RET, Flt-3 Angiogenesis III 
NCT00361309 
Vandetanib VEGFR, EGFR Angiogenesis II 
NCT00508001 
PD-0332991  CDK 4/6 Growth II 
NCT01356628 
Erlotinib EGFR 
EGFR 
signaling II 
NCT00881751 
BIIB022  IGF-1R IGF signaling I 
NCT00956436 
Cixutumumab  IGF-1R IGF signaling II 
NCT00906373 
MEDI-573  IGF-1, IGF-2 IGF signaling I 
NCT01498952 
OSI-906  IGF-1R, IR IGF signaling II 
NCT01101906 
AZD8055 mTOR 
mTOR 
signaling I 
NCT00999882 
Everolimus mTOR 
mTOR 
signaling III 
NCT01035229 
Sirolimus mTOR 
mTOR 
signaling II / III 
NCT00328770 
Temsirolimus mTOR 
mTOR 
signaling II 
NCT01687673 
Selumetinib  MEK 
MEK 
signaling II 
NCT00604721 
INC280  c-Met 
HGF/MET 
signaling II 
NCT01737827 
Tivantinib  c-Met 
HGF/MET 
signaling III 
NCT01755767 
Mapatumumab  TRAIL-R1 Apoptosis II 
NCT01258608 
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CT-011 PD-1 Immunity II 
NCT00966251 
GC33  Glypican 3 Immunity II 
NCT01507168 
MK2206  AKT 
AKT 
signaling II 
NCT01239355 
LY2157299  TGFβ 
TGFβ 
signaling II 
NCT01246986 
OPB-31121  STAT 3 
STAT 
signaling I / II 
NCT01406574 
 
 
1.3. Molecular Hallmarks of HCC 
 HCC drive from initially quiescent hepatocytes, whose growth is tightly 
controlled. Hepatic injury leads to chronic liver disease, where hepatocytes gain 
several growth-promoting characteristics to become tumorigenic. During progression 
from chronic liver disease to HCC, tumorigenic cells acquire phenotypic hallmarks 
of cancer and eventually become malignant.  
 Six core and two emerging cancer hallmark capabilities have been suggested 
by Hanahan and Weinberg: sustaining proliferative signaling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis, along with deregulating cellular 
energetics, and avoiding immune destruction (Hanahan & Weinberg, 2011). 
Acquisition of these capabilities is facilitated by two enabling characteristics: 
genome instability and tumor-promoting inflammation. Recent advances in sequenc-
ing and molecular profiling of HCC emphasize its intra-tumoral heterogeneity and 
uncover how molecular alterations promote hallmark capabilities of cancers and 
favor tumor progression (Figure 1.2). Therapeutic agents used in clinical trials 
mostly target individual tumor-promoting processes such as angiogenesis and growth 
factor signaling (Table 1.2). So far, none of the targeted agents have shown enhanced 
therapeutic benefit compared to Sorafenib. The failure of clinical trials emphasizes 
the requirement of combinational therapies that can increase overall survival and 
prevent resistance and tumor recurrence in HCC patients by simultaneous targeting 
of all hallmark capabilities. 
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Figure 1.2: Molecular Hallmarks of Hepatocellular Carcinoma. Molecular 
alterations promote hallmark capabilities through either activation/expression/up-
regulation (red) or inactivation/loss/down-regulation (green). (Modified from 
Hanahan & Weinberg, 2011 with copyright permission). 
 
 
1.4. PI3K/AKT signaling-mediated acquisition of cancer hallmark capabilities 
during hepatocarcinogenesis 
 Recent advances in large-scale molecular profiling of HCC revealed the role 
of PI3K/Akt/mTOR signaling in the acquisition of all cancer hallmark capabilities 
(Figure 1.3). The phosphatidylinositol 3-kinase (PI3K) / AKT / mammalian target of 
rapamycin (mTOR) signaling pathway is one of the most frequently activated 
signaling pathways in cancer and regulates a broad spectrum of cellular mechanisms 
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including survival, proliferation, growth and metabolism (Figure 1.4) (Engelman, 
2009; Fruman & Rommel, 2014; Manning & Cantley, 2007).  
 
 
Figure 1.3: PI3K/AKT signaling-mediated acquisition of cancer hallmark 
capabilities in HCC. PI3K/AKT signaling is involved in the regulation of all cancer 
hallmark capabilities. Major downstream proteins of PI3K/AKT pathway that are 
regulated to maintain tumor-promoting characteristics are demonstrated. 
Mechanisms of regulation are explained in text. 
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Figure 1.4: PI3K/Akt/mTOR signaling pathway. Growth factor-stimulated 
activation of receptor tyrosine kinases (RTKs) leads to activation of class IA 
phosphoinositide 3‐kinases (PI3Ks), which converts phosphatidylinositol‐4,5‐
bisphosphate (PtdIns(4,5)P2) to phosphatidylinositol‐3,4,5‐trisphosphate 
(PtdIns(3,4,5)P3) at the membrane, recruiting AKT kinase. PDPK1 and mTORC2 
phosphorylate and activate AKT, which regulates a broad range of downstream 
proteins and cellular processes. Activation of Akt is antagonized by PTEN 
(phosphatase and tensin homologue). (Modified from Liu, Cheng, Roberts, & Zhao, 
2009 with copyright permission). 
 
 PI3Ks are grouped into three classes based on their structures and substrate 
specificities (Vanhaesebroeck, Guillermet-Guibert, Graupera, & Bilanges, 2010). 
The most commonly studied PI3Ks in cancer are the class I enzymes, which are 
heterodimers of the p110 catalytic subunit and the p85 regulatory subunit. There are 
four catalytic isoforms of with different functions. The PI3K isoform p110α 
(encoded by PIK3CA) is the major effector kinase downstream of receptor tyrosine 
kinases (RTKs) and the RAS oncogene. PI3K signaling mostly depends on p110α in 
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cancers with oncogenic alterations in RTK, RAS or PIK3CA and regulates 
proliferation, growth, metabolism and angiogenesis. The PI3K isoform p110β, 
encoded by PIK3CB, is regulated mostly by G protein‐coupled receptors (GPCRs) 
and has critical functions in inflammatory cells (Figure 1.5) (Liu et al., 2009). p110γ 
and p110δ also mediate inflammation and p110δ controls adaptive immunity, but 
their roles in cancer development and progression are not well-defined.  
 
Figure 1.5: Isoform-specific PI3K signaling. A) Differential roles of p110α and 
p110β are indicated. B) Inactivation of either p110α or p110β can counteract loss of 
PTEN tumor suppressor (Berenjeno et al., 2012). In PTEN-deficient tumors, 
differences in PI3K-isoform (p110α or p110β) dependence can be explained by the 
upstream activation mechanisms. PTEN-loss can confer dependence on p110α 
isoform upon input signaling from receptor tyrosine kinases (RTKs) or RAS and on 
p110 β isoform when signals are from G protein‐coupled receptors (GPCRs) (Jia, 
Roberts, & Zhao, 2009). (from Liu et al., 2009 with copyright permission) 
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 The PI3K/AKT/mTOR signaling pathway is constitutively hyper-activated in 
HCC, through inactivating mutations or loss of heterozygosity (LOH) of PTEN, 
activating mutations of PIK3CA or a disrupted negative-feedback loop from mTOR 
(Bae et al., 2007; Buontempo et al., 2011; Engelman, 2009; Fujiwara et al., 2000; 
Kawamura et al., 1999; Yao et al., 1999). Upon growth factor induced activation of 
receptor tyrosine kinases (RTKs), PI3Ks convert phosphatidylinositol‐4,5‐
bisphosphate (PtdIns(4,5)P2) (PIP2) to phosphatidylinositol‐3,4,5‐trisphosphate 
(PtdIns(3,4,5)P3) (PIP3) at the cell membrane. Conversion of PIP2 to PIP3 provides 
docking sites for 3-phosphoinositide-dependent kinases, PDK1 and mTORC2 
(PDK2), which in turn phosphorylate the Akt serine/threonine kinase at Thr308 and 
Ser473, respectively and result in its activation. Activation of Akt is antagonized by 
PTEN (phosphatase and tensin homologue), which dephosphorylates PIP3.  
 Active Akt phosphorylates several proteins, including glycogen synthase 
kinase 3 (GSK3α/β), forkhead box O transcription factors (FOXO), MDM2, BCL2-
associated agonist of cell death (BAD), BCL2-interacting mediator of cell death 
(BIM), tuberous sclerosis 2 (TSC2), and NF-κB, thereby regulating cell survival, 
proliferation, protein synthesis and metabolism (Manning & Cantley, 2007; Camillo 
Porta, Paglino, & Mosca, 2014). AKT-mediated phosphorylation of TSC2 and 
subsequent activation of RHEB activates mTORC1 kinase. Active mTORC1 
stimulates protein translation through 4E-BP1 and P70S6K. During insufficiency of 
energy and nutrients, mTOR activity is down-regulated in order to reduce 
biosynthesis. Moreover, when mTOR is bound to Rictor in the mTORC2 complex, 
instead of mTORC1, mTOR functions as a PDK2 and phosphorylates AKT. 
 Knockout studies of Akt isoforms revealed isoform-specific functions of Akt 
(Chin & Toker, 2009; Gonzalez & McGraw, 2009). Loss of Akt1 caused growth 
retardation, increased apoptosis, defective ischemia and VEGF-induced angiogenesis 
in mice (Ackah et al., 2005; W. S. Chen et al., 2001; Cho, Thorvaldsen, Chu, Feng, 
& Birnbaum, 2001). Loss of Akt2 impaired glucose utilization and developed a type 
2 diabetes-like phenotype in mice (Cho, Mu, et al., 2001; Dummler et al., 2006; 
Garofalo et al., 2003). Akt3 knockout mice exhibited impaired brain development 
but contribution of Akt3 in cancer development has not been identified (Tschopp et 
al., 2005). Overexpression of AKT2 was frequently observed in HCC (21 cases 
(38%)), while AKT1 was only moderately expressed (Xu et al., 2004). Increased 
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Akt2 expression was shown to correlate with the progression of HCC. Moreover, a 
recent study showed that PTEN-deficient prostate tumors depend on AKT2 for 
maintenance and survival (Chin, Yuan, Balk, & Toker, 2014). Depletion of AKT2, 
but not AKT1, promoted regression of PTEN-deficient prostate cancer xenografts. 
 Several small molecule inhibitors targeting the PI3K/AKT/mTOR pathway 
are currently in clinical development, including PI3K inhibitors, isoform-specific 
PI3K inhibitors, mTOR inhibitors, dual PI3K/mTOR inhibitors, and AKT inhibitors 
(Figure 1.6). Although most existing ATP‐competitive small‐molecule AKT 
inhibitors target all three Akt isoforms (Akt1, Akt2, Akt3) non-selectively, recent 
studies on isoform-specific functions of Akt suggest that isoform-specific targeted 
agents might show enhanced efficacy.  
 
Figure 1.6: Targeting PI3K/AKT signaling. Clinical phase inhibitors that target 
key nodes of PI3K/Akt/mTOR pathway. (from Rodon, Dienstmann, Serra, & 
Tabernero, 2013 with copyright permission) 
 
1.5. Genome Instability and Mutations 
 Chronic inflammation in the liver is associated with high levels of oxidative 
stress that can cause severe DNA damage and hence increase genomic instability 
(Ha, Shin, Feitelson, & Yu, 2010). DNA damage leads to hyper-activation of PARP 
(poly ADP-ribose polymerase), which is the key regulator of cell death during 
inflammation-related oxidative stress (Bai & Virág, 2012; Nomura et al., 2000; 
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Shimizu et al., 2004). PARP1 is over-expressed in HCC tumors compared to normal 
liver and is essential for base excision repair (BER) (Audeh et al., 2010; Bryant et al., 
2005; Farmer et al., 2005; Fong et al., 2009). 
 While the defects in one DNA repair pathway create genomic instability that 
favors the progression of cancer, the cancer cell meanwhile becomes dependent on 
the compensatory repair mechanisms for its survival. Therefore, tumors with 
dysfunctional homologous replication repair (HRR), due to either BRCA1/BRCA2 
mutations or deficiency in other HRR components, including RAD51, RAD54, ATR, 
ATM, CHK1 and CHK2, are sensitive to PARP inhibition (Drew et al., 2011; 
McCabe et al., 2006; Williamson et al., 2010). This vulnerability can be exploited in 
HCC by dual-targeting of PARP and PI3K, since inhibitors of PI3K impair HRR by 
increasing DNA damage and reducing RAD51 focus formation (Juvekar et al., 2012; 
Kimbung et al., 2012).  
 Moreover, the tumor suppressor phosphatase and tensin homolog (PTEN), 
which suppresses PI3K/AKT signaling, is a major guardian of genomic stability in 
addition to its role in cell growth, survival and energy metabolism (Song, Salmena, 
& Pandolfi, 2012). Nuclear PTEN maintains chromosomal stability through physical 
interaction with centromeres and control of DNA repair (Shen et al., 2007). The 
inactivating mutations or deletions of PTEN are observed in many tumors, including 
HCC (Bae et al., 2007; Buontempo et al., 2011; Fujiwara et al., 2000; Kawamura et 
al., 1999; Yao et al., 1999). Loss of PTEN disrupts PI3K pathway mediated Rad51 
expression and leads to HRR dysfunction and PARP inhibitor sensitivity (Dedes et 
al., 2010; McEllin et al., 2010; Mendes-Pereira et al., 2009; Shen et al., 2007).  
 
1.6. Sustaining Proliferative Signaling and Evading Growth Suppressors 
 Cell cycle progression and sustained proliferation of HCC cells are achieved 
by inactivation of p53, Rb, and p16, overexpression of c-myc and Cyclin D1, and 
overexpression of E2F family members. Enhanced stimulation of growth factor 
receptors EGFR, IGFR and MET leads to constitutive activation of proliferative 
signaling, especially through Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways 
(Boyault et al., 2007; Challen, Guo, Collier, Cavanagh, & Bassendine, 1992; Hwang 
et al., 2004; Takada & Koike, 1989; Tsuda et al., 1989; Xu et al., 2013). AKT 
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promotes cell proliferation and growth primarily through activation of mTORC1, 
which activates 4E-BP1 and P70S6K and initiates protein translation. Moreover, 
active Akt signaling suppresses FOXO transcriptional activity, induces Cyclin D, 
inhibits p21, p27 and GADD45G (Growth arrest and DNA damage 45G), and 
thereby contributes to cell cycle progression (Manning & Cantley, 2007). 
Additionally, PI3K/AKT-mediated up-regulation of the oncoprotein Gankyrin 
mediates degradation of the tumor suppressor proteins Rb and p53 and thereby 
accelerates cell cycle progression in HCC (Dong et al., 2011). 
 PI3K/AKT contributes to evasion of growth-inhibitory signals not only by 
inactivating Rb and p53, but also through converting tumor-suppressing signal of 
TGF-β/SMAD to a tumor-promoting signal. Transforming growth factor-beta (TGF-
β) signaling has a growth suppressive role in the early stages of HCC, whereas in the 
late stages, down-regulation of TGF-β receptors and up-regulation of EGFR and 
Raf/MEK/ERK pathways confer resistance to TGF-β signaling-mediated growth 
inhibition (Bierie & Moses, 2006; Caja et al., 2009; Caja, Sancho, Bertran, & 
Fabregat, 2011; Mazzocca et al., 2010; Sugano et al., 2003; van Zijl et al., 2009; 
Yamazaki, Masugi, & Sakamoto, 2011). Indeed, TGF-β-induced AKT activation 
leads to inactivation of GSK-3β, and consequent accumulation of epithelial 
repressors Snail, Slug and Twist results in the suppression of E-Cadherin and 
subsequently promotes epithelial–mesenchymal transition (EMT), invasion, and 
metastasis (Lamouille, Xu, & Derynck, 2014; Zhang, Zhou, & Dijke, 2013). 
 
1.7. Resisting Cell Death 
 HCC cells can resist apoptotic cell death by up-regulating anti-apoptotic 
factors (Bcl-2, Bcl-xL, Mcl-1, IAP) and down-regulating pro-apoptotic factors (Bax, 
Bim, Puma) through dysregulation of PI3K/AKT, Raf/MEK/ERK and NF-κB 
signaling (Fabregat, Roncero, & Fernández, 2007). Loss of p53 activity is the best 
known strategy to circumvent DNA damage response and inhibit apoptotic stimuli 
(Honda et al., 1998; Hussain, Schwank, Staib, Wang, & Harris, 2007). Hence, 
inhibitory signaling through PI3K/AKT/MDM2/p53 axis is critical in HCC cells with 
hyperactive Akt pathway. PI3K/AKT signaling, suppresses PUMA through 
inhibiting p53. Deficiency of pro-apoptotic BH3-only protein Puma (p53 up-
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regulated modulator of apoptosis) protects cells from cell death (Villunger et al., 
2003; J. Yu & Zhang, 2008). Sorafenib is known to activate PUMA through GSK3β 
and NF-κB to suppress growth and induce apoptosis (Dudgeon et al., 2012). Indeed, 
resistance to Sorafenib-mediated apoptosis was shown to correlate with PUMA 
down-regulation (Sonntag, Gassler, Bangen, Trautwein, & Liedtke, 2014). 
Furthermore, PI3K/Akt pathway protects hepatocytes from TNF-alpha- and Fas-
mediated apoptosis by suppressing the expression of their ligands TRAIL and FasL 
and further activating anti-apoptotic NK-κB pathway (Deng et al., 2010; Hatano & 
Brenner, 2001; Imose et al., 2003; Ladu et al., 2008). PI3K/Akt pathway also confers 
resistance to c-Myc-driven apoptosis by increasing expression of E2F family 
members (Deng et al., 2010; Hatano & Brenner, 2001; Imose et al., 2003; Ladu et al., 
2008). 
 
1.8. Enabling Replicative Immortality 
 Telomere shortening in dysplastic nodules is an early event in multistep 
hepatocarcinogenesis that induces chromosomal instability in hepatocytes. During 
transition from dysplasia to early HCC, reactivation of telomerase maintains 
telomere length and replicative immortality (Oh et al., 2003, 2008; Plentz et al., 
2004; Yildiz et al., 2013). High telomerase activity and long telomeres in advanced 
HCC is associated with aggressive behavior and poor prognosis (Hu et al., 2011; Toh 
et al., 2013). Human telomerase reverse transcriptase (hTERT) is composed of a 
catalytic subunit (TERT) and an RNA component (hTR). RNAi gene therapies 
targeting hTERT or hTR effectively down-regulate telomerase activity and suppress 
the growth of HCC cells (Hu et al., 2011; Liu, Zhu, Li, Zhao, & Li, 2008). The 
catalytic subunit, TERT, interacts with the 90 kDa heat shock protein (HSP90) and 
Akt. Phosphorylation of TERT by Akt promotes its nuclear localization, and thereby 
enhances telomerase activity (Haendeler, Hoffmann, Rahman, Zeiher, & Dimmeler, 
2003; Kang, Kwon, Kwon, & Do, 1999). 
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1.9. Inducing Angiogenesis and Activating Invasion and Metastasis 
 HCC is a highly vascularized cancer and the up-regulation of angiogenic 
factors and receptors including vascular endothelial growth factor (VEGF), VEGF 
receptors (VEGFR-1, VEGFR-2), fibroblast growth factors (FGF), platelet-derived 
growth factor (PDGF), angiopoietin-2 (Ang-2) and Tie-2 are associated with 
aggressiveness and poor prognosis of HCC (Campbell et al., 2007; Chiang et al., 
2008; Li, Tang, Zhou, Lui, & Ye, 1998; Mitsuhashi et al., 2003; Ng et al., 2001; 
Pang & Poon, 2006; Poon et al., 2004; Shimamura et al., 2000).  
 Hypoxia, which occurs during fibrosis, cirrhosis and malignant 
transformation of HCC, enhances proliferation, angiogenesis and metastasis (Wu et 
al., 2012). Sorafenib-resistant HCC exhibit increased intra-tumoral hypoxia 
compared to Sorafenib-sensitive HCCs and HCCs before treatment (Liang et al., 
2013). Hypoxia induced by sustained Sorafenib treatment confers resistance to 
Sorafenib through activation of Hypoxia induced factor 1 alpha (HIF-1α) and NF-κB. 
Under hypoxic conditions, signaling through PI3K/AKT/HIF-1α promotes 
hepatocyte EMT, which is associated with enhanced metastatic potential and poor 
prognosis in HCC (Copple, 2010; Liu et al., 2010; Yan et al., 2009). Moreover, 
signaling from PI3K, particularly α isoform, regulates migration of endothelial cells 
through RhoA (Graupera & Potente, 2013; Graupera et al., 2008). Angiopoietin 
(Ang)/Tie vascular signaling activates PI3K/Akt pathway. In turn, active AKT 
signaling through FOXO induces Ang-2 expression and promotes vascular 
remodeling (Augustin, Koh, Thurston, & Alitalo, 2009; Graupera & Potente, 2013; 
Potente et al., 2005). Furthermore, Akt increases expression of VEGF through HIF-
1α and facilitates VEGF-mediated angiogenesis and endothelial nitric oxide synthase 
(eNOS)-mediated vascular remodeling and angiogenesis (Manning & Cantley, 
2007). 
 Disappointingly, results of anti-angiogenic therapies showed that anti-
angiogenic agents induce intra-tumoral hypoxia, which in turn, promotes invasion 
and metastasis (Bergers & Hanahan, 2008). Invasion and metastasis are associated 
with chemoresistance and recurrence in patients with advanced HCC. Epithelial-
mesenchymal transition (EMT), which involves up-regulation of Twist, Snail, Slug, 
Zeb1/2, and Vimentin, and down-regulation of E-cadherin and hepatocyte nuclear 
factor (HNF)-4α, is critical for triggering invasion and metastasis of HCC and 
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correlate with poor prognosis in liver cancer (Lamouille et al., 2014; Lee et al., 2006; 
Niu et al., 2007; van Zijl et al., 2009; Yang et al., 2009).  
 EMT-inducing transcription factors Twist, Snail and Zeb1 are highly 
expressed in HCC through PI3K/AKT signaling and facilitate invasion and 
metastasis of HCC (Lee et al., 2006; Matsuo et al., 2009; Yang et al., 2009). 
Different isoforms of Akt have distinct effects on migration, invasion and metastasis. 
Isoform-specific roles of Akt are more extensively studied in breast cancer (Figure 
1.7). Akt1 suppresses migration by inhibiting ERK and TSC2, inducing degradation 
of NFAT and down-regulating genes involved in invasion and metastasis of breast 
cancer cells (Chin & Toker, 2011). On the contrary, Akt2 up-regulates integrins and 
promotes migration. 
 
 
Figure 1.7: Isoform-specific role of Akt on migration, invasion and metastasis in 
breast cancer. In breast cancer cells, Akt1 suppresses cell migration through 
inducing degradation of NFAT or blocking activity of ERK and TSC2, whereas Akt2 
enhances migration by up-regulating integrins (from Chin & Toker, 2009 with 
copyright permission). 
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1.10. Reprogramming Energy Metabolism 
 Recent transcriptomics and metabolomics studies revealed that HCC has 
lower levels of glucose and other metabolites involved in energy production 
compared to healthy liver (Beyoğlu et al., 2013). Cancer cells reprogram their energy 
metabolism to maintain high rates of aerobic glycolysis for ATP generation, known 
as the Warburg effect, and use glutamine to provide intermediates of the 
tricarboxylic acid (TCA) cycle (Cantor & Sabatini, 2012; Sun & Denko, 2014; 
Warburg, 1956). Alterations in metabolism related enzymes are frequent in cancers 
including HCC (Teicher, Linehan, & Helman, 2012). 28 metabolites and 169 genes 
involved in energy metabolism were found to be correlated with aggressive HCC 
(Budhu et al., 2013). Metabolic reprogramming is regulated by PI3K/AKT/mTOR 
pathway, especially through PTEN, HIF-1α, p53 and TSC2 (Elstrom et al., 2004; 
Levine & Puzio-Kuter, 2010).  
 Hyper-active PI3K/Akt/mTOR and paracrine Hedgehog signaling in 
malignant hepatocytes promote metabolic changes that favor aerobic glycolysis 
during tumorigenesis (Chan et al., 2012; Elstrom et al., 2004). For instance, up-
regulation of the endoplasmic reticulum enzyme ENTPD5 in PTEN-null cells 
exhibiting hyper-active Akt causes increased protein translation, promotes ATP 
consumption, and favors aerobic glycolysis through a compensatory increase in 
glucose flux (Fang et al., 2010; Z. Shen, Huang, Fang, & Wang, 2011).  
 Low cellular energy levels activate AMP-activated protein kinases (AMPKs) 
and LKB1/AMPK signaling pathway suppresses mTORC1 activity to restore energy 
homeostasis by reducing biosynthesis and promoting catabolism (Guertin & Sabatini, 
2007; Hanahan & Weinberg, 2011; Xu, Ye, Araki, & Ahmed, 2012). In healthy cells, 
activation of AMPK by the tumor suppressor p53 stimulates oxidative 
phosphorylation and reduces the rate of glycolysis through the up-regulation of 
TP53-induced glycolysis and apoptosis regulator (TIGAR) (Bensaad et al., 2006; 
Budanov & Karin, 2008). In HCC, deregulation of AMPK leads to metabolic 
reprogramming towards aerobic glycolysis to provide enough ATP for the 
continuous growth of cancer cells and is correlated with aggressiveness and poor 
prognosis in HCC patients (Zheng et al., 2013).  
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1.11. Tumor-promoting inflammation and Evading Immune Destruction 
 Injured hepatocytes promote chronic inflammation leading to a cycle of 
hepatocyte death and compensatory proliferation. Necrotic hepatocytes stimulate 
release of pro-inflammatory cytokine interleukin-6 (IL-6) from Kupffer cells, leading 
to recruitment of macrophages (Sakurai et al., 2008). Macrophages activate 
JAK/STAT signaling and constitutive activation of STAT3 mediates tumor-
promoting inflammation and suppresses anti-tumor immune responses (Yu, Pardoll, 
& Jove, 2009). Elevated levels of IL-6 and constitutively activated STAT3 are 
frequent in HCC patients and blocking STAT3 can effectively alter cytokine profile 
of the immunosuppressive tumor microenvironment and enhance natural killer (NK) 
cell cytotoxicity (Calvisi et al., 2006; Li et al., 2006; Liu, Fuchs, Li, & Lin, 2010; 
Niwa et al., 2005; Porta et al., 2008; Rebouissou et al., 2009; Sun, Sui, Zhang, Tian, 
& Zhang, 2013; Trikha, Corringham, Klein, & Rossi, 2003; Yoshikawa et al., 2001).  
 Recent studies identified crosstalk between PI3K and STAT3 (Vogt & Hart, 
2011). HCV-induced STAT3 activation is dependent on the PI3K/AKT pathway 
(Tacke, Tosello-Trampont, Nguyen, Mullins, & Hahn, 2011). PI3K/Akt signaling 
through GSK3 increases production of the immunosuppressive cytokine Interleukin-
10 (IL-10) and regulates TLR-mediated production of pro- and anti-inflammatory 
cytokines (Antoniv & Ivashkiv, 2011; Martin, Rehani, Jope, & Michalek, 2005). 
PI3K/AKT signaling through mTOR induces the production of pro-inflammatory 
cytokines and regulates the activation of antigen-presenting cells (APCs), effector T 
cells and regulatory T cells (Tregs) (Thomson, Turnquist, & Raimondi, 2009). 
Tumor-infiltrating Tregs are critical for immune evasion in HCC, since they suppress 
tumor-specific CD4+ T cell responses. Tregs are characterized by up-regulated 
expression of GITR (glucocorticoid-induced tumor necrosis factor receptor) and 
ICOS (inducible T cell co-stimulator) (Pedroza-Gonzalez et al., 2013). These 
receptors activate PI3K/Akt signaling, suggesting a role for PI3K/Akt in immune 
escape (Noh et al., 2009). Another escape mechanism from phagocyte-mediated 
immune destruction in HCC involves CD47–SIRPα (signal regulatory protein α) 
interaction between tumor cells and macrophages (Pan et al., 2013). SIRPα prevents 
activation of Akt and NF-κB in tumor-associated macrophages (TAMs). In order to 
increase the capacity of macrophages for migration, survival, and pro-inflammatory 
cytokine production, tumor-derived factors down-regulate expression of SIRPα on 
 21 
TAMs, relieving inhibitory signal on Akt pathway, and hence contribute to the 
progression of HCC. 
 In chronic HCV patients, natural killer (NK) cells have reduced cytotoxicity 
(Brenndörfer & Sällberg, 2012). Yet, treatment with Sorafenib not only targets 
malignant cells but also suppresses proliferation and activation of NK cells (Zhang et 
al., 2013). Consequently, reduced cytotoxicity of NK cells renders HCC patients 
more susceptive to tumor growth and metastasis. Therefore, there is an urgent need 
to develop new therapeutic agents with less severe off-target effects or design 
optimal combinational treatments of Sorafenib with immunotherapeutic agents that 
activate NK cells. 
 
1.12. Large scale drug transcriptomics 
 Hepatocarcinogenesis develops through acquisition of multiple genetic, 
epigenetic, and molecular alterations that are regulated by complex interconnected 
signaling networks (Figure 1.1, Table 1.1). Current mono-target- or single pathway-
centric drug designs are not sufficient for effective targeting of this highly 
heterogeneous and aggressive cancer. Not only should genetic backgrounds, 
feedback loops and pathway redundancies be considered for each individual subtype 
of HCC, but also off-targets of drugs should be foreseen to prevent chemoresistance 
and recurrence. 
 Integration of omics data with network-centered computational biology offers 
a systems-level perspective on mechanism of action of critical proteins and uncovers 
the crosstalk among pathways. Global understanding of the interplay between drug 
targets provides a rational basis for multi-target drug development and discovery of 
optimal combinations of targeted therapeutics. 
 There are many approved or clinical phase drugs with known targets for 
various kinds of diseases, including cancer. Although these drugs are developed to 
interact with specific targets, most of them activate or inhibit off-targets (unexpected 
targets) and consequently manipulate more biological processes and pathways than 
anticipated (Yang et al., 2011). Effective bench-to-clinic translational research, 
which integrates omics data with systems biology, will identify primary therapeutic 
targets, secondary or off-targets, compensatory signaling and drug resistance 
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mechanisms. Following this perspective, new approaches such as drug combination 
and drug repositioning have emerged (Harrold, Ramanathan, & Mager, 2013; Wu, 
Wang, & Chen, 2013). Drug repositioning (drug repurposing) is the process of 
revealing new roles of existing drugs and is currently the most outstanding approach 
in drug discovery and development for personalized medicine (Li & Jones, 2012; 
Shim & Liu, 2014). These analyses have great potential to identify previously 
unrecognized drug targets and improve single drug repositioning or drug 
combination strategies of new and existing therapeutic agents with enhanced efficacy 
and minimized side effects. Therefore, we analyzed drug transcriptomics from a 
network-based perspective searching for optimal drug combination partners for 
Sorafenib. 
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CHAPTER 2. OBJECTIVES AND RATIONALE 
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related 
mortality worldwide (Ferlay et al., 2010; Jemal et al., 2011). Patients with HCC are 
often diagnosed at advanced stage, where chemotherapy is the only treatment option. 
Sorafenib (Nexavar, BAY43-9006), a multi-kinase inhibitor, is the only FDA-
approved molecular-targeted agent for the treatment of patients with advanced HCC 
(Cheng et al., 2012; Raoul et al., 2012; Wilhelm et al., 2006). None of the therapeutic 
agents under clinical trials showed an improvement in overall survival compared to 
Sorafenib so far (Shen et al., 2013; Wörns & Galle, 2014). Systematic mechanism of 
action of Sorafenib is still poorly understood due to its wide-range of targets.  
HCC patients treated with Sorafenib showed limited overall survival benefit, 
acquired resistance and tumor recurrence. Compensatory up-regulation of 
proliferator and angiogenic signals upon Sorafenib treatment is anticipated to be the 
major mechanisms of acquired resistance to Sorafenib and tumor recurrence. 
Sorafenib primarily inhibits Raf, VEGFR, and PDGFR kinases, and thereby targets 
cell proliferation and angiogenesis. Yet, signaling from VEGFR, PDGFR kinases and 
Ras protein through Raf/MEK/ERK is not the only pathway with tumor-promoting 
functions. Cancer cells can up-regulate existing alternative/parallel pathways to 
compensate for the inhibited pathway. Indeed, the phosphatidylinositol 3-kinase 
(PI3K) / AKT / mammalian target of rapamycin (mTOR) signaling pathway is an 
alternative pathway that can be induced with the same up-stream elements and can 
transmit signal to mostly overlapping downstream effectors. Moreover, 
PI3K/AKT/mTOR pathway is constitutively activated in HCC and correlates with 
aggressiveness and poor prognosis (Bae et al., 2007; Buontempo et al., 2011; 
Engelman, 2009; Fujiwara et al., 2000; Kawamura et al., 1999; Yao et al., 1999).  
We analyzed small molecule inhibitors targeting the PI3K/AKT/mTOR 
pathway, including pan-PI3K inhibitors, isoform-specific PI3K inhibitors, mTOR 
inhibitors, dual PI3K/mTOR inhibitors, and isoform-specific or non-specific AKT 
inhibitors with a network-based therapeutic perspective. We aimed to find potential 
PI3K/AKT/mTOR inhibitors to be used in the clinic and to increase efficacy of 
Sorafenib by combinational treatments. We searched for the most effective 
PI3K/AKT/mTOR inhibitors that can reduce tumor growth alone or in combination 
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with Sorafenib in vitro and in vivo and further revealed their mechanism of action via 
network-based drug transcriptomics. 
 
Figure 2.1: Objective of this study.   
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CHAPTER 3. MATERIALS AND METHODS 
3.1. MATERIALS 
 
3.1.1. Cell culture reagents and materials 
Dulbecco’s modified Eagle’s medium (DMEM), Roswell Park Memorial Institute 
(RPMI) 1640 medium, penicillin/streptomycin, trypsin-EDTA, fetal bovine serum 
(FBS) and L-glutamine were from GIBCO (Invitrogen, Carlsbad, CA, USA). Cell 
culture flasks, petri dishes, plates, cryovials were from Corning Life Sciences 
Incorporated (USA). Serological pipettes and sealed-cap polycarbonate centrifuge 
tubes were from Costar Corporation (Cambridge, UK).  
 
3.1.2. Kinase inhibitors 
Multi-kinase inhibitor Sorafenib (BAY 43-9006, Nexavar) targets angiogenic 
VEGFR/PDGFR kinases and RAF/MEK/ERK pathway. Experimental pan-PI3K 
inhibitors LY294002 and Wortmannin target all isoforms of PI3K. ZSTK474 is also 
a novel PI3K inhibitor that targets all isoforms. PIK-75 (PI3Ki-!) and TGX-221 
(PI3Ki-!) are isoform specific inhibitors of PI3K that target p110! and p110!, 
respectively. PI-103 is a dual PI3K/mTOR inhibitor. Rapamycin is an inhibitor of 
mTORC1. Akt inhibitor viii (Akti-1,2) is an inhibitor of Akt1 and Akt2 isoforms and 
Akt xii (Akti-2) is a selective inhibitor of Akt2 isoform. 
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Table 3.1: Kinase inhibitors used in this study 
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Figure 3.1: Schematic representation of kinase inhibitors and their targets  
 
 
 
3.1.3. Sulforhodamine B (SRB) and Real-time cell electronic sensing (RT-CES) 
cytotoxicity assay reagents 
Trichloroacetic acid (TCA) was from Merck (Darmstadt, Germany). Sulforhodamine 
B (SRB) sodium salt was from Sigma Aldrich (St. Louis, MO, USA). Tris was from 
Amresco (USA). The RTCA (Real-Time Cell Analyzer) SP (Single Plate) Instrument 
and E-Plate 96 were from Roche Applied Sciences (Mannheim, Germany). ELISA 
reader was from Beckman Instruments (CA, USA). CloneFill Instrument for solution 
distribution into 96-well plates was from Genetix (Hampshire, UK). 
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3.1.4. RNA extraction, cDNA synthesis and polymerase chain reaction (PCR) 
reagents 
Total RNA isolation kit Nucleospin RNA II was from Macherey-Nagel (Duren, 
Germany). RevertAid First Strand cDNA synthesis kit and Polymerase Chain 
Reaction (PCR) reagents; 10X Taq DNA Polymerase Buffer (+(NH4)2SO4, -MgCl2), 
Taq DNA Polymerase, 2 mM dNTP, 25 mM MgCl2, were from Fermentas (Leon-
Rot, Germany). DyNAmo HS SYBR Green qPCR Kit for quantitative PCR reactions 
was purchased from Finnzymes (Finland). NanoDrop ND-1000 spectrophotometer 
used for nucleic acid concentration measurements was from Thermo Fisher Scientific 
(Wilmington, DE, USA). Semi-quantitative PCR machine was Techne TC-512. 
iCycler iQ real-time RT-PCR machine was from Bio-Rad. 
 
3.1.5. Oligonucleotides 
All primers used in this study were synthesized by İONTEK (Istanbul, Turkey). The 
list of primers is given in Table 3.2. 
Table 3.2: Primer list 
Gene  Primer Oligo sequence (5'→3') Amplicon size (bp) 
AARS sense CCAGTGGCAGAAGGATGAAT 206 
antisense GCTTCAAGGCTTCATTCAGG 
ACTB sense GGACTTCGAGCAAGAGATGG 234 
antisense AGCACTGTGTTGGCGTACAG 
CFL1 sense GTGCTCTTCTGCCTGAGTGA 247 
antisense TCTTCTTGATGGCGTCCTTG 
EEF2 sense AACGGCAAGTTCAGCAAGTC 182 
antisense TTGTCCTTGTCCTCGCTGTC 
GAPDH sense GGCTGAGAACGGGAAGCTTGTCAT 272 
antisense CAGCCTTCTCCATGGTGGTGAAGA 
GSTO1  sense TCGATCCGCATCTACAGCAT 271 
antisense TTCCAGAACTGGCACCAGAC 
H2AFZ sense GTGCGACGAAGGAGTAGGTG 176 
antisense CTCTGCGGTGAGGTACTCCA 
HBXIP sense GCAGCACTTGGAAGACACAA 294 
antisense TCCTATGACAGGCTGCTGAA 
RPL30 sense CCTAAGGCAGGAAGATGGTG 171 
antisense GGCAGTTGTTAGCGAGAATG 
RPL41 sense AAGATGAGGCAGAGGTCCAA 248 
antisense TCCAGAATGTCACAGGTCCA 
RPL7 sense AAGGTGTTGCAGCTTCTTCG 164 
 29 
antisense TTGCCATAACCACGCTTGTA 
RPN2 sense GCTCTCGCATAATCGCTACC 289 
antisense CCGGTTGTCACCTTCAACTT 
RPS10 sense CGCAGAGATGTTGATGCCTA 162 
antisense AGAGACTGCATGGCCTTCAT 
RPS17 sense CAACGACTTCCACACGAACA 210 
antisense ATCTCCTGATCCAAGGCTGA 
RPS3A sense CCGATGGTTACTTGCTTCGT 193 
antisense CCAATGCTGTCTGGAATCAAT 
SOD1 sense AGGCTGTACCAGTGCAGGTC 193 
antisense ATGATGCAATGGTCTCCTGA 
TPT1 sense ATGAATCCAGATGGCATGGT 167 
antisense TGTGGATGACAAGCAGAAGC 
 
3.1.6. Agarose gel electrophoresis, photography and spectrophotometer 
Electrophoresis grade agarose (Basica Le) was from Prona (Spain). 1kb and 100bp 
DNA ladders and 6x gel loading buffer were from Fermentas (Leon-Rot, Germany). 
Horizontal electrophoresis equipment was from Thermo Scientific (Wilmington, 
USA). Power supplies Power-PAC200 and Power-PAC300 were from Bio Rad 
Laboratories (CA, USA). The Chemi-Capt software for image acquisition was from 
Vilber Lourmat (France).  
 
3.1.7. Protein gel electrophoresis, autoradiography and spectrophotometer 
NuPAGE pre-cast 10% and 12% Bis-Tris mini gels, MOPS and MES running 
buffers, transfer buffer, 4X sample loading buffer, 10X sample reducing agent, 
antioxidant and electrophoresis and transfer equipments were from Invitrogen. 
SMO671 prestained protein ladder was from Fermentas (Leon-Rot, Germany). 
Phosphatase inhibitor cocktail (PhosStop) and Protease inhibitor cocktail tablet 
(complete EDTA free) were from Roche Applied Sciences. ECL-Plus Western blot 
detection kit and nitrocellulose membrane (0.2µm) were from Amersham GE 
Healthcare Life Sciences (Buckinghamshire, UK). Bradford reagent was from Sigma 
Aldrich (St. Louis, MO, USA). Beckman Spectrophotometer Du640 was purchased 
from Beckman Instruments Inc. (CA. USA). Ponceau S was from Applichem 
Biochemica (Darmstadt, Germany). 3MM filter paper was from Whatman 
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International Ltd. (Madison, USA). The films used for autoradiography were from 
Kodak. The films were developed with Hyperprocessor (Amersham, UK).  
 
3.1.8. Antibodies 
Sources, and working dilutions of all primary antibodies used in this study are listed 
in Table 3.3. Working dilutions indicated in the table are for 2 hours incubation at 
room temperature. 
Table 3.3: Antibody list 
Antibody Company Cat. No. Working Dilution  
PI3K p110 alpha Cell Signaling 4249S 1:500 in 5%BSA-0.1%TBS-T  
PI3K p110 beta Cell Signaling 3011S 1:500 in 5%BSA-0.1%TBS-T  
PTEN Cell Signaling 9552 1:300 in 5%BSA-0.2%TBS-T  
p-Akt (Ser 473) Cell Signaling 9271L 1:100 in 5%BSA-0.1%TBS-T  
Akt Cell Signaling 9272 1:300 in 5%BSA-0.2%TBS-T  
p-ERK 1/2 (Thr 
202/Tyr 204) Santa Cruz sc-16982 1:200 in 5%BSA-0.1%TBS-T  
ERK 1/2 (MK1) Santa Cruz sc-135900 1:200 in 5%BSA-0.1%TBS-T  
Phospho-GSK3-a/ß 
(Ser21/9) Cell Signaling 9331L 1:200 in 5%BSA-0.1%TBS-T  
GSK3-a/ß Santa Cruz sc-7291 1:500 in 5%BSA-0.1%TBS-T  
a-Phospho-FoxO1 
(Ser256)   FKHR Cell Signaling 9461S 1:200 in 5%BSA-0.1%TBS-T  
Phospho-Rb 
(Ser807/811) Cell Signaling 9308S 1:200 in 5%BSA-0.1%TBS-T  
Rb BD Biosciences 554136 1:300 in 5%BSA-0.2%TBS-T  
Phospho-Bad 
(Ser136) Cell Signaling 9295 1:200 in 5%BSA-0.1%TBS-T  
Bad Cell Signaling 9292 1:300 in 5%BSA-0.2%TBS-T  
PARP-1 (46D11) Cell Signaling 9532 1:200 in 5%BSA-0.1%TBS-T  
p21 Calbiochem OP64 1:200 in 5%milk-0.1%TBS-T 
cyclin D1 (HD11) Santa Cruz sc246 1:200 in 5%milk-0.1%TBS-T 
Actin (I-19) Santa Cruz sc1616 1:200 in 5%milk-0.1%TBS-T  
 
3.1.9. Cell cycle distribution analysis with flow cytometry 
RNaseA was from Fermentas (Leon-Rot, Germany). Propidium iodide was from 
Sigma Aldrich (St. Louis, MO, USA). FACSCalibur Flow Cytometer and CellQuest 
software were from Becton Dickinson (BD Biosciences, San Jose, CA). 
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3.1.10. Immunofluorescence staining reagents 
Fluorescent mounting medium was from Dako (Denmark). Hoechst stain was from 
Sigma Aldrich (St. Louis, MO, USA).  
 
3.1.11. General reagents 
Most of the laboratory chemicals, including Haematoxylin, Ethanol and Methanol 
were from Sigma Aldrich (St. Louis, MO, USA). X-Gal was from Fermentas (Leon-
Rot, Germany). Dimethyl sulfoxide (DMSO) was from AppliChem Biochemica 
(Darmstadt, Germany).  
 
3.2. SOLUTIONS AND MEDIA 
3.2.1. Cell culture solutions 
DMEM complete medium: 10% Fetal bovine serum (FBS), 1% 
penicillin/streptomycin, 1% non-
essential amino acid. Stored at 4oC. 
RPMI complete medium: 10% Fetal bovine serum (FBS), 1% 
penicillin/streptomycin, 1% non-
essential amino acid, 1% L-Glutamine. 
Stored at 4oC. 
10X Phosphate buffered saline (PBS): 80 g NaCl, 2 g KCl, 14.4 g Na2HPO4, 
2.4 g KH2PO4 in 1L ddH2O. atoclaved. 
pH of 10X buffer=6.8 When diluted to 
1X working concentration pH=7.4.  
Starvation medium: Same as the complete medium but has 
1% Fetal bovine serum (FBS) instead of 
10%. Stored at 4oC. 
Freezing Medium:  20% FBS, 7% DMSO, 73% complete 
medium  
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3.2.2. Reconstitution of kinase inhibitors 
Kinase inhibitors are solubilized in dimethyl sulfoxide (DMSO). Stock solutions 
(ranging from 10mM to 40mM) are prepared based on their solubility in DMSO. 
Solubilized inhibitors are stored at -20°C. For all the experiments with drug-treated 
cells, solvent (DMSO)-treated cells are used as controls. 
 
3.2.3  Sulphorhodamine B assay solutions 
SRB stain solution: 0.04gr SRB stain in 10ml 1% acetic acid 
solution. 
10% TCA solution: 100% TCA diluted into 10% in cold 
ddH2O. 
10mM TrisBase: 0.6gr Tris was dissolved in 1L cold 
ddH2O. 
 
3.2.4. Electrophoresis buffers 
50x Tris Acetate EDTA (TAE): 242 g Tris base, 37.2 g EDTA, 57.1 ml 
glacial acetic acid, in 1L ddH2O. 
pH=8.5. Stir to dissolve. Dilute with 
ddH2O for 1X working solution. 
Ethidium bromide: 10 mg/mL in water (stock solution),      
1 µg/mL (working solution) 
2% Agarose gel: 2 g agarose in 100 ml TAE buffer. 
Boiled, 1 µg/µL etidium bromide added, 
swirled, poured onto gel casting 
apparatus. 
DEPC-treated water: 0.1% Diethylpyrocarbonate (DEPC) 
(v/v) solubilized in ddH2O overnight 
under the hood in a loosely plugged 
bottle. Then autoclaved. 
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3.2.5. Microarray reagents 
All reagents used for the microarray experiments (GeneChip Human Genome U133 
Plus 2, One-Cycle cDNA synthesis kit, IVT labeling kit, Poly-A exogenous positive 
controls) were purchased from Affymetrix.  
 
3.2.6. Western blotting reagents 
NP-40 lysis buffer: 150 mM NaCl, 50 mM TrisHCl (pH 8), 
1% NP-40, 0.1% SDS, 1x protease 
inhibitor cocktail, 1x phosphatase 
inhibitor cocktail in ddH2O. 
10X Tris buffered saline (TBS): 12.2 g Trisma base, 87.8 g NaCl in 1 
liter ddH2O.  pH 7.6. 
TBS-Tween (TBS-T): 0.1% Tween-20 in 1x TBS. 
Ponceau S: 0.1% (w/v) Ponceau, 5 % (v/v) acetic 
acid in ddH2O. 
Blocking solution: 5% (w/v) non-fat dry milk or bovine 
serum albumin (BSA) in 0.1% TBS-T. 
 
3.2.7. Cell cycle distribution analysis solutions 
Propidium Iodide staining solution: 50 mg/mL propidium iodide, 0.1 
mg/mL RNase A and 0.05% TritonX-
100 in PBS. 
 
3.2.8. Immunofluorescence solutions 
Hoechst-33258 stock solution: 300µg/ml Hoechst-33258 dissolved in 
ddH2O. Stored at +4oC in dark. 
Hoechst-33258 working solution: 1µg/ml Hoechst-33258 diluted from 
300µg/ml stock in 1x PBS. 
Blocking solution 3% BSA, 0.1% Triton-X in PBS. 
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4% paraformaldehyde: 4 g paraformaldehyde, in 100 ml PBS, 
Stirred 4 hours at 58°C, pH 7.4. Stored 
at -20oC in dark. 
 
3.3. METHODS 
 
3.3.1 Cell culture methods 
14 HCC cell lines (Huh7, HepG2, Hep3B, Hep3B-TR, Hep40, PLC/PRF/5, FOCUS, 
Mahlavu, Snu182, Snu387, Snu398, Snu423, Snu449, Snu475) were used in this 
study. Snu cell lines were cultured in RPMI-1640 medium and the rest of the cell 
lines were cultured in DMEM medium, both supplemented with 10% fetal bovine 
serum (FBS), 1% penicillin/streptomycin (P/S) and 1% non-essential amino acids 
(NEA). All cell lines were incubated in humidified 37 °C incubators with 5% CO2. 
 
3.3.1.1 Growth and sub-culturing of cells 
Cells were passaged regularly when they reached 70–80% confluency. Briefly, the 
old medium was aspirated, cells were washed twice with PBS. After aspirating the 
PBS, trypsin-EDTA solution was applied on to the cells (500µl for 100mm dish). 
When the adherent cells started to detach from the surface of the dish, they were 
collected in fresh medium (at least of 4ml so that the FBS inside the medium can 
inactivate the trypsin) and mixed thoroughly with serological pipettes to prevent 
aggregates and cell clumps. Cells were re-seeded on new culture dishes with fresh 
medium. The new dishes were moved back and forth and left to right gently in order 
to allow the cells to be distributed evenly and without any clumps.  Sub-culturing 
ratios for the used HCC cell lines were between 1:4 – 1:10 depending on the growth 
rate and cell size. Media, PBS, trypsin-EDTA and NEA were stored at +4ºC. FBS 
stock solutions were stored at -20ºC, thawed at 4ºC, heat-inactivated at 56ºC for 30 
minutes, then aliquoted into sterile 50 ml falcons and stored at -20ºC. P/S and L-
Glutamine were stored at -20ºC. All solutions and media were warmed to 37ºC in 
water bath prior to use. For the experiments with a defined number of cells, the 
trypsinized cells were collected in falcons and after a thorough mixing, 10µl of cell 
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suspension was applied to both sides of the haemocytometer and the cells were 
counted. The number of cells counted in the defined area of the haemocytometer was 
multiplied with 104 to get the number of cells in 1 ml of the cell suspension. 
 
3.3.1.2. Cryopreservation of cells 
Cells that were in their exponential growth phase, at approximately 60% confluency, 
were washed, trypsinized, collected in fresh medium and centrifuged at 1500 rpm for 
5 minutes. The supernatant was aspirated and the pellet was resuspended in freezing 
medium (20% FBS, 7% DMSO, 73% complete medium). 1ml of the cell suspension 
was transferred into a cryovial. More than 5 vials were prepared especially from the 
early passaged cells to prevent over-passaging. Cryovials were placed at -20ºC for 1 
hour, then kept in -80ºC overnight and finally transferred into liquid nitrogen tanks 
for long term storage. 
 
3.3.1.3. Thawing of frozen cells 
One vial of the frozen cell line was taken out from the nitrogen tank or -800C and put 
into 37oC waterbath for 1-2 minutes so that the cell solution starts to thaw. Before the 
cells were completely thawed, while they were still icy, the cell suspension was 
transferred into a 15ml falcon with 5ml medium and centrifuged at 1500rpm for 3 
minutes, to remove the DMSO that was present in the freezing medium. The 
supernatant was aspirated, pellet was resuspended in 10ml complete medium and 
transferred into a 100mm culture dish. The dish was moved back and forth and left to 
right gently in order to allow the cell suspension to be distributed evenly. Cells were 
incubated overnight at a 37ºC humidified incubator with 5% CO2. The next day, 
culture mediums were replaced with fresh complete mediums. 
 
3.3.2. Sulforhodamine B (SRB) cytotoxicity assay 
 Huh7 (2000cell/well) and Mahlavu (1000cell/well) cell lines were seeded into 
96-well plates in 150µl of medium/well. Next day, medium was discarded and 150µl 
of new complete medium was applied to each well. Extra 150µl medium was added 
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into the first wells of the dilution series. Then, the starting highest concentration 
desired for each drug was applied to the corresponding wells.  Stock&Conc&(mM)&x&Volume&(2l)&&=&&Final&Conc&(2M)&x&Final&Volume&(3002l)&20&mM&&&&&&&x&&&&&0.6&2l& &&&=&&& 40&2M&&&&&&&&&&&&&&x&300&2l&
 In order to use only 1 common DMSO control for 5 different drugs, the stock 
concentrations of the inhibitors were prepared such that for the first wells of each 
dilution series the volume added (0.6µl) into the final volume (300µl) was the same. 
With a multichannel pipette adjusted to 150µl, 2-fold dilution series were done until 
the last concentration. Each drug treatment was performed in triplicates. Dilutions 
were done from the ends of the plate to the middle, so that the highest concentrations 
were always at the far end and the lowest concentrations were close to DMSO 
control. In this study, all drugs except one were solubilized in DMSO. Therefore, 
DMSO was used as control. For Akti-2 inhibitor, which was soluble in water, non-
treated cells were used as control. One of the plates was not treated but instead fixed 
at the time of treatment, so that the initial cell density before drug treatment can be 
obtained. The other plates were fixed at the desired times (24h, 48h, 72h). For the 
fixation process, the media was discarded, wells were washed once with PBS, 50µl 
of 10% cold TCA was applied to each well. The plates were incubated with TCA at 
+4oC in dark for 1 hour. After 1 hour TCA was discarded, wells were washed with 
ddH2O 4 times and the plates were air-dried at room temperature. Finally, 50µl of 
0.4% sulphorhodamine B (SRB) solution in 1%acetic acid was applied to each well 
and the plates were incubated for 10min in dark at room temperature. After the 
incubation, excess dye was washed off with 1% acetic acid until no dye comes out of 
the wells (4 or 5 washes). The plates were air-dried at room temperature. Finally, 
200µl of 10mM cold Tris-Base was applied o each well to solubilize SRB. Then, the 
absorbance was measured at 515nm with Elisa reader. OD values were analyzed to 
determine the effect of each drug on cell proliferation as compared to control.  
Formulas for IC50 calculation in Excel: %inhibiton&=&(1A(AVERAGE(ODDrug)/AVERAGE(ODDMSO)))*100&yAint&=&INDEX(LINEST(J6:O6,LN(J5:O5),TRUE,FALSE),2)&slope&=&INDEX(LINEST(J6:O6,LN(J5:O5),TRUE,TRUE),1)&R2&=&INDEX(LINEST(J6:O6,LN(J5:O5),TRUE,TRUE),3)&IC50&=&EXP((50&A&yAint)/slope)&
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Figure 3.2: Schematic representation of SRB assay.  
 
3.3.3. Real-time cell electronic sensing (RT-CES) system for cell growth and 
cytotoxicity analysis 
50µl complete medium was added to each well of the E-Plate 96. Background 
reading (1 min) was done to eliminate background noise and to check that data can 
be collected from each well. Huh7 (2000cell/well) and Mahlavu (1000cell/well) cell 
lines were seeded into 96-well plates in 100µl of medium/well. Proliferation was 
monitored and cell index (CI) data was collected every 30 min for 24 h. Next day, 
medium was discarded and 150 µl fresh medium was added to each well. Inhibitors 
with indicated concentrations were applied as it was done for the SRB assay. CI 
values were taken every 10 min for 4 h to get the fast drug response and then every 
30 min to obtain the long-term drug response. Impedance measurements that were 
displayed as Cell Index (CI) values reflect cell growth. When the cells adhere to 
electrodes on the bottom of the wells, CI values increase in parallel to the cell growth 
due to the insulating properties of the cell membrane. As the number of cells 
covering the electrodes increases the electrical impedance (Z) increases (Z0 = 0 ! Z 
= Zcell). The effect of the inhibitors on cell growth was calculated compared to 
DMSO control (CIDrug/CIDMSO). 
 
Figure 3.3: Schematic representation of RTCES system. 
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3.3.4. RNA extraction and cDNA synthesis 
 Total RNA was isolated with NucleoSpin RNA II Kit (Macherey-Nagel) 
according to the manufacturer’s protocol (MN, Duren, Germany) with small 
modifications such as 30min of DNA digestion instead of 15min and 2-step elution 
with 20µl water instead of one elution with 60µl. RNA concentration was measured 
with NanoDrop and A260/A280, A260/A230 ratios were checked for RNA quality 
and purity. First-strand cDNA synthesis was carried out from 2 µg of total RNA 
using Oligo(dT)18 primers with the RevertAid First Strand cDNA synthesis kit 
(Fermentas). cDNAs were stored at -20°C. In order to check for genomic DNA 
contamination, RT (-) cDNA samples were also synthesized from total RNA, where 
no reverse transcriptase enzyme was added in the reaction, so that any amplification 
with this control cDNA would indicate genomic DNA contamination. 
 For microarray experiments, quality of extracted RNA was assessed with 
Agilent 2100 bioanalyzer using RNA 6000 Nano Kit, which reports an RNA 
Integrity Number (RIN) as a measure of quality. RIN value of 1 represents the most 
degraded and 10 represents the most intact RNA. RNAs having RIN values higher 
than 9 were used in microarray experiments.  
 
3.3.5. Primer design for expression analysis with semi-quantitative and 
quantitative real-time RT-PCR  
 The sequences of the genes of interest were obtained from NCBI (National 
Center for Biotechnology Information) website at: http://www.ncbi.nlm.nih.gov/, and 
UCSC (University of California, Santa Cruz) Genome Bioinformatics website at: 
http://genome.ucsc.edu/. Primers were designed using the Primer3 online web tool, 
provided by Steve Rozen and Helen J. Skaletsky (2000) at the website: 
http://frodo.wi.mit.edu/primer3/. The designed primer pairs were checked to confirm 
that they amplify only the desired specific region using the in silico PCR online tool 
of UCSC Genome Bioinformatics website. Primers with a length of 18-22bp were 
designed to amplify the genes of interest so that they are long enough for adequate 
specificity and short enough to bind easily to the template at the annealing 
temperature. Primers were designed to have a GC% of 40%-60% and a melting 
temperature of around 60°C. Difference between the melting temperatures of forward 
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and reverse primers were set to be no greater than 1ºC. Repeats and runs of the same 
nucleotide more then 3bp and hairpins and primer dimers were avoided. Primers 
were specifically designed for the particular gene of interest so that they do not 
amplify a different region, and this was further confirmed with BLAST analysis. 
Moreover, forward and reverse primers were positioned on different exons of the 
gene of interest, so that if the primer pair amplifies a longer product than expected, 
this would indicate genomic DNA contamination. All primers used for gene 
expression analysis are listed in Table 3.2. 
 
3.3.6. Expression analysis with semi-quantitative RT-PCR 
 Before continuing with gene expression analysis, the housekeeping gene 
GAPDH was amplified to rule out any possible genomic DNA contamination and to 
normalize the cDNA amounts to be used during further analysis. GAPDH primers 
were designed to amplify a 151 bp fragment from cDNA, and a 250 bp fragment 
from genomic DNA if any genomic DNA contamination is present. GAPDH RT-
PCR was performed with 1 µl of each sample and the products were run on an 
agarose gel. By comparing the band intensities using the Molecular Analyst software, 
the cDNA amount to be used from each sample was determined. All the other RT-
PCRs were performed with these determined cDNA amounts. GAPDH RT-PCR was 
done with 20 cycles. The optimum cycle number for each semi-quantitative RT-PCR 
reaction was determined by setting up multiple PCR reactions with different cycle 
numbers to achieve the minimum cycle number that allows the visualization of the 
desired product to prevent erronous results due to possible saturation of the bands at 
high cycle numbers. PCR conditions for gene expression analysis were an initial 
denaturation step at 95°C for 5 min; a loop cycle of 95°C for 30 sec, at Tm (mostly 
600C) for 30 sec, at 720C for 30sec; and a final extension at 72°C for 10 minutes.  
 
3.3.7. Expression analysis with quantitative RT-PCR 
 Primer efficiency was calculated by running a qPCR reaction with a 10-fold 
cDNA dilution series for each primer set in triplicate. The cycle where the 
fluorescence of the sample exceeds a threshold level, termed quantification cycle 
(Cq) value, was determined by the BioRad iCycler software. A standard curve (Cq vs 
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log of starting quantity) was plotted and efficiency of each primer pair was calculated 
using the linear regression slope of the dilution series with the equation:   & E&=&10(A1/slope) for 10-fold dilutions. 
 Real-time quantitative PCR assays were performed in triplicate for each 
candidate gene using 1µl of 1:100 diluted cDNA template. The following program 
was used: Initial denaturation at 95 °C 15 min amplification for 45 cycles (95°C 15 s 
followed by 57°C 30 s and 72°C 30 s), and final extension at 72°C 10 min. Melting 
curve analysis was done to confirm the amplicon size and to check the presence of 
any primer-dimer or genomic DNA amplification.  
 Cq values generated by BioRad iCycler system were transformed into 
quantities (relative expression values) according to Vandesompele et al. 
(Vandesompele et al., 2002). Relative expression (amplification) values were 
calculated with the equation:  Relative&Expression&=&E(A!Cq).&
Relative expression levels between two samples were calculated with the equation:  R&=&(Etarget)ΔCqtarget(controlAsample)&/(Eref)&ΔCqref(controlAsample)&
, where Etarget and Eref represent the primer efficiencies for target and reference genes, 
respectively.  
 
3.3.8. Agarose gel electrophoresis of PCR products 
 Agarose was completely dissolved in TAE buffer in microwave. 1 µg/µL 
ethidium bromide was added, swirled, and the buffer was poured onto gel casting 
apparatus. PCR products that were mixed with 6X loading buffer were loaded onto 
gels. According to the size of the expected product either a 100 bp ladder or a 1 kb 
ladder was used. The gel was run at 100-120 V at room temperature until the 
fragments were separated. Bands were visualized under UV transillumination. 
 
3.3.9. Expression Analysis with Affymetrix 
 cDNA and eventually cRNA were synthesized from the high quality RNA 
samples (RIN above 9) using the One-Cycle cDNA Synthesis Kit from Affymetrix. 
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cRNA (~5µg) from each clone was hybridized to Affymetrix HGU133Plus2 Chips. 
Signals from the chips were exported as .CEL files. Raw .CEL files were processed 
using ‘R’ software. Bioconductor Packages such as Biobase, affy, genefilter, 
simpleaffy, AnnotationDbi, annotate, affyQCReport, affyPLM, and limma were used 
for quality control, preprocessing and differential gene expression in R.  
 Quality of arrays was checked using the simpleaffy or the affyQCReport 
package. For quality control, RNA degradation plots (probe vs mean intensity), 
boxplots and histograms for probe intensity distribution analysis (log intensity vs 
density), RLE (Relative Log Expression) plots and NUSE (Normalized Unscaled 
Standard Error) plots were drawn and % presence of probes, 3'/5' ratios for GAPDH 
and Actin were compared. Hierarchical clustering and principal component analysis 
(PCA) were performed to check correlation between replicate arrays. 
 Robust Multi-array Average (RMA) was used for data normalization and 
computation of expression values. Boxplots, histograms, RLE and NUSE plots were 
drawn again ensure successful normalization. Differentially expressed genes were 
identified by performing t-tests with function rowttests() from package “limma”. 
Results were exported with function write.table(). 
 
3.3.10. Identification of optimal reference genes for microarray normalization 
 Gene expression data were downloaded from the NCBI Gene Expression 
Omnibus (NCBI-GEO) database [5] and were mean-normalized. A rank value was 
assigned for each gene in each sample using percentile ranking. The average change 
in the rank of each gene in each GEO dataset (GDS) was calculated as the ratio of the 
standard deviation to the mean and was used as a measure of coefficient of variation 
(CV). To account for genes having CV values only for a subset of the available 
GDSs, a new expression stability measure, Ratiot(Gi), was introduced. Ratiot(Gi) is 
the ratio of GDSs, in which a gene has CV less than t. However, since a gene that is 
present in only a single GEO dataset but has a small enough CV value can get a 
perfect Ratiot(Gi), the percentage of datasets in which that gene is present 
(percentage of occurrence PO(Gi)) was introduced as a new parameter to adjust 
Ratiot(Gi).  
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 As result of testing various CV thresholds of t=0.5, t=0.1, t=0.05, and t=0.01 
and minimum PO values of PO=75%, 50%, 25% and 5% to analyze normalized gene 
expression values, CV was used to set a classifier with fixed PO and Ratiot values at 
75% and 0.90 respectively. Specificity and sensitivity of the classifier was 
demonstrated by plotting receiver-operating characteristic (ROC) curves. Since 
candidate reference genes are anticipated to have lower CV and higher Ratiot(Gi) 
than that of randomly selected genes, the classifier was tested by comparing a 
previously published reference gene dataset of 566 housekeeping genes by Eisenberg 
et al. to five different randomly selected sets of non-housekeeping genes having the 
same mean rank distribution (Eisenberg & Levanon, 2003). The ratio distribution 
(Ratiot) of housekeeping genes was significantly different than that of randomly 
selected non-housekeeping gene sets (p<0.0001), supporting steady expression of the 
tested housekeeping genes across different experiment sets compared to randomly 
selected gene sets. 
 
3.3.11. Signal transduction score flow algorithm 
 Raw expression data from microarray was normalized by Robust Multi-array 
Average (RMA). Normalized and log2-transformed gene expression values were 
provided as the input score of each gene. Next, the rank score of each gene was 
computed based on fold change ratios between experiments (treated versus control). 
If r(x) indicates the order of the score x when all the scores are sorted in ascending 
order, and TS is the total number of scores, then the rank of x, R(x) is calculated as:  
R(x) = r(x) / TS. Score of each gene was assigned to its node (protein) in signaling 
pathway. Nodes transmitted their scores to their first downstream neighbour node 
and signal flowed through edges connecting the nodes (regulatory relationship: 
activation or inhibition). The initial score of the node (protein) was partitioned to the 
interacting edges based on the weights of the interacting neighborhood nodes’ raw 
data score (Figure 3.4). Sum of the incoming edge score and the initial score of the 
node itself provided the final score of the node. Score partitioning was based on 
protein concentrations, where raw data scores were used as the stoichiometric 
concentrations of the node. Activator edges passed positive values and inhibitory 
edges passed negative values on the interacting nodes. A modified breadth-first 
search (BFS) algorithm was applied to simulate the effect of negative and positive 
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feedback loops. The algorithm was iterated 10–15 times over the entire cyclic graph 
until the convergence of gene node scores was attained. Score flow algorithm 
traversed the signaling pathway until a pre-defined biological target response was 
reached. The score flow calculation algorithm is publicly available as a Cytoscape 
plug-in (Isik, Ersahin, Atalay, Aykanat, & Cetin-Atalay, 2012). 
 
Figure 3.4: Schematic representation of signal transduction score flow 
algorithm Raw data scores are given in square protein nodes. Protein A transforms 
its score to Proteins B and C based on their weights (raw data scores of proteins B 
and C). The 8/10 fraction of the score of A (20) is partitioned to B and the 2/10 
fraction to C. The new scores of proteins B and C become 24 (8 + 16) and 6 (2 +4) 
respectively. Then, protein B partitions its new score to proteins D and E based on 
their weights. Since, the interaction between proteins B and D is of inhibitory type, 
score is transferred with a negative value (from Isik et al., 2012 with copyright 
permission). 
 
3.3.12. Crude total protein extraction from cultured cells 
 Huh7 (250,000 cell in 100mm dish), HepG2 (250,000 cell in 100mm dish) 
and Mahlavu (100,000 cell in 100mm dish) cell lines were cultured into 100mm 
dishes. Next day, medium was aspirated and the cells were washed twice with PBS. 
6ml of new complete medium with the kinase inhibitor or DMSO control was given 
to the cells. All kinase inhibitors were used at a concentration of 10µM, except 
PI3Kalpha inhibitor and Rapamycin, which were used at 0.1µM concentrations. 
Cells were collected after 72 hours and changes in protein levels were analyzed with 
western blot. When collecting the cells, first the medium containing the swimming 
apoptotic cells was transferred into a 15ml falcon. Then the possible remaining but 
detached cells were collected with PBS and transferred to the same falcon. The 
adherent cells were then trypsinized and collected with new complete medium and 
This journal is c The Royal Society of Chemistry 2012 Mol. BioSyst., 2012, 8, 3224–3231 3225
profiles by identifying experimental condition related genes or
pathways based on traditional statisti al tests. Hence they
generate gene co-expression networks of only the selected pool
of genes. Most of the methods perform pathway analysis based on
either significant gene sets or gene functional class identifications.
Although some tools provide quantitative enrichment scores for
the genes or gene-groups, they do not use the topological structure
of the pathway or the biological activity of a specific sub-cellular
process responsible for the observed phenotype. Therefore, this
study aims to design and implement a signal transduction score
flow algorithm to quantitatively assess biological activities of
cellular processes and to identify significant sub-paths (down-
stream process) within that pathway using not only a selected
subset of genes but for all the gene nodes in a given pathway.
We previously described a feed-forward score flow algorithm
for large-scale data annotation and its relation to cellular
networks.16 Our current study focuses on the design and
implementation of a signal trans uction score flow algorithm
that quantitatively assesses biological activities of a cyclic
cellular network and identifies sig ificant sub-paths and target
cellular processes in a given pathway. The cyclic network
algorithm was also implemented as a Cytoscape plug-in, then
applied on 30 diﬀerent KEGG pathways by using two diﬀerent
data sets. Significance analysis of final activity scores of target
processes was performed. In silico knock-out studies were
analysed on a curated pathway. Our approach fuses and
ex loits both data and model, eﬀectively benefiting from topo-
logical information brought in by cell signalling pathways.
A pathway was converted into a graph and the individu l gene
scores were mapped onto the nodes of the graph. Gene scores
were transferred en route to the biological pathway to form a
final activity score, describing the behaviour of a specific
process in the pathway while enriching the gene node scores.
Methods
Pathway node score calculation
Based on the omics data, an initial score was assigned to each
protein node of a given pathway. The protein node scores were
obtained by taking products of the rank scores extracted from
experimental data (explained in Raw Data Preparation
Documentation, ESIw). Initial raw data analysis for micro-
array and ChIP-seq was done by R and CisGenome frame-
works respectively.17 Then score computation on the pathway
with the partitioned score transfer procedure was initiated.
Usually, cell signaling flows from cell membrane towards the
nucleus in order to activate certain cellular activities upon a
signal from receptors. Therefore our algorithm simulates this
signal flow after the initial score assignment. First the nodes
(proteins), which are close to the membrane transmit their scores
to their immediate edges, then to nodes in their immediate
neighborhood. If a protein has two or more interacting
partners in the immediate neighborhood, the initial score of
the protein is partitioned to the interacting edges based on the
weights of the interacting neighborhood nodes’ raw data score
(Fig. 1). Then the new edge score and the interacting node
score ar added up in order to calculate the output of the next
step in the signaling path. The partitioning idea of this
approach is based on the stoichiometric concentrations of
protein–protein interactions. The number of interactions/
reactions in a cellular system is based on the substance
concentration; therefore we adopted raw data scores as the
stoichiometric concentrations of the node and partitioned raw
data scores, based on their interacting partners’ stoichiometric
concentrations. A fraction of the raw data score is transferred
to one neighbour based on its raw score while the rest of the
raw data score is transferred to the other interacting partner.
During the transfer if the edge is of inhibitory type, then the
dge has a negative value on the interacting partner (Fig. 1).
However when there is negative or positive feedback, score
calculation cannot be solved with the above-explained pro-
cedure. Therefore, we applied a modified breadth-first search
(BFS) algorithm to overcome this problem (see Algorithm 1).
The algorithm had to iterate 10–15 times over the entire cyclic
graph until the convergence of gene node scores was attained.
Fig. 2 illustrates the general process diagram of our pathway
node score flow algorithm.
The score flow calculation algorithm was implemented as a
Cytoscape plug-in (ESIw) and it is publicly available. This
plug-in can be used by following the directions given in the
ESI.w Score calculation can be performed on custom (manually)
generated pathways as well as KEGG pathways.
In addition, in order to evaluate the significance of scores
obtained with the algorit m, we randomized input data several
times and reran the algorithm to calculate new activity scores.
Then p-values of pathway enrichment scores were calculated
so that the consistencies of the final activity scores could be
assessed and demonstrated.
Datasets
We applied the score flow algorithm to two datasets: ChIP-seq
and expression array data sets from Estradiol-treated MCF7
breast cancer cells (GSE11352 and GSE19013) obtained
simultaneously,18,19 and the gene expression profile of the
Colo741 cell line transfected by KRas-G12D or KRas-G12V
mutant proteins (GSE12398).20 The datasets were pre-processed
as explained in Raw Data Preparation Documentation (ESIw).
Analysis of Estradiol-treated MCF7 ChIP-seq was performed
Fig. 1 Demonstration of the score flow operation on a three step
hypothetical pathway wit final cellular activity processes (apopt sis,
cell cycle etc.). Raw data scores are shown in protein nodes in squares.
Protein A is the initiator protein, which transforms the 8/10 fraction
(10 is the sum of the scores of B and C) of its score to protein B and the
2/10 fraction to protein C. Then protein B gives out the sum of its raw
score plus the incoming score from A (+16 + 8 = 24) to proteins D
and E. Interaction with protein D is f inhibitory type, theref re protein
D’s incoming edge gets a negative value of !8. Hence, its target final
cellular process is inactive with a negative score (!8 + 2 = !6). Other
target processes are active according to the accumulated scores.
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combined with the swimming cells in the same falcon. Since trypsin can disrupt 
membrane proteins, for the analysis of E-cadherin, cells were not trypsinized but 
instead, at this step ice-cold PBS was applied to the adherent cells in the dish and the 
cells were scraped using rubber scrapers. The scraped cells were collected into the 
falcon containing the swimming cells. Then, for both the trypsinized and scraped 
cells, cell suspensions in the falcons were centrifuged at 1600rpm for 10min +4°C. 
Supernatant was discarded and cells were resuspended in 5ml ice-cold PBS and 
centrifuged at 1600rpm for 10min +4°C. The supernatant was discarded and cell 
pellets were either lysed immediately for the following western blot analysis or 
frozen in liquid nitrogen and stored in -80°C. Cell pellets were lysed in twice their 
volume of lysis buffer (150mM NaCl, 50mM Tris-HCl pH=7.6, 1% NP40, 0.1% 
SDS, 1x Protease inhibitor cocktail and 1x PhosStop) by vortexing every 5 min and 
incubating on ice for 30 min. If the lysate was viscous after this 30 min of 
incubation, samples were sonicated to shear DNA. Then the lysates were centrifuged 
at 13000rpm for 20 minutes at +4ºC and the supernatant containing total protein was 
transferred into new eppendorphs and stored at -20ºC.  
 
3.3.13. Western Botting 
 Protein concentrations of the cell lysates were measured by the conventional 
Bradford assay using a spectrophotometer at 595 nm. Bovine serum albumin (BSA) 
protein of known concentrations was used as reference for standard curve formation. 
Sample protein concentrations were normalized with respect to the standard curve. 
2µl of sample was used for Bradford assay and to calibrate the spectrophotometer, 
lysis buffer was used as blank. 
 
 
 Blank BSA Standards from 1mg/ml stock 
 BSA (µl) 0 1 2 4 8 16 32 
ddH2O (µl) 100 99 98 96 92 84 68 
Bradford (µl) 900 900 900 900 900 900 900 
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Protein samples were prepared by mixing equal amounts of cell lysates (25 – 40 µg 
protein) with 4x NuPAGE loading dye and 10X sample reducing agent (or 25mM 
DTT) in ddH2O in a total volume of 12µl for 15-well gels and 25µl for 10-well gels. 
The samples were heated at 70ºC for 10 min for denaturation and put on ice for 1 
min. Then the samples were spinned down for 3 sec and were loaded into the gel. 
10%, 12% or 4-12% Bis-Tris gels were used depending on the protein of interest. 
MOPS running buffer was used for high kDa proteins (PARP, E-cadherin, Rb, etc.) 
and MES running buffer was used for low kDa proteins (p21, Caspase 3, etc). 10% 
methanol was added to the transfer buffer before use. NuPAGE NOVEX pre-cast gel 
system was used for electrophoresis and transfer following the manufacturer’s 
protocol. Electrophoresis was carried out for 1.5 to 3 hours depending on the protein 
of interest and transfer was done at 30V for 90 min for all proteins. The gels were 
transferred to HyBond ECL nitrocellulose membranes. After transfer, the membranes 
were stained with Ponceau S for 1 min to control whether the transfer was successful. 
Ponceau S was washed off with ddH2O and the membrane was incubated in blocking 
solution (%5 milk powder in 1xTBS-T(0.1%tween)) on shaker overnight at +4°C. 
Then, the membrane was probed with primary antibody for 2 hours at room 
temperature or overnight at +4°C depending on the antibody. Unbound antibodies 
were washed off extensively for 30 min (5 min, 10 min, 10 min, 5 min) with 1xTBS-
T(0.1%tween). Afterwards, the membrane was incubated with the secondary 
antibodies conjugated with horse-radish peroxidase (HRP) for 1 hour at room 
temperature. Membrane was washed again for 30 min. Finally, chemiluminescent 
detection was performed by using ECL+ western blot detection kit from Amersham, 
according to the manufacturer’s protocol. X-ray films were exposed to the emitted 
chemiluminescence for different exposure times depending on the antibody (30 sec – 
20 min). 
 
3.3.14. Cell cycle distribution analysis with flow cytometry 
 Huh7 (250,000 cell in 100mm dish), HepG2 (250,000 cell in 100mm dish) 
and Mahlavu (100,000 cell in 100mm dish) cell lines were cultured into 100mm 
dishes. Next day, medium was aspirated and the cells were washed twice with PBS. 
6ml of new complete medium with the kinase inhibitor or DMSO control was given 
to the cells. All kinase inhibitors were used at a concentration of 10µM, except 
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PI3Kalpha inhibitor and Rapamycin, which were used at 0.1µM concentrations. 
Cells were collected at 72h and changes in cell cycle distribution were analyzed with 
flow cytometry. When collecting the cells, first the medium containing the 
swimming apoptotic cells was transferred into a 15ml falcon tube. Then the possible 
remaining but detached cells were collected with PBS and transferred to the same 
falcon tube. The adherent cells were then trypsinized and collected with new 
complete medium and combined with the swimming cells in the same falcon. The 
cell suspensions in the falcon tubes were centrifuged at 1600rpm for 10min +4°C. 
Supernatant was discarded and cells were resuspended in 5ml ice-cold PBS and 
centrifuged at 1600rpm for 10min +4°C. The supernatant was discarded and cell 
pellets were resuspended in 1ml ice-cold PBS and fixed by dropwise addition of 
2.5ml 100% EtOH (obtaining a final concentration of 70% ethanol) while vortexing 
at the same time to prevent cells to form aggregates. The samples were either 
incubated at +4oC for 30 min before continuing with PI staining or they were stored 
at this step at +4oC for up to 2 weeks. The cell pellet was resuspended in 500µl 
Propidium iodide (PI) staining solution (50µg/ml PI (from 1mg/ml stock), 0.1mg/ml 
RNaseA (from 10mg/ml stock), 0.05% Tritron-X-100 (from 100% stock) in cold 
PBS) and incubated 40min at 37oC in dark. After the incubation, 3ml PBS was added 
onto the samples and the samples were centrifuged at 1500rpm for 5min, +4oC. 
Supernatant was discarded and pellet was transferred to polystyrene tubes with 500 
mL PBS and analyzed with FACSCalibur Flow Cytometer (BD Biosciences). Cell 
cycle distribution and apoptotic cells were assessed by analyzing the proportion of 
cells in the G1, S, and G2/M fractions and sub-G1 respectively, using the Cell Quest 
3.2 software. 
 
3.3.15. Wound Healing 
 In the wound-healing assay, a wound was made in the middle of a confluent 
cell monolayer and the migration of cells to this area was assessed by taking photos 
at different time points and calculating the wound closure with respect to the initial 
wound width. Since the wounds were done by hand with a 30µl tip, the width of the 
wounds can differ from area to area. To assure that photos taken at different time 
points were from the exact same location inside a well, bottom of 12-well plates were 
marked by drawing vertical straight lines into the middle of each column and the 
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photos were taken from left and right sides of this mark. Cells were seeded in 1ml 
complete medium into 12-well plates. Next day, a horizontal wound was made into 
the middle of each well by scratching the bottom of the well with a 30µl tip. To 
remove the detached cells from the scratched area, the medium was aspirated and the 
cell layers were washed twice with PBS. Immediately, the time-zero photos of the 
wounds were taken to note the initial wound width. 1 ml of new starvation medium 
(containing 1% FBS instead of 10% so that migration will be promoted rather than 
proliferation) with the kinase inhibitor or DMSO control was given to the cells. All 
kinase inhibitors were used at a concentration of 10µM, except PI3Kalpha inhibitor 
and Rapamycin, which were used at 0.1µM concentrations. Photos of the wounds 
were taken after 24h and 48h. The sizes of the wounds were calculated at all time 
points. At least 12 different wound distances were noted for each condition at each 
time point and the averages were taken to construct graphs. 
 
3.3.16. Immunofluorescence 
 Huh7 (90,000 cell/well) and Mahlavu (30,000 cell/well) cell lines were 
seeded in 2ml complete medium on autoclaved sterile coverslips placed into 6-well 
plates. Next day, medium was aspirated and the cells were washed twice with PBS. 
1.5ml of new complete medium with the kinase inhibitor or DMSO control was 
given to the cells. All kinase inhibitors were used at a concentration of 10µM, except 
PI3Kalpha inhibitor and Rapamycin, which were used at 0.1µM concentrations. 
After 72h of incubation, cells were washed twice with cold PBS and fixed and 
permeabilized with 100% ice-cold methanol for 10 min. Methanol was discarded and 
the cells were washed once with cold PBS. (If the cells were fixed with 
paraformaldehyde, then they were permeabilized with 100% ice-cold methanol.) 
After fixation, cells were blocked in 1 ml blocking solution (3% BSA in PBS-
T(0.1%)) for 1h on shaker at room temperature. Coverslips were then probed with 
primary antibody in appropriate dilution for 2h at room temperature. Coverslips were 
then washed 3 times with PBS-T for 5 min, and then either appropriate FITC-
conjugated or AlexaFluor secondary antibody was applied for 1h at room 
temperature. All steps after the addition of secondary antibody were performed in 
dark. Cells were washed 3 times with PBS-T for 5 min and counterstained with 
1µg/ml Hoechst dye (250µl/well) at dark for 5 min. Then, Hoechst was discarded, 
 48 
cells were washed once with ddH2O briefly and then they were de-stained in ddH2O 
for 10 min. Excess water was removed from the coverslips by tissue paper, and they 
were mounted onto slides containing DAKO Fluorescent Mounting Medium. Stained 
cells were examined under fluorescence microscope (ZEISS) and pictures were 
captured in a digital ZEISS AxioCam MRc5 camera. 
 
3.3.17. In vivo tumor xenografts 
 Mahlavu cells (10x106 cells) were injected subcutaneously in nude mice. 
Mice were randomly divided into four groups: control (simple syrup), Sorafenib (30 
mg/kg), Akti-2 (7.5 mg/kg) and combination (30 mg/kg Sorafenib plus 7.5 mg/kg 
Akti-2). There were 5 animals per group, except Akti-2, which had 4 animals. 
Treatments were initiated when tumors reached an average volume of 150 mm3. 
Drugs were administered by oral gavage 5 days a week for 3 weeks. Tumor volumes 
were measured twice a week. After 3 weeks of treatment, animals were anesthetized 
and tumors were visualized by MR imaging. Tumors were excised and their weights 
were recorded. 
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CHAPTER 4. RESULTS 
4.1. Differential PTEN expression and AKT phosphorylation in HCC cell lines 
 Inactivating mutations of the tumor suppressor gene Phosphatase and tensin 
homolog (PTEN), which is a negative regulator of PI3K/Akt survival pathway, are 
frequently observed in HCC (Bae et al., 2007; Buontempo et al., 2011; Fujiwara et 
al., 2000; Kawamura et al., 1999; Yao et al., 1999). Decreased PTEN expression is 
correlated with increased tumor grade, advanced disease stage and reduced overall 
survival in patients with HCC (Hu et al., 2003). Aberrant mTOR signaling is also 
frequent in HCC and is associated with IGF pathway activation, EGF up-regulation, 
and PTEN dysregulation (Villanueva et al., 2008). 
 Therefore, we initially analyzed expression and activity status of the 
PI3K/Akt pathway. Total Akt protein levels were the same in all HCC cell lines. 
Loss of PTEN protein expression in Mahlavu and Snu475 poorly-differentiated 
aggressive HCC cell lines were associated with hyper-phosphorylation of Akt 
(Figure 4.1). 
 
Figure 4.1: Expression of PTEN and activating phosphorylation of Akt in HCC 
cell lines. Whole-cell lysates (40 µg) were analyzed by Western blotting. 
 
 Next, we examined mRNA level expression of PTEN and showed that gene 
fragment within exons 4 and 5 is lost in the Mahlavu cell line. Akt-specific 
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phosphorylation of downstream proteins GSK3훼/훽 and Bad in the absence of PTEN 
showed that loss of PTEN results in hyper-phosphorylation and hyper-activation of 
Akt as seen by Akt-specific phosphorylation of downstream proteins GSK3훼/훽 and 
Bad (Figure 4.2.B,C). Although the phosphorylation of Bad on Ser136 and GSK3훼/훽 
on Ser21/9 residues are Akt-specific, we also performed kinase activity assay with 
exogenous GSK3훼/훽 to validate Akt-specific activity (Figure 4.2.D). 
 
Figure 4.2: Differential expression of PTEN and subsequent activity of Akt in 
HCC cell lines. A) PCR analysis of the PTEN gene in HCC cell lines. The gene 
fragment within exons 4 and 5 is lost in Mahlavu cell line. B) Whole-cell lysates (40 
µg) were analyzed by Western blotting. Loss of PTEN results in hyper-
phosphorylation of Akt. C) Hyper-phosphorylated Akt hyper-actively phosphorylates 
its downstream targets Bad and GSK3훼/훽. D) Kinase assay on exogenous GSK3훼/훽.  
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4.2. Response of HCC cell lines to PI3K/AKT pathway inhibition 
4.2.1. Cytotoxic activity analysis of classic PI3K/AKT pathway inhibitors 
 We analyzed the cytotoxic activity of two pan-PI3K inhibitors (LY294002, 
Wortmannin) and one Akt inhibitor (Akti-1/2) in Huh7 and Mahlavu cell lines using 
Sulforhodamine B (SRB) assay, as described in the methods section. All inhibitors 
caused growth inhibition, even after 24 hours of exposure (Figure 4.3). However, 
their cytotoxic effect was transient, since remaining cells resumed growing in the 
presence of these inhibitors. For instance, although the highest dose of Wortmannin 
(50 µM) caused 60% growth inhibition at 24 hours, inhibition was lowered to 30% 
after 96 hours. Lower doses resisted growth inhibition completely. We showed that 
these inhibitors can target growth of HCC cells but cannot establish complete 
blockage. Calculation of IC50 values for each time point showed that the required 
concentration of inhibitor to suppress growth and induce cytotoxicity increases with 
time (Table 4.1). 
 
 
Figure 4.3: Inhibitory effects of LY294002, Wortmannin and Akti-1,2 on HCC 
cell growth. % inhibition of cell growth after 24, 48,72 and 96 hours of treatment 
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with the indicated inhibitors. SRB was performed in quadruplets with different 
concentrations (50 µM, 15 µM, 10 µM, 5 µM, 1 µM) 
 
Table 4.1: Time-dependent IC50 values, calculated based on SRB 
    Huh7 HepG2 Mahlavu 
LY294002 24h 4.0 µM 25.0 µM 7.0 µM 
48h 2.2 µM 3.4 µM 8.0 µM 
72h 3.8 µM 5.8 µM 8.7 µM 
96h 4.2 µM 10.5 µM 24.0 µM 
Wortmannin 24h 26.0 µM 29.0 µM 20.0 µM 
48h 5.5 µM 18.9 µM 8.1 µM 
72h 17.8 µM 11.3 µM 36.9 µM 
96h 36.1 µM 37.6 µM > 50 µM 
Akti-1,2 24h 4.5 µM 18.0 µM 10.0 µM 
48h 2.3 µM 2.7 µM 21.1 µM 
72h 5.3 µM 4.5 µM 9.0 µM 
96h 9.8 µM 5.6 µM 69.4 µM 
 
4.2.2. Apoptotic cell death caused by classic PI3K/AKT pathway inhibitors 
 After showing the growth-inhibitory function of kinase inhibitors, we 
examined their role in the induction of apoptotic cell death. Inhibitors were used at 
their IC50 (concentration causing 50% inhibition) values calculated from the growth 
inhibition graphs, as explained in methods section (LY294002 (Huh7: 4 µM, HepG2: 
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25 µM, Mahlavu: 7 µM), Wortmannin (Huh7: 26 µM, HepG2: 29 µM, Mahlavu: 20 
µM), Akti-1,2 (Huh7: 4.5 µM, HepG2: 18 µM, Mahlavu: 10 µM). Cells were treated 
with the indicated inhibitors for 24 hours and their pro-apoptotic effect was assessed 
by Poly ADP-ribosyl polymerase (PARP) cleavage analysis using western blot. All 
inhibitors induced typical PARP cleavage from 113 kDa to 89 and 24 kDa fragments 
by caspase-3 during apoptosis (Figure 4.4.A) (Soldani & Scovassi, 2002). Pro-
apoptotic effect of kinase inhibitors was further validated by Hoechst staining, which 
shows morphological features of apoptosis, i.e. chromatin condensation and 
fragmented nuclei (Figure 4.4.B). We showed that inhibition of PI3K/AKT signaling 
with well-known kinase inhibitors disrupts growth of HCC cells and induces cell 
death independent of Akt activation status.  
 
Figure 4.4: Induction of apoptosis in HCC cells upon treatment with LY294002, 
Wortmannin and Akti-1,2 for 24 hours at their IC50s. A) Western blot analysis of 
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PARP cleavage. B) Immunofluorescence analysis of Hoechst-stained apoptotic cells. 
White arrows indicate apoptotic cells. 
   
4.3. Expression and activity of critical components of PI3K/AKT/mTOR and 
RAF/MEK/ERK signaling pathways 
 We selected the well-differentiated (epithelial-like, less malignant) Huh7 cell 
line with intact PTEN and the poor-differentiated (mesenchymal-like, highly 
malignant) Mahlavu with PTEN loss for our further experiments. Initially, we 
demonstrated PI3K/AKT and MEK/ERK signaling status in these cell lines (Figure 
4.5). Not only Akt, but also Erk kinase is hyper-active in the aggressive Mahlavu cell 
line. Active Akt phosphorylates and thereby inhibits the FoxO1 transcription factor, 
and promotes cell cycle progression through Rb. 
    
Figure 4.5: Expression and activity of PI3K/AKT/mTOR and RAF/MEK/ERK 
signaling pathways in selected HCC cell lines. 
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4.4. Cytotoxic activity analysis of PI3K/AKT signaling pathway inhibitors 
 We analyzed the cytotoxic activity of PI3K/AKT signaling pathway 
inhibitors in Huh7 and Mahlavu cell lines using the SRB assay, and calculated their 
IC50 values at 72 hours of incubation (Table 4.2). In addition to SRB, we used 
RTCES assay to monitor real-time, dynamic changes in cell growth in inhibitor-
treated Huh7 (Figure 4.6) and Mahlavu cells (Figure 4.7) and calculated their IC50 
values at 72 hours of incubation (Table 4.3). 
 
Table 4.2: IC50 values at 72 hours, calculated based on SRB 
 
Huh7 Mahlavu 
Sorafenib 8.0 µM 6.6 µM 
LY294002 3.8 µM 8.7 µM 
Wortmannin 17.8 µM 36.9 µM 
ZSTK474 6.6 µM 6.7 µM 
PI-103 4.0 µM 1.7 µM 
Rapamycin 0.1 µM 0.1 µM 
PI3Ki-α <0.3 µM <0.3 µM 
PI3Ki-β >40.0 µM >40.0 µM 
Akti-1,2 5.3 µM 9.0 µM 
Akti-2 22.7 µM 13.8 µM 
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Figure 4.6: Real-time cell growth analysis of kinase inhibitors in Huh7 cells. 
Huh7 cells were treated with the indicated kinase inhibitors for 72 hours. Black line 
represents control cells treated with DMSO. Dose curves are color-coded, red 
representing the highest dose and orange representing the lowest for each inhibitor. 
Best dose ranges of each inhibitor were selected to demonstrate dose-dependent 
cytotoxicity.  
Sorafenib, PI3Ki-β, Akti-2, Akti-1,2, LY294002: 40µM, 20µM, 10µM, 5µM, 2.5µM 
ZSTK474, PI-103: 20µM, 10µM, 5µM, 2.5µM, 1.25µM 
PI3Ki-α: 1µM, 0.5µM, 0.25µM, 0.125µM,  0.0625µM 
Rapamycin: 6.4µM, 1.6µM, 0.4µM, 0.1µM, 0.025µM 
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Figure 4.7: Real-time cell growth analysis of kinase inhibitors in Mahlavu cells. 
Mahlavu cells were treated with the indicated kinase inhibitors for 72 hours. Black 
line represents control cells treated with DMSO. Dose curves are color-coded, red 
representing the highest dose and orange representing the lowest for each inhibitor. 
Best dose ranges of each inhibitor were selected to demonstrate dose-dependent 
cytotoxicity.  
Sorafenib, PI3Ki-β, Akti-2, Akti-1,2, LY294002: 40µM, 20µM, 10µM, 5µM, 2.5µM 
ZSTK474, PI-103: 20µM, 10µM, 5µM, 2.5µM, 1.25µM 
PI3Ki-α: 1µM, 0.5µM, 0.25µM, 0.125µM,  0.0625µM 
Rapamycin: 6.4µM, 1.6µM, 0.4µM, 0.1µM, 0.025µM 
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Table 4.3: IC50 values at 72 hours, calculated based on RTCES 
 
Huh7 Mahlavu 
Sorafenib 10 µM 10 µM 
LY294002 10 µM 10 µM 
Wortmannin 10 µM 10 µM 
ZSTK474 10 µM 8 µM 
PI-103 12 µM 10 µM 
Rapamycin 0.1 µM 0.1 µM 
PI3Ki-α 0.1 µM 0.1 µM 
PI3Ki-β 10 µM 15 µM 
Akti-1,2 10 µM 10 µM 
Akti-2 10 µM 8 µM 
 
 Differences in the calculated IC50 values based on SRB and RTCES can be 
explained with regard to the underlying principle of the assays. SRB assay measures 
protein content of attached cells and uses the amount of protein-bound SRB to 
estimate the number of adherent alive cells. RTCES, on the other hand, uses the area 
occupied by cells in the plate to estimate the number of adherent alive cells. Both 
assays have their own advantages and disadvantages. For instance, SRB can biasedly 
estimate lower IC50 in cells treated with drugs that can inhibit protein synthesis, 
such as PI-103. Likewise, RTCES can biasedly estimate higher IC50 in cells treated 
with drugs that cause vacuolization. Therefore, we treated cells with various 
concentrations of drugs and analyzed their morphology under light microscope 
(Figure 4.8). Finally we decided to use the concentrations given in Table 4.4 for our 
further experiments. 
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Figure 4.8: Light microscope images of HCC cells treated with inhibitors at 
concentrations given in Table 4.4.  
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Table 4.4: Concentration of each inhibitor chosen for our experiments 
Inhibitor Concentration 
Sorafenib 10 µM 
LY294002 10 µM 
Wortmannin 10 µM 
ZSTK474 10 µM 
PI-103 10 µM 
Rapamycin 0.1 µM 
PI3Ki-α 0.1 µM 
PI3Ki-β 10 µM 
Akti-1,2 10 µM 
Akti-2 10 µM 
 
4.5. Effect of PI3K/AKT signaling pathway inhibitors on cell cycle 
 First of all, we analyzed the effect of all inhibitors on viability and cell cycle 
progression in HCC cells. Cells were treated with concentration indicated in Table 
4.4, and were incubated for 72 hours. Propidium iodide, which intercalates into 
double-stranded DNA, was used to evaluate cell viability and DNA content in flow 
cytometric cell cycle analysis. Distribution of viable cells in G1, S and G2/M phases 
of cell cycles, and the percentage of apoptotic cells represented by the sub-G1 
population were analyzed. None of the inhibitors had significant effect on the cell 
cycle distribution of cells. Treatment with Sorafenib and PI3Ki-훼 resulted in 
enhanced sub-G1 population, indicating induction of apoptosis in both cell lines 
(Figure 4.9). Sorafenib was more effective in Huh7 cells, while PI3Ki-훼 was more 
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effective in Mahlavu cell lines, which depend on PTEN-loss mediated hyper-active 
PI3K signaling. 
 
Figure 4.9: Flow Cytometric Analysis of Cellular DNA Content. Sub-G1 
population represents apoptotic cells. 
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4.6. Effect of PI3K/AKT signaling pathway inhibitors on migration 
 In addition to cell survival and proliferation, PI3K/AKT/mTOR and 
Raf/MEK/ERK pathways are known to regulate migration of cells. Since the 
inhibitors, except Sorafenib and PI3Ki-훼, did not affect cell cycle progression and 
viability of HCC cells, we examined their role in migration.  We performed a wound-
healing assay (scratch assay), and took pictures immediately after the scratch was 
made, after 24 hours and after 48 hours to show the migration of cells to the 
wounded area. Wound closure percentage after 48 hours was calculated to show the 
migratory capacity of cells in the presence of kinase inhibitors in Huh7 (Figure 4.10) 
and Mahlavu (Figure 4.11) cell lines. Wortmannin and Rapamycin could not reduce 
migration of Mahlavu cells, but they were able to affect Huh7 cells. Sorafenib, 
PI3Ki-!, Akti-1,2 and Akti-2 reduced migration significantly (p<0.001) in both 
Huh7 and Mahlavu. 
 
 63 
Figure 4.10: Effect of kinase inhibitors on migration of Huh7 cells. Wound 
closure percentage after 48 hours of incubation with the indicated kinase inhibitors 
represents the effect of inhibitors on migration. Pictures were taken at 3 time points: 
immediately after the scratch was made, after 24 hours and after 48 hours. 
Statistically significant differences in migration compared to DMSO controls were 
represented (**: p<0.001, *: p<0.01). 
 
 
Figure 4.11: Effect of kinase inhibitors on migration of Mahlavu cells. Wound 
closure percentage after 48 hours of incubation with the indicated kinase inhibitors 
represents the effect of inhibitors on migration. Pictures were taken at 3 time points: 
immediately after the scratch was made, after 24 hours and after 48 hours. 
Statistically significant differences in migration compared to DMSO controls were 
represented (**: p<0.001, *: p<0.01). 
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4.7. Effect of PI3K/AKT signaling pathway inhibitors on apoptosis 
  PI3K/AKT/mTOR and Raf/MEK/ERK signaling pathways maintain cell 
survival, proliferation and migration. All kinase inhibitors in this study showed 
cytotoxic anti-proliferative activity at various doses ranging from 40µM to 0.1µM. 
Analysis of their cytotoxic mechanism of actions at clinically relevant doses (10µM 
at most) revealed anti-migratory effects of Akti-1,2 and Akti-2 and pro-apoptotic 
roles of Sorafenib and PI3Ki-훼. We further examined the effect of kinase inhibitors 
on apoptotic cell death and showed caspase-mediated PARP cleavage in cells treated 
with Sorafenib and PI3Ki-훼, as an indicator of apoptosis  (Figure 4.12.A) (Soldani & 
Scovassi, 2002). Apoptotic cell death in both Huh7 and Mahlavu cells were 
associated with cytochrome c release from mitochondria, which is necessary to 
activate pro-apoptotic caspase cascade (Goldstein, Waterhouse, Juin, Evan, & Green, 
2000). Pro-apoptotic effect of kinase inhibitors was further validated by Hoechst 
staining, which shows morphological features of apoptosis, i.e. chromatin 
condensation and fragmented nuclei (Figure 4.12.B). 
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Figure 4.12: Effect of kinase inhibitors on apoptotic cell death. A) PARP 
cleavage analysis with Western blot using 25µg whole cell lysates. Cells were treated 
with the indicated inhibitors for 72 hours. B) Immunofluorescence analysis of 
Cytochrome c (green) and Hoechst (blue) staining. Cells were treated with the 
indicated inhibitors for 48 hours. 
 
 66 
4.8. Combinational treatment of most potential PI3K/AKT signaling pathway 
inhibitors with Sorafenib 
4.8.1 Synergistic cytotoxicity analysis  
 PI3Ki-!, Akti-1,2 and Akti-2 were the most promising drug candidates in our 
9 PI3K/AKT/mTOR pathway kinase inhibitor panel. We showed that Sorafenib and 
PI3Ki-! effectively inhibits growth and induces apoptosis in Huh7 and Mahlavu cell 
lines. PI3Ki-! is effective even at very low doses (0.1µM). Although Akti-1,2 and 
Akti-2 did not induce significant anti-growth or pro-apoptotic mechanisms at 10µM 
concentration, they were highly effective in reducing migration in both cell lines. 
Therefore, we addressed the effectiveness of a combined treatment of Sorafenib with 
PI3Ki-!, Akti-1,2 and Akti-2. We compared growth of Sorafenib-treated cells and 
combination-treated cells with the RTCES assay.  
 Co-treatment of Sorafenib and PI3Ki-! resulted in synergistic growth 
inhibition in both cell lines. Both PI3Ki-! and PI3Ki-! showed synergistic growth 
inhibition in Huh7 (Figure 4.13). However, only co-treatment with PI3Ki-! led to 
synergistic growth inhibition in the Mahlavu cell line (Figure 4.14). Interestingly, 
combined treatment of Sorafenib with PI3Ki-! exhibited an antagonistic effect and 
promoted cell growth.  Co-targeting Raf with Sorafenib and alpha-isoform of PI3K 
with PI3Ki-! simultaneously can inhibit growth completely in Mahlavu cells. Yet, 
co-targeting Raf with Sorafenib and beta-isoform of PI3K (p110!) with PI3Ki-! 
probably intensifies signaling from the alpha isoform (p110!) and promotes growth. 
Indeed, Mahlavu cells are more sensitive to co-treatment of Sorafenib and PI3Ki-! 
than Huh7 cells. Collectively, these findings suggest that PTEN-loss induced 
constitutively active PI3K/Akt signaling in Mahlavu cells depend primarily on the 
alpha isoform (p110!).  
 We have shown that Akti-1 and Akti-2 cause growth inhibition and reduce 
migration but cannot induce apoptosis when used at 10µM. Interestingly, co-
treatment of Sorafenib and either Akti-1 or Akti-2 resulted in synergistic growth 
inhibition in both cell lines (Figures 4.15 and 4.16).  These results highlight the 
therapeutic potential of combining Sorafenib with PI3Ki-!, Akti-1,2 or Akti-2 for the 
treatment of HCC (Figure 4.17). 
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Figure 4.13: Real-time cell growth analysis of Huh7 cells targeted with isoform-
specific PI3K kinase inhibitors in combination with Sorafenib. Huh7 cells were 
treated with the indicated kinase inhibitors for 72 hours. RTCES-based cell growth 
values (y-axis) were plotted against time (x-axis). Black line represents control cells 
treated with DMSO. Growth of Sorafenib treated cells are represented in blue and 
PI3K inhibitor treated cells are in green. Red plot represents the growth of cells 
treated with both Sorafenib and PI3K inhibitor in combination. 
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Figure 4.14: Real-time cell growth analysis of Mahlavu cells targeted with 
isoform-specific PI3K kinase inhibitors in combination with Sorafenib. Huh7 
cells were treated with the indicated kinase inhibitors for 72 hours. RTCES-based 
cell growth values (y-axis) were plotted against time (x-axis). Black line represents 
control cells treated with DMSO. Growth of Sorafenib treated cells are represented in 
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blue and PI3K inhibitor treated cells are in green. Red plot represents the growth of 
cells treated with both Sorafenib and PI3K inhibitor in combination.  
 
Figure 4.15: Real-time cell growth analysis of Huh7 cells targeted with isoform-
specific Akt inhibitors in combination with Sorafenib. Huh7 cells were treated 
with the indicated kinase inhibitors for 72 hours. RTCES-based cell growth values 
(y-axis) were plotted against time (x-axis). Black line represents control cells treated 
with DMSO. Growth of Sorafenib treated cells are represented in blue and Akt 
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inhibitor treated cells are in green. Red plot represents the growth of cells treated 
with both Sorafenib and Akt inhibitor in combination. 
 
Figure 4.16: Real-time cell growth analysis of Mahlavu cells targeted with 
isoform-specific Akt inhibitors in combination with Sorafenib. Mahlavu cells 
were treated with the indicated kinase inhibitors for 72 hours. RTCES-based cell 
growth values (y-axis) were plotted against time (x-axis). Black line represents 
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control cells treated with DMSO. Growth of Sorafenib treated cells are represented in 
blue and Akt inhibitor treated cells are in green. Red plot represents the growth of 
cells treated with both Sorafenib and Akt inhibitor in combination. 
 
 
Figure 4.17: Synergistic growth-inhibitory effects of Sorafenib and PI3K/Akt 
inhibitors. RTCES-based cell growth values (y-axis) were plotted against time (x-
axis). Cell growth inhibition was calculated as described in the methods section. 
Growth of cells treated with Sorafenib is represented in blue and growth of cells 
treated with other inhibitors is in green. Red plot represents the growth of cells 
treated with combination of two inhibitors. 
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4.8.2 Effect of combined therapy on downstream signaling 
 We showed that enhanced cytotoxicity in combination of Sorafenib with 
either PI3Ki-! or Akti-2 involves complete inhibition of p-Akt, p-Erk, cyclin D1 and 
Rb and activation of p21 (Figure 4.18). 
 
Figure 4.18: Inhibition of cell cycle progression in combined therapies. 
 
4.8.3 Enhanced apoptotic cell death in combinational treatments 
 Synergistic growth-inhibitory effects of Sorafenib and PI3K/Akt inhibitors 
were in correlation with apoptotic morphology of cells. Co-treatment of Sorafenib 
with PI3Ki-훼, Akti-1,2 and Akti-2 reduced the number of cells compared to single 
treatment of Sorafenib and induced apoptosis, as seen by rounded cells detaching 
from the surface (Figure 4.19). 
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Figure 4.19: Light microscope images of HCC cells co-treated with Sorafenib 
and PI3K/Akt inhibitors. Images were color-coded for easier interpretation. DMSO 
controls are in gray. Blue pictures represent Sorafenib treated cells. Green pictures 
represent cells treated only with PI3K/Akt inhibitors. Images of cells co-treated with 
Sorafenib and PI3K/Akt inhibitors are in red. 
 
 We assessed cell viability with flow cytometric analysis using DNA-
intercalating stain propidium iodide. Cells treated with Sorafenib were compared to 
co-targeted cells. Combination treatments with PI3Ki-훼, Akti-1,2 and Akti-2 
enhanced apoptotic sub-G1 population compared to single treatment with Sorafenib. 
Sorafenib/PI3Ki-훽 combination in Mahlavu showed antagonistic effect as anticipated 
from the previous RTCES results (Figure 4.20). Isoform-specific Akt inhibitor, Akti-
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2, did not induce apoptosis by itself but enhanced pro-apoptotic effect of Sorafenib 
significantly (from 31% to 100% in Huh7 and from 22% to 87% in Mahlavu). 
 
Figure 4.20: Flow Cytometric Analysis of Cellular Viability in cells co-treated 
with Sorafenib and PI3K/Akt inhibitors. Sub-G1 population represents apoptotic 
cells.  
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4.8.4 Synergistic anti-tumor activity of combinational treatments in vivo  
 Our in vitro experiments showed that combining Sorafenib with PI3Ki-훼 or 
Akti-2 synergistically inhibits growth and induces apoptosis in HCC cells as 
compared to single-agent treatment. While PI3Ki-훼 has cytotoxic activity as single 
agent at 0.1µM in both cell lines, Akti-2 has no effect as single agent even at 10µM. 
However, synergistic cytotoxicity induced by combination of Sorafenib with Akti-2 
is much more striking. Therefore, we performed in vivo xenograft experiments to 
assess the anti-tumor effects of Sorafenib/Akti-2 combination. 
 Nude mice inoculated subcutaneously with Mahlavu cells were treated with 
30 mg/kg Sorafenib or 7.5 mg/kg Akti-2 or combination of both 5 days a week for 3 
weeks. At the end of the 3-week treatment, MRI images were taken and tumors were 
excised. MRI images showed reduction of tumor size in mice treated with 
combination compared to Sorafenib alone (Figure 4.21).  
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Figure 4.21: Synergistic anti-tumor activity of Sorafenib and Akti-2 in vivo. 
Mahlavu xenograft nude mice were treated with 30 mg/kg Sorafenib or 7.5 mg/kg 
Akti-2 or combination of both 5 days a week for 3 weeks by oral gavage. At the end 
of 3-week treatment, MRI images were taken. 
 
 Reduction of the tumor size was significant in all treatments compared to 
control group (p<0.005). However, combination of Sorafenib and Akti-2 did not 
result in significant reduction in tumor volume compared to Sorafenib as single agent 
(Figure 4.22). Large tumors in combination-treated mice became softer than tumors 
of Sorafenib-treated mice after 1 weeks of treatment, suggesting presence of 
necrosis-induced inflammation and swelling. After 2 weeks of treatment, 2 out of 5 
mice developed large visible intra-tumoral necrotic areas  (Figure 4.23).  
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Figure 4.22: Reduced tumor size in mice treated with Sorafenib and Akti-2. 
Mahlavu xenograft nude mice were treated with 30 mg/kg Sorafenib or 7.5 mg/kg 
Akti-2 or combination of both 5 days a week for 3 weeks by oral gavage. Reduction 
of tumor size was significant in all treatments compared to control group (*: 
p<0.005, **: p<0.001). 
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Figure 4.23: Temporary increase in tumor size associated with intra-tumoral 
necrosis in combination-treated mice. Mahlavu xenograft nude mice were treated 
with 30 mg/kg Sorafenib and 7.5 mg/kg Akti-2 for 3 weeks.  
 
 In HCC patients, anti-angiogenic effect of Sorafenib is characterized by intra-
tumoral necrosis and a temporary, but substantial, increase in tumor size (Horger et 
al., 2009).  Studies in HCC xenograft models showed that Sorafenib causes growth 
inhibition at 30 mg/kg and partial tumor regressions at 100 mg/kg (Liu, Ho, Chen, & 
Lai, 2012; Liu et al., 2006). Since Sorafenib is a multi-kinase inhibitor with systemic 
side effects, we addressed whether low dose (30 mg/kg) Sorafenib can establish 
higher anti-tumor efficacy when combined with a specific inhibitor, Akti-2. Single 
treatment with Sorafenib initiated intra-tumoral necrosis in 1 out of 5 mice 3 weeks 
post-treatment, while combination treatment resulted in substantial tumor necrosis 
and reduced tumor density (Figure 4.24). Enhanced anti-angiogenic effects of 
combination therapy promoted tumor necrosis and reduced tumor mass significantly 
(Sorafenib: 85% reduction, Combination: 93% reduction, p<0.001) (Figure 4.25).  
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Figure 4.24: Enhanced anti-angiogenic effects of combination therapy 
supporting tumor necrosis. Mahlavu xenograft nude mice were treated with 30 
mg/kg Sorafenib and 7.5 mg/kg Akti-2 for 3 weeks. 
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Figure 4.25: Reduced tumor mass in mice treated with Sorafenib and Akti-2. 
Mahlavu xenograft nude mice were treated with 30 mg/kg Sorafenib or 7.5 mg/kg 
Akti-2 or combination of both 5 days a week for 3 weeks by oral gavage. A) Line-
graph representation of tumor growth. B) Bar-graph representation of tumor weight. 
(*: p<0.005 , **: p≤0.001) 
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4.9. Identification of optimal reference genes for microarray normalization 
We performed microarray experiments to reveal transcriptome level 
alterations in HCC cells in response to drug treatment. The basic, yet the most 
critical requirement of microarray analysis and all other platforms that process omics 
data is selection of reference genes in order to ensure reliable and statistically 
accurate comparison of samples. Housekeeping genes are constitutively expressed in 
all cells in all conditions and are involved in the maintenance of basal cellular 
functions such as metabolism, gene expression, protein synthesis and cell signaling 
(Hsiao et al., 2001; Warrington, Nair, Mahadevappa, & Tsyganskaya, 2000). Hence, 
they are presumed to have steady expression levels unaffected by tissue type or 
experimental condition and therefore have been used as reference genes for 
normalization of transcriptome data. However, even the most commonly used 
reference genes (ACTB, GAPDH, TBP) are differentially expressed in different 
pathological stages of HCC (Gao et al., 2008; Waxman & Wurmbach, 2007). 
Moreover, GAPDH and ACTB are direct targets of miR-644a and have several 
pseudogenes, making them less reliable to be used as reference genes (Sikand, Singh, 
Ebron, & Shukla, 2012; Stark, Brennecke, Bushati, Russell, & Cohen, 2005; Sun, Li, 
Luo, & Liao, 2012). Therefore, first step in the analysis of transcriptome data should 
be selection of the most suitable reference genes. In order to confirm the reliability of 
available housekeeping gene sets and to determine a global list of constitutively and 
invariably expressed genes that can be used as reference genes in HCC, we analyzed 
expression patterns of 9090 microarray samples grouped into 381 NCBI-GEO 
datasets. We identified novel reference genes based on their coefficient of variation 
and percentage of occurrence in all GEO datasets using Receiver Operating 
Characteristic (ROC) curves and classified them based on Medical Subject Headings 
(MeSH) associated with the transcriptome study that was published and indexed by 
the National Library of Medicine. 
Expressions of 17 genes (AARS, ACTB, CFL1, EEF2, GAPDH, GSTO1, 
H2AFZ, HBXIP, RPL30, RPL41, RPL7, RPN2, RPS10, RPS17, RPS3A, SOD1, 
TPT1), which were most commonly observed in gene sets associated with various 
MeSH categories, were compared in 8 HCC cell lines (HepG2, FOCUS, Mahlavu, 
Hep3B, Hep3B-TR, Huh7, SkHep1, and PLC) by RT-qPCR.  Coefficient of 
Variation (CV) of each gene was calculated as the ratio of standard deviation to the 
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mean relative expression. geNorm and NormFinder software were used for stability 
analysis (Table 4.5). GeNorm calculates an expression stability value for each gene 
based on the average pairwise variation between all tested genes. The genes are 
ranked according to their expression stability through stepwise exclusion of the least 
stable gene (Vandesompele et al., 2002). NormFinder ranks the candidate reference 
genes with minimal estimated intra- and inter-group variation and calculates an 
expression stability value for each gene (Andersen, Jensen, & Ørntoft, 2004). The 
selected reference genes were ranked according to their CV determined by qPCR and 
stability measures determined by geNorm and NormFinder (Table 4.6, Figure 4.26). 
Ribosomal genes are the optimal reference genes for normalization of HCC cell 
lines. 
 
Table 4.5: Stability values of reference genes calculated by NormFinder and 
geNorm. Genes with the lowest values are the most stable genes. 
 
NormFinder geNorm 
RPS10 0.19 0.00 
RPL41 0.29 0.00 
RPL7 0.19 0.22 
RPS17 0.19 0.27 
RPS3A 0.23 0.30 
RPL30 0.11 0.31 
GAPDH 0.25 0.38 
CFL1 0.29 0.42 
HBXIP 0.29 0.45 
H2AFZ 0.33 0.48 
ACTB 0.43 0.50 
EEF2 0.38 0.53 
AARS 0.60 0.58 
SOD1 0.75 0.65 
TPT1 0.72 0.72 
RPN2 0.78 0.79 
GSTO1 1.17 0.91 
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Figure 4.26: Stability of reference genes in HCC cell lines. NormFinder and 
geNorm results were represented in dark gray and light gray respectively. 
 
Table 4.6: Stability order of reference genes based on CV, NormFinder and 
geNorm analysis. Genes are sorted from the most stable to the least stable. 
CV NormFinder geNorm 
RPL7 RPL30 RPL41 
RPS17 RPL7 RPS10 
RPL30 RPS17 RPL7 
CFL1 RPS10 RPS17 
EEF2 RPS3A RPS3A 
GAPDH GAPDH RPL30 
RPS10 CFL1 GAPDH 
RPS3A HBXIP CFL1 
H2AFZ RPL41 HBXIP 
RPL41 H2AFZ H2AFZ 
ACTB EEF2 ACTB 
HBXIP ACTB EEF2 
AARS AARS AARS 
TPT1 TPT1 SOD1 
RPN2 SOD1 TPT1 
SOD1 RPN2 RPN2 
GSTO1 GSTO1 GSTO1 
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4.10 Large-scale gene expression analysis of classic PI3K/AKT pathway 
inhibitors 
 In order to identify the effect of kinase inhibitors at the gene expression level, 
we performed microarray experiments. Initially we analyzed the effect of classic 
PI3K/AKT/mTOR inhibitors, LY294002, Wortmannin, Akti-1,2 and Rapamycin on 
gene expression in Huh7 and Mahlavu cells. Most differentially expressed top 100 
genes (p < 0.05, fold-change ≥ 2) in response to treatment with LY294002, 
Wortmannin and Rapamycin for 48 hours were similar in cells, while Akti-1,2 
treatment led to a different gene expression profile (Figure 4.27). All treatments lead 
to alterations in genes associated with metabolic processed in Huh7. LY294002 
regulates chromatin assembly and nucleosome organization in both cell lines.  
LY294002, Wortmannin and Rapamycin promote expression of pro-apoptotic genes 
in Mahlavu cell line. Wortmannin and Rapamycin also regulate genes involved in 
cell cycle in Mahlavu. Additionally, Wortmannin regulates development, 
angiogenesis, migration and immune response in Mahlavu cells. Akti-1,2, on the 
other hand, regulates migration in Huh7 and is associated mostly with anti-apoptotic 
processes in Mahlavu (Tables 4.7 and 4.8). 
 Although in vitro experiments showed that inhibiting the PI3K/AKT/mTOR 
pathway with LY294002, Wortmannin, Akti-1,2 and Rapamycin is cytotoxic in HCC 
cells, transcriptome-level gene expression changes in inhibitor treated cells compared 
to untreated cells were not more than 1.5 fold (log2(fold change) ≤ 1.5). Therefore, 
we implemented a signal transduction score-flow algorithm that uses transcriptome 
data to imitate protein-level signal flow inside cells and assigns a quantitative score 
for each gene in the interactome networks gathered from KEGG database as 
described in the methods section (Isik et al., 2012). Network-level signaling analysis 
showed that kinase inhibitors targeting PI3K/AKT/mTOR pathway regulate cell 
cycle, apoptosis, migration, angiogenesis and DNA repair processes, through 
differential regulation of downstream effectors (Figures 4.28 – 4.31). 
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Figure 4.27: Heatmap representation of top 100 differentially expressed genes.  
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Table 4.7: Biological processes associated with top 100 differentially expressed 
genes in Huh7 cells (enriched with p<0.05) 
Treatment GO ID GO Term 
LY294002 
GO:0006334 nucleosome assembly 
GO:0031497 chromatin assembly 
GO:0065004 protein-DNA complex assembly 
GO:0034728 nucleosome organization 
GO:0006323 DNA packaging 
GO:0006333 chromatin assembly or disassembly 
GO:0034622 cellular macromolecular complex assembly 
GO:0045661 regulation of myoblast differentiation 
GO:0034621 cellular macromolecular complex subunit organization 
GO:0008203 cholesterol metabolic process 
Wortmannin 
GO:0043434 response to peptide hormone stimulus 
GO:0007398 ectoderm development 
GO:0042493 response to drug 
GO:0015838 betaine transport 
GO:0015879 carnitine transport 
GO:0000050 urea cycle 
GO:0019627 urea metabolic process 
Akti-1,2 
GO:0016125 sterol metabolic process 
GO:0019318 hexose metabolic process 
GO:0008202 steroid metabolic process 
GO:0033555 multicellular organismal response to stress 
GO:0005996 monosaccharide metabolic process 
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GO:0006952 defense response 
GO:0006006 glucose metabolic process 
GO:0009611 response to wounding 
Rapamycin 
GO:0042493 response to drug 
GO:0016125 sterol metabolic process 
GO:0015838 betaine transport 
GO:0015879 carnitine transport 
GO:0008203 cholesterol metabolic process 
GO:0015697 quaternary ammonium group transport 
GO:0008202 steroid metabolic process 
GO:0051181 cofactor transport 
GO:0015695 organic cation transport 
GO:0051180 vitamin transport 
GO:0006694 steroid biosynthetic process 
GO:0016126 sterol biosynthetic process 
 
 
Table 4.8: Biological processes associated with top 100 differentially expressed 
genes in Mahlavu cells (enriched with p<0.05) 
Treatment GO ID GO Term 
LY294002 
GO:0034621 cellular macromolecular complex subunit organization 
GO:0034728 nucleosome organization 
GO:0034622 cellular macromolecular complex assembly 
GO:0030203 glycosaminoglycan metabolic process 
GO:0042981 regulation of apoptosis 
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GO:0043067 regulation of programmed cell death 
GO:0010941 regulation of cell death 
GO:0006022 aminoglycan metabolic process 
GO:0043933 macromolecular complex subunit organization 
GO:0030212 hyaluronan metabolic process 
Wortmannin 
GO:0001525 angiogenesis 
GO:0001944 vasculature development 
GO:0042981 regulation of apoptosis 
GO:0051094 positive regulation of developmental process 
GO:0043067 regulation of programmed cell death 
GO:0010941 regulation of cell death 
GO:0032570 response to progesterone stimulus 
GO:0048514 blood vessel morphogenesis 
GO:0043525 positive regulation of neuron apoptosis 
GO:0001568 blood vessel development 
GO:0048641 regulation of skeletal muscle tissue development 
GO:0022402 cell cycle process 
GO:0006955 immune response 
GO:0008219 cell death 
GO:0010033 response to organic substance 
GO:0016265 death 
GO:0040017 positive regulation of locomotion 
GO:0002520 immune system development 
GO:0051329 interphase of mitotic cell cycle 
GO:0007050 cell cycle arrest 
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GO:0051325 interphase 
GO:0007049 cell cycle 
GO:0016202 regulation of striated muscle tissue development 
GO:0048634 regulation of muscle development 
GO:0051726 regulation of cell cycle 
GO:0045597 positive regulation of cell differentiation 
GO:0000082 G1/S transition of mitotic cell cycle 
GO:0045785 positive regulation of cell adhesion 
GO:0007179 transforming growth factor beta receptor signaling pathway 
GO:0043066 negative regulation of apoptosis 
GO:0007184 SMAD protein nuclear translocation 
GO:0032026 response to magnesium ion 
GO:0051240 positive regulation of multicellular organismal process 
GO:0006915 apoptosis 
GO:0043069 negative regulation of programmed cell death 
GO:0060548 negative regulation of cell death 
GO:0008285 negative regulation of cell proliferation 
GO:0045765 regulation of angiogenesis 
GO:0012501 programmed cell death 
GO:0043536 
positive regulation of blood vessel endothelial cell 
migration 
GO:0009725 response to hormone stimulus 
GO:0000278 mitotic cell cycle 
Akti-1,2 
GO:0042981 regulation of apoptosis 
GO:0043067 regulation of programmed cell death 
GO:0010941 regulation of cell death 
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GO:0006916 anti-apoptosis 
GO:0043066 negative regulation of apoptosis 
GO:0043069 negative regulation of programmed cell death 
GO:0060548 negative regulation of cell death 
GO:0032355 response to estradiol stimulus 
GO:0010639 negative regulation of organelle organization 
Rapamycin 
GO:0007049 cell cycle 
GO:0042981 regulation of apoptosis 
GO:0043067 regulation of programmed cell death 
GO:0010941 regulation of cell death 
GO:0043632 modification-dependent macromolecule catabolic process 
GO:0019941 modification-dependent protein catabolic process 
GO:0051603 proteolysis involved in cellular protein catabolic process 
GO:0044257 cellular protein catabolic process 
GO:0030163 protein catabolic process 
GO:0006508 proteolysis 
GO:0070271 protein complex biogenesis 
GO:0006461 protein complex assembly 
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Figure 4.28: Cytoscape representation of differential regulation of PI3K/Akt 
pathway in Huh7 cells treated with LY294002 and Wortmannin. 
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Figure 4.29: Cytoscape representation of differential regulation of PI3K/Akt 
pathway in Huh7 cells treated with Akti-1,2 and Rapamycin. 
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Figure 4.30: Cytoscape representation of differential regulation of PI3K/Akt 
pathway in Mahlavu cells treated with LY294002 and Wortmannin. 
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Figure 4.31: Cytoscape representation of differential regulation of PI3K/Akt 
pathway in Mahlavu cells treated with Akti-1,2 and Rapamycin. 
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4.11 Large-scale gene expression analysis of cells co-treated with Sorafenib and 
PI3K/AKT pathway inhibitors  
 We addressed transcriptome level alterations in HCC cells upon treatment 
with Sorafenib and PI3Ki-!! as single agents or co-treatment with both inhibitors. 
Differentially expressed genes (p < 0.01, fold-change > 2) in response to treatment 
with Sorafenib, PI3Ki-!! and combination for 48 hours revealed common and 
inhibitor-specific targets (Figure 4.32). Microarray experiments further identified 
genes that are uniquely targeted in cells receiving combination treatment. Biological 
processes enriched in treated cells (Tables 4.9, 4.10), molecular functions of 
differentially expressed genes involved in these processes (Tables 4.11, 4.12), and 
their contribution to pathways in KEGG database (Tables 4.13, 4.14) were analyzed 
with DAVID and GSEA (gene set enrichment analysis).  
 
 
 
Figure 4.32: Venn diagram showing differentially expressed genes in HCC cells 
upon treatment with Sorafenib and PI3Ki-!! as single agents or co-treatment 
with both inhibitors.  
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Table 4.9: Biological processes affected in treated Huh7 cells (p<0.01) 
 GO ID GO Term 
So
ra
fe
ni
b 
GO:0007584 response to nutrient 
GO:0010033 response to organic substance 
GO:0033273 response to vitamin 
GO:0016125 sterol metabolic process 
GO:0008203 cholesterol metabolic process 
GO:0032526 response to retinoic acid 
GO:0033189 response to vitamin A 
GO:0010038 response to metal ion 
GO:0008202 steroid metabolic process 
GO:0010035 response to inorganic substance 
GO:0031667 response to nutrient levels 
GO:0009891 positive regulation of biosynthetic process 
GO:0010560 positive regulation of glycoprotein biosynthetic process 
GO:0031328 positive regulation of cellular biosynthetic process 
GO:0009991 response to extracellular stimulus 
GO:0016126 sterol biosynthetic process 
GO:0009611 response to wounding 
GO:0009719 response to endogenous stimulus 
GO:0010876 lipid localization 
GO:0006869 lipid transport 
GO:0010557 positive regulation of macromolecule biosynthetic process 
GO:0001568 blood vessel development 
GO:0045935 
positive regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 
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GO:0051173 positive regulation of nitrogen compound metabolic process 
GO:0015718 monocarboxylic acid transport 
GO:0033554 cellular response to stress 
GO:0001944 vasculature development 
GO:0042127 regulation of cell proliferation 
GO:0030522 intracellular receptor-mediated signaling pathway 
GO:0042921 glucocorticoid receptor signaling pathway 
GO:0051291 protein heterooligomerization 
GO:0009725 response to hormone stimulus 
GO:0007242 intracellular signaling cascade 
GO:0051592 response to calcium ion 
GO:0008283 cell proliferation 
GO:0031958 corticosteroid receptor signaling pathway 
GO:0042692 muscle cell differentiation 
GO:0043062 extracellular structure organization 
GO:0031175 neuron projection development 
GO:0006695 cholesterol biosynthetic process 
GO:0008610 lipid biosynthetic process 
GO:0009636 response to toxin 
GO:0070271 protein complex biogenesis 
GO:0006461 protein complex assembly 
GO:0043933 macromolecular complex subunit organization 
PI
3K
i-!  GO:0015031 protein transport GO:0045184 establishment of protein localization 
GO:0008104 protein localization 
GO:0044271 nitrogen compound biosynthetic process 
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C
om
bi
na
tio
n 
GO:0001568 blood vessel development 
GO:0001944 vasculature development 
GO:0048514 blood vessel morphogenesis 
GO:0046907 intracellular transport 
GO:0001525 angiogenesis 
GO:0051270 regulation of cell motion 
GO:0009101 glycoprotein biosynthetic process 
GO:0016192 vesicle-mediated transport 
GO:0009611 response to wounding 
GO:0042551 neuron maturation 
GO:0009100 glycoprotein metabolic process 
GO:0042127 regulation of cell proliferation 
GO:0030334 regulation of cell migration 
GO:0042312 regulation of vasodilation 
GO:0040012 regulation of locomotion 
GO:0016125 sterol metabolic process 
GO:0034383 low-density lipoprotein particle clearance 
GO:0043062 extracellular structure organization 
GO:0010557 positive regulation of macromolecule biosynthetic process 
GO:0010604 positive regulation of macromolecule metabolic process 
GO:0008284 positive regulation of cell proliferation 
GO:0070085 glycosylation 
GO:0043413 biopolymer glycosylation 
GO:0006486 protein amino acid glycosylation 
GO:0031328 positive regulation of cellular biosynthetic process 
GO:0048878 chemical homeostasis 
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GO:0016322 neuron remodeling 
GO:0008203 cholesterol metabolic process 
 
 
Table 4.10: Biological processes affected in treated Mahlavu cells (p<0.01) 
 GO ID GO Term 
So
ra
fe
ni
b 
GO:0006952 defense response 
GO:0009611 response to wounding 
GO:0006954 inflammatory response 
GO:0009620 response to fungus 
PI
3K
i-!  
GO:0051789 response to protein stimulus 
GO:0010604 positive regulation of macromolecule metabolic process 
GO:0045893 positive regulation of transcription, DNA-dependent 
GO:0051254 positive regulation of RNA metabolic process 
GO:0006357 regulation of transcription from RNA polymerase II promoter 
GO:0045935 positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 
GO:0051173 positive regulation of nitrogen compound metabolic process 
GO:0031328 positive regulation of cellular biosynthetic process 
GO:0045941 positive regulation of transcription 
GO:0009891 positive regulation of biosynthetic process 
GO:0010628 positive regulation of gene expression 
C
om
bi
na
tio
n 
GO:0006888 ER to Golgi vesicle-mediated transport 
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Table 4.11: Molecular functions of differentially expressed genes in treated 
Huh7 cells (p<0.01) 
  GO ID GO Term 
Sorafenib 
GO:0046870 cadmium ion binding 
GO:0046914 transition metal ion binding 
GO:0046872 metal ion binding 
GO:0043169 cation binding 
GO:0043167 ion binding 
GO:0008270 zinc ion binding 
GO:0005507 copper ion binding 
GO:0016717 oxidoreductase activity 
GO:0004620 phospholipase activity 
GO:0005543 phospholipid binding 
GO:0019899 enzyme binding 
GO:0003712 transcription cofactor activity 
GO:0008289 lipid binding 
GO:0005545 phosphatidylinositol binding 
GO:0004768 stearoyl-CoA 9-desaturase activity 
GO:0001786 phosphatidylserine binding 
 PI3Ki-! 
GO:0019904 protein domain specific binding 
GO:0032559 adenyl ribonucleotide binding 
GO:0030554 adenyl nucleotide binding 
GO:0019207 kinase regulator activity 
GO:0001883 purine nucleoside binding 
GO:0000166 nucleotide binding 
GO:0001882 nucleoside binding 
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GO:0005524 ATP binding 
GO:0032553 ribonucleotide binding 
GO:0032555 purine ribonucleotide binding 
GO:0017076 purine nucleotide binding 
GO:0042623 ATPase activity, coupled 
GO:0016887 ATPase activity 
GO:0019887 protein kinase regulator activity 
Combination 
GO:0046870 cadmium ion binding 
GO:0005507 copper ion binding 
GO:0008375 acetylglucosaminyltransferase activity 
 
Table 4.12: Molecular functions of differentially expressed genes in treated 
Mahlavu cells (p<0.01) 
  GO ID GO Term 
Sorafenib  -   -  
PI3Ki-!  -   -  
Combination GO:0003723 RNA binding 
 
Table 4.13: KEGG pathways enriched in treated Huh7 cells (p<0.05) 
  KEGG pathway # of Genes 
Sorafenib 
hsa00100:Steroid biosynthesis 5 
hsa04110:Cell cycle 14 
hsa04520:Adherens junction 10 
hsa05215:Prostate cancer 10 
hsa04010:MAPK signaling pathway 21 
hsa01040:Biosynthesis of unsaturated fatty acids 4 
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PI3Ki-! hsa04114:Oocyte meiosis 7 hsa04110:Cell cycle 7 
hsa04914:Progesterone-mediated oocyte maturation 5 
Combination  -  - 
 
Table 4.14: KEGG pathways enriched in treated Mahlavu cells (p<0.05) 
  KEGG pathway # of Genes 
Sorafenib 
hsa04621:NOD-like receptor signaling pathway 3 
hsa04060:Cytokine-cytokine receptor interaction 5 
PI3Ki-! hsa04010:MAPK signaling pathway 5 
Combination  -  - 
 
 Microarray analysis emphasized the wide-ranging effect of the multi-kinase 
inhibitor, Sorafenib. Cellular processes that are regulated specifically in response to 
treatment with combination of Sorafenib and PI3Ki-! but not with single treatment 
of Sorafenib were identified (Tables 4.15, 4.16). Additionally, identification of 
cellular processes affected specifically in response to treatment with Sorafenib but 
not with combination therapy revealed unanticipated side effects of Sorafenib 
therapy that could explain therapeutic resistance to Sorafenib (Tables 4.17, 4.18). 
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Table 4.15: Cellular processes affected specifically by up-regulated genes in 
response to treatment with combination of Sorafenib and PI3Ki-! but not with 
single treatment of Sorafenib in Huh7 cells (p<0.05) 
GO ID GO Term 
GO:0006886 intracellular protein transport 
GO:0016192 vesicle-mediated transport 
GO:0033365 protein localization in organelle 
GO:0031331 positive regulation of cellular catabolic process 
GO:0048193 Golgi vesicle transport 
GO:0006892 post-Golgi vesicle-mediated transport 
GO:0034613 cellular protein localization 
GO:0030162 regulation of proteolysis 
GO:0043065 positive regulation of apoptosis 
GO:0006917 induction of apoptosis 
GO:0070727 cellular macromolecule localization 
GO:0051247 positive regulation of protein metabolic process 
GO:0010608 posttranscriptional regulation of gene expression 
GO:0015031 protein transport 
GO:0008104 protein localization 
GO:0045184 establishment of protein localization 
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Table 4.16: Cellular processes affected specifically by up-regulated genes in 
response to treatment with combination of Sorafenib and PI3Ki-! but not with 
single treatment of Sorafenib in Mahlavu cells (p<0.05) 
GO ID GO Term 
GO:0007218 neuropeptide signaling pathway 
GO:0006888 ER to Golgi vesicle-mediated transport 
GO:0010608 posttranscriptional regulation of gene expression 
GO:0006334 nucleosome assembly 
GO:0031497 chromatin assembly 
GO:0006323 DNA packaging 
GO:0051276 chromosome organization 
 
Table 4.17: Cellular processes affected specifically by up-regulated genes in 
response to treatment with Sorafenib but not with combination therapy in Huh7 
cells (p<0.05) 
GO ID GO Term 
GO:0030522 intracellular receptor-mediated signaling pathway 
GO:0007242 intracellular signaling cascade 
GO:0030518 steroid hormone receptor signaling pathway 
GO:0010628 positive regulation of gene expression 
GO:0045893 positive regulation of transcription, DNA-dependent 
GO:0043065 positive regulation of apoptosis 
GO:0043068 positive regulation of programmed cell death 
GO:0031667 response to nutrient levels 
GO:0032526 response to retinoic acid 
GO:0007584 response to nutrient 
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GO:0009719 response to endogenous stimulus 
GO:0032869 cellular response to insulin stimulus 
GO:0032870 cellular response to hormone stimulus 
GO:0033554 cellular response to stress 
GO:0006974 response to DNA damage stimulus 
GO:0032321 positive regulation of Rho GTPase activity 
GO:0043087 regulation of GTPase activity 
GO:0007257 activation of JUN kinase activity 
GO:0043507 positive regulation of JUN kinase activity 
GO:0010557 positive regulation of macromolecule biosynthetic process 
GO:0031328 positive regulation of cellular biosynthetic process 
GO:0010560 positive regulation of glycoprotein biosynthetic process 
GO:0051254 positive regulation of RNA metabolic process 
GO:0045935 
positive regulation of nucleobase, nucleoside, nucleotide and 
nucleic acid metabolic process 
GO:0006796 phosphate metabolic process 
GO:0010906 regulation of glucose metabolic process 
GO:0046068 cGMP metabolic process 
GO:0048812 neuron projection morphogenesis 
GO:0000904 cell morphogenesis involved in differentiation 
GO:0032330 regulation of chondrocyte differentiation 
GO:0045453 bone resorption 
GO:0048771 tissue remodeling 
GO:0030182 neuron differentiation 
GO:0030521 androgen receptor signaling pathway 
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Table 4.18: Cellular processes affected specifically by up-regulated genes in 
response to treatment with Sorafenib but not with combination therapy in 
Mahlavu cells (p<0.05) 
GO Term GO ID 
GO:0006952 defense response 
GO:0006955 immune response 
GO:0009611 response to wounding 
GO:0006954 inflammatory response 
GO:0006968 cellular defense response 
GO:0002252 immune effector process 
GO:0045087 innate immune response 
 Collectively, our transcriptome level expression data delineate redundant 
functions and compensatory relationship between Raf/MEK/ERK and 
PI3K/AKT/mTOR pathways and explain mechanisms of resistance to Sorafenib. 
Therapeutic efficiency of Sorafenib is based on its ability to down-regulate MAPK 
signaling, reduce cell proliferation, growth, and angiogenesis and induce apoptosis. 
However, Sorafenib induces multiple other intracellular signaling cascades, activates 
Ras and Rho GTPase activities and consequent enhanced signaling through 
Ral/Rac/Rho cascades result in the activation of the PI3K/Akt pathway. Another 
unforeseen side effect of Sorafenib was the induction of pro-inflammatory and 
immune responses, which promote tumor growth. Combination of Sorafenib and 
PI3K inhibitor effectively down-regulated MAPK and PI3K pathways, overcame the 
compensatory activation of Ral/Rac/Rho cascades, and prevented production of pro-
inflammatory and immune responses. These extremely encouraging results highlight 
the potential of combined targeted therapies with Sorafenib and PI3K inhibitors for 
the treatment of advanced HCC. 
 Although we included only significantly differentially expressed genes in our 
analysis, we realized that the fold changes between drug treated and control samples 
were low. Therefore, we decided to perform RNA sequencing with these inhibitors. 
RNA-seq analysis of Huh7 and Mahlavu cells treated with PI3Ki-! showed that 
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RNA-seq can capture more data on transcriptome level regulation. We analyzed 
modulation of gene expression regulated by the major transcription factors FOXO1 
and p53 (Figures 4.33 and 4.34). RNA-seq analysis will be performed with Sorafenib 
and combination of Sorafenib and PI3Ki-! soon, in order to interpret differences 
between mono- and dual-treatments. 
 
Figure 4.33: Effect of PI3Ki-!! on FOXO-mediated gene expression. Genes 
regulated by FOXO transcription factor were obtained from KEGG database and 
visualized using Cytoscape based on the fold changes in gene expression between 
drug treated cells and control cells. Genes that were down-regulated and up-regulated 
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in response to PI3Ki-!!treatment are shown in blue and red, respectively. Genes with 
gray color did not have significant alterations in their expression levels upon drug 
treatment. 
 
Figure 4.34: Effect of PI3Ki-!!on p53-mediated gene expression. Genes regulated 
by FOXO transcription factor were obtained from KEGG database and visualized 
using Cytoscape based on the fold changes in gene expression between drug treated 
cells and control cells. Genes that were down-regulated and up-regulated in response 
to PI3Ki-!!treatment are shown in blue and red, respectively. Genes with gray color 
did not have significant alterations in their expression levels upon drug treatment. 
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CHAPTER 5. DISCUSSION AND CONCLUSION 
 Extensive studies on resistance to Sorafenib and tumor recurrence in HCC 
patients suggest that Sorafenib-mediated anti-growth and anti-angiogenic signals 
mainly through the Raf/MEK/ERK cascade can facilitate signaling from the 
compensatory PI3K/AKT/mTOR pathway. Proliferation, growth, angiogenesis and 
metastasis are multifaceted cellular processes regulated by redundant and 
compensatory signaling. Besides, they are in close interaction with other processes 
whose deregulation confers hallmark capabilities of cancer, i.e. metabolism, 
inflammation, immune response. Growth factors and angiogenic signals are not 
exclusive inducers of compensatory pathways. Cytokines and chemokines, which are 
associated with tumor promoting pro-inflammatory and immune responses, also 
activate the Raf/MEK/ERK and PI3K/AKT/mTOR pathways. Yet, another obstacle 
in resolving therapeutic resistance is the variable predominance of isoform-specific 
signaling within a single pathway based on cellular context. Therefore, targeted 
therapy studies in HCC should focus not only on signaling redundancy and 
compensatory relationship between the Raf/MEK/ERK and PI3K/AKT/mTOR 
pathways, but also on how intra-pathway redundancies affect inter-pathway 
compensability. Here, we provide in vitro experimental evidence for therapeutic 
potential of combining Sorafenib with p110α-isoform specific inhibitor of PI3K 
kinase (PI3Ki-α, PIK-75) and in vivo evidence for the enhanced therapeutic 
efficiency of combining Sorafenib with the Akt2-isoform specific inhibitor of Akt 
kinase (Akti-2). 
 We showed that p110α isoform specific inhibition of PI3K results in 
synergistic inhibition of cell growth in both Huh7 and Mahlavu cells. The synergistic 
cytotoxicity was more pronounced in Mahlavu, since PTEN-loss mediated 
constitutive activation of PI3K/Akt pathway renders these cells more susceptible to 
PI3K inhibition. On the other hand, p110! isoform specific inhibition of PI3K results 
in synergistic inhibition of cell growth in Huh7, but produces an antagonistic effect 
in Mahlavu probably by enhancing signaling through p110α (Figure 5.1). These 
results indicate the predominant role of p110α in PTEN-deficient HCC cells. 
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Figure 5.1: Differential cytotoxic effects of combining Sorafenib and isoform-
specific PI3K inhibitors in HCC cells based on PTEN status. 
 
 Based on microarray results, cell cycle progression and cell proliferation 
(GO:0008283, GO:0022402, KEGG:hsa04110), wound healing (GO:0042060, 
GO:0009611), regulation of protein catabolic process (GO:0042176) and kinase 
regulator activity (GO:0019207) were down-regulated in both cell lines upon single 
treatment with Sorafenib, single treatment with PI3Ki-! and combined treatment of 
both. Moreover, up-regulation of MAPK kinase activity in cells treated with PI3Ki-! 
as single agent, was overcame upon co-treatment with Sorafenib, as a result of 
significant increase in MAP kinase phosphatase activity (GO:0017017, GO:0033549, 
hsa04010). 
 In Sorafenib treated HCC cells, there was a significant increase in 
inflammatory and immune responses (GO:0006954, GO:0006955). It is well 
established that release of pro-inflammatory cytokines and chemokines from cancer 
cells promote modulation of immune response in favor of tumor proliferation, 
angiogenesis and metastasis (Balkwill, 2004; Gerber, Hippe, Buhren, Müller, & 
Homey, 2009; Sethi & Kang, 2011; Zlotnik, Burkhardt, & Homey, 2011). Besides, 
activation of the chemokine pathway is suggested as a mechanism of therapeutic 
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resistance. Indeed, Sorafenib increases tumor hypoxia and subsequently intensifies 
chemokine network. Recent studies targeting pro-inflammatory chemokine network 
and related tumor-associated macrophages (TAMs) have shown increase in the 
efficacy of Sorafenib treatment (Chen et al., 2014; Duda et al., 2011; Tang, Mo, 
Wang, Wei, & Xiao, 2013). PI3K/Akt signaling also increases production of various 
pro-inflammatory cytokines and the immunosuppressive cytokine IL-10 (Antoniv & 
Ivashkiv, 2011; Martin et al., 2005; Thomson et al., 2009). Hence, targeting 
PI3K/Akt pathway can increase the efficacy of Sorafenib by modulating chemokine 
network.  
 HCC proceeds from chronic liver inflammation and is prominently regulated 
by inflammatory microenvironment and immune response (Aravalli, 2013; Brownell 
& Polyak, 2013; Capece et al., 2013). Under hypoxic conditions of tumor 
microenvironment, endothelial cells up-regulate CXCR7, and CXCL11/CXCR7 
pathway supports HCC progression (Monnier et al., 2012). HCC patients exhibit 
significantly higher CXCR7 and CXCL11 in tumors compared to normal liver. 
Microarray analysis identified significant up-regulation of pro-inflammatory 
cytokines CXCL11, CCL5, and TSLP and pro-inflammatory receptor TNFRSF9 in 
Sorafenib treated Mahlavu cells. CCL5 secreted from stromal cells is known to 
induce migration and invasion of HCC cells through PI3K/Akt pathway, suggesting a 
compensatory activation of PI3K/Akt in response to Sorafenib treatment (Bai et al., 
2014). As anticipated, up-regulation of tumor-promoting inflammation in response to 
Sorafenib treatment was effectively counteracted by co-treatment with PI3Ki-!. 
 Single treatment of PI3Ki-! did not provoke any inflammatory or immune 
responses in either Huh7 or Mahlavu cells. Combination of PI3Ki-! and Sorafenib 
resulted in reduced proliferation and enhanced apoptosis compared to single 
treatments in Mahlavu cells, without any tumor-promoting side effect. In Huh7, 
inflammatory response was enhanced in cells co-treated with Sorafenib and PI3Ki-! 
compared to cells treated only with PI3Ki-alpha, whereas there was no significant 
change in Mahlavu cells. Additionally, although apoptotic and anti-proliferative 
processes were up-regulated in combination treated Huh7 cells compared to 
Sorafenib treated cells, combined treatment of PI3Ki-! and Sorafenib resulted in 
increased angiogenesis and vasculature development (GO:0001525, GO:0048514, 
GO:0001944), migration (GO:0030334, GO:0051270), response to wounding 
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(GO:0009611) and inflammatory response (GO:0006954) compared to single 
treatment with PI3Ki-!. In Mahlavu cells there was no such compensatory up-
regulation. These results suggest that although combination of Sorafenib and PI3Ki-! synergistically reduces proliferation and growth and increases apoptosis in both 
Huh7 and Mahlavu cells, it can also promote migration, angiogenesis and 
inflammatory response in Huh7, probably through p110β isoform of PI3K and 
therefore targeted therapies should be designed based on cellular context of HCC 
cells.  
 Microarray analysis revealed that in Sorafenib treated Huh7 cells, Ras 
GTPase binding (GO:0017016), Rac GTPase binding (GO:0048365), 
phosphatidylinositol binding (GO:0005545), steroid hormone receptor binding 
(GO:0035258) and transcription factor binding (GO:0008134) are elevated and 
protein serine/threonine kinase (GO:0004674) and transcription coactivator 
(GO:0003713) activities are increased. Ras effectors, include PI3K, MAPK and 
Ral/Rac/Rho cascades, which crosstalk with each other. PI3K is activated by Ras and 
Rho family small GTPases and RhoA, in turns, acts as an antagonist of PI3K via 
stimulating the phospholipid phosphatase activity of PTEN through RhoA-associated 
kinase (Rock) (Li et al., 2005; Yang et al., 2012). Recently, interactions of Ras and 
Rho GTPases with PI3K were identified to be isoform-specific. Ras cannot bind 
p110β, but instead RAC1 and CDC42 e Rho GTPases bind and activate p110β. 
Hence, in Huh7 cells, Sorafenib induced Rho GTPase activity can transmit signals 
predominantly through p110β rather than p110!.!Therefore,!combination!of!p110β 
isoform specific PI3K inhibitor with Sorafenib is highly synergistic and cytotoxic in 
Huh7 cells, but shows antagonistic actions in Mahlavu cells, which depend primarily 
on p110!!isoform  (Figure 4.18). The synergistic cytotoxic activity of Sorafenib and 
PI3Ki-β is partly mediated by reducing Sorafenib-induced Rho GTPase activity 
(Table 4.16). As expected, co-treatment of Sorafenib and PI3Ki-!! was! more!effective! on!Mahlavu! cells! (Figure! 4.18).! Herein,! we! postulate! that! PTENCloss!mediated!hyperCactivation!of!PI3K!signaling is dependent on p110!. In addition to 
blocking Akt-mediated survival signlas, ROCK is also known to affect membrane 
ion channels, which is in parallel with our microarray results in Sorafenib-treated 
Huh7 cells (Table 4.17). 
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 Besides, it is known that the liver-specific tumor suppressor DLC1 (deleted in 
liver cancer), which is a Rho GTPase-activating protein, suppresses cell proliferation 
and invasion in HCC by negatively regulating the activity of Rho proteins (Wong et 
al., 2005). Hence compensatory positive regulation of Ral/Rac/Rho cascade in 
Sorafenib treated Huh7 cells can be a major mechanism of resistance. Combination 
of PI3Ki-! and Sorafenib prevented up-regulation of Ral/Rac/Rho cascade, 
suggesting a critical role of co-targeting PI3K pathway to overcome resistance. Yet, 
combining Sorafenib with PI3Ki-β instead of PI3Ki-! in Huh7 cells should be 
studied in transcriptomics level and in vivo. 
 Our microarray experiments revealed activation of JUN kinase activity 
(GO:0007257) specifically in Sorafenib treated Huh7 cells. However, our in vitro 
experiments and microarray analysis demonstrated that Sorafenib up-regulates 
cyclin-dependent kinase inhibitor, p21 to halt cell cycle progression (Figure 4.19). 
Yet, it is known that p21 inhibits apoptosis-signal-regulating kinase 1 (ASK1) and 
blocks activation of c-JUN N-terminal kinase (JNK) – mediated apoptosis. ASK1 is 
one of the common effectors of Raf/MEK/ERK and PI3K/AKT/mTOR pathways. 
Akt activates ASK1 through inhibiting p21 or activating mTORC1. Hence, inhibition 
of PI3K/AKT/mTOR signaling leads to activation of ASK1 and consequent 
induction of c-JUN N-terminal kinase (JNK) results in apoptosis (Bjornsti & 
Houghton, 2004). Therefore, combined use of PI3Ki-!! and Sorafenib effectively 
intensifies apoptotic stimuli. 
 JNK and other mitogen-activated protein kinases (MAPK) family members 
p38 and ERK are activated in immune system to promote production of cytokines 
and inflammatory mediators. Dual-specificity MAP kinase phosphatases (DUSPs or 
MKPs) are negative regulators of MAPK. PI3K/Akt signaling increases production 
of the immunosuppressive cytokine Interleukin-10 (IL-10) and maintains anti-
inflammatory processes through DUSP regulation and IL-10/Jak/Stat3 pathway 
(Antoniv & Ivashkiv, 2011; Martin et al., 2005). DUSP1 inhibits activity of p38 and 
JNK. We observed an increase in DUSP1 and the anti-inflammatory cytokine IL-10 
in Sorafenib treated Huh7 cells. Co-treatment of Sorafenib with PI3Ki-! resulted in 
reduction of DUSP1 and IL-10 levels. Since IL-10 is also critical for immune 
evasion, combining Sorafenib and PI3Ki-! confers therapeutic advantage by 
targeting inflammatory- and immune-response based acquired capabilities of HCC. 
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 Collectively, these results demonstrate isoform-specific functions of PI3K 
and selective dependence on different isoforms based on molecular alterations. Our 
transcriptome level expression data delineate redundant functions and compensatory 
relationship between Raf/MEK/ERK and PI3K/AKT/mTOR pathways and explain 
mechanisms of resistance to Sorafenib. Furthermore, in vitro microarray results of 
PI3K isoform alpha inhibitor emphasize therapeutic potential of using PI3K/AKT 
pathway inhibitors to overcome resistance to Sorafenib and increase its efficiency 
(Figure 5.2). 
 
 
 
Figure 5.2: Therapeutic potential of using PI3K inhibitors to overcome 
resistance to Sorafenib 
 
 We showed that Akt2 isoform specific and non-specific inhibition of Akt 
cannot promote cell growth inhibition or apoptosis as single agents at 10 µM in both 
Huh7 and Mahlavu cells. Strikingly, combination of these inhibitors with Sorafenib 
results in synergistic inhibition of cell growth (Figure 5.3). These results indicate the 
therapeutic potential of combination therapies with Sorafenib and Akt inhibitors for 
the targeted therapy of HCC. 
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Figure 5.3: Cytotoxic effects of combining Sorafenib and isoform-specific and 
non-specific Akt inhibitors in HCC cells. 
 
 Although Akti-2 has not shown significant cytotoxicity in vitro when used as 
single agent, it produced significant reduction in tumor volume (45% compared to 
control) and tumor weight (50% compared to control). Sorafenib produced 66% 
reduction in tumor volume and 85% reduction in tumor weight compared to control. 
Combination of Sorafenib and Akti-2 showed significant superiority in reducing 
tumor volume (74% reduction compared to control) and tumor weight (93% 
compared to control). Tumor weight is a better measure of cytotoxic effects of drugs, 
since necrosis-induced inflammation and swelling in combination-treated mice 
produced a temporary increase in tumor size compared to Sorafenib-treated mice. 2 
out of 5 mice developed visible intra-tumoral necrotic areas after 2 weeks of 
receiving combination treatment. In HCC patients, anti-angiogenic effect of 
Sorafenib is also characterized by intra-tumoral necrosis and a temporary, but 
substantial, increase in tumor size (Horger et al., 2009).  Previous studies in HCC 
xenograft models showed that Sorafenib causes growth inhibition at 30 mg/kg and 
partial tumor regressions at 100 mg/kg (Liu et al., 2012; Liu et al., 2006). Here, we 
show that while 30 mg/kg Sorafenib causes tumor growth inhibition as single agent, 
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and co-treatment with 30 mg/kg Sorafenib and 7.5 mg/kg Akti-2 causes tumor 
regressions. Single treatment with Sorafenib initiated intra-tumoral necrosis in 1 out 
of 5 mice 3 weeks post-treatment, while combination treatment resulted in intra-
tumoral necrosis in 4 out of 5 mice and reduced tumor density. Our results provide in 
vivo experimental evidence of the therapeutic potential of combination therapies with 
Sorafenib and Akt inhibitors for the treatment of advanced HCC (Figure 5.4). 
 
 
Figure 5.4: Therapeutic potential of using Akt inhibitors to enhance efficiency 
of Sorafenib. 1 out of 5 Sorafenib treated mice initiated intratumoral necrosis after 3 
weeks of treatment. 4 out of 5 combination treated mice initiated intratumoral 
necrosis after 2 weeks of treatment. Substantial necrosis was clearly visible in 2 
combination treated mice and others could be detected by MRI. 1 out of 5 
combination treated mice directly reduced tumor volume without signs of necrosis. 
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    CHAPTER 6. FUTURE PERSPECTIVES 
 Combining signal transduction inhibitors for simultaneous targeting of 
compensatory pathways with redundant functions is the most effective therapeutic 
strategy to overcome resistance to targeted agents. With the advance of high-
throughput technologies and interpretation of various omics data, network-level 
understanding of molecular alterations enable identification of critical primary 
targets, anticipate possible side effects and facilitate design of optimal combinations 
to increase therapeutic efficiency. Our results showed the isoform-specific functions 
of PI3K and Akt kinases. Use of isoform-specific rather than general kinase 
inhibitors can minimize side effects and reduce the required dose thereby minimizing 
toxicity. We performed microarray experiments with Sorafenib, PI3Ki-α (PIK-75) 
and their combination in Huh7 and Mahlavu cell lines. Microarray experiments 
should also be performed for PI3Ki-! (TGX-221) and its combination with Sorafenib 
to better reveal isoform-specific functions of PI3K. We showed that PI3Ki-! and 
Sorafenib are antagonistic in Mahlavu cells. Microarray experiments will identify the 
molecular mechanism of compensatory growth-promoting signaling in Mahlavu cells 
treated with PI3Ki-!. PI3Ki-α (PIK-75), PI3Ki-! (TGX-221) and their combinations 
with Sorafenib should be tested in tumor xenografts in vivo to assess advantage of 
combination therapy over mono-therapy with Sorafenib. 
 Cytotoxic activities of PI3Ki-α (PIK-75), PI3Ki-! (TGX-221), Akti-1,2 and 
Akti-2 should be tested in normal cells, to ensure that they will specifically target 
cancer cells with minimum toxicity on normal healthy cells. 
 We demonstrated anti-tumor effect of Sorafenib and Akti-2 combination in 
Mahlavu xenografts in vivo. The significant reduction in tumor volume and weight 
should be supported with hematoxylin-eosin (H&E) staining and 
immunohistochemistry assays. Alterations in expression levels of critical effectors of 
PI3K/AKT/mTOR and RAF/MEK/ERK pathways upon combinational treatment in 
vivo should be determined with western blot. In order to identify molecular 
mechanism of synergy between Sorafenib and Akti-2, microarray or RNAseq 
experiments should be performed. Additionally, proteomics studies and 
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phosphorylation based kinase activity assays could be extremely informative on 
signaling pathway alterations since kinases regulate their downstream effectors 
through phosphorylation. 
 In order to validate the dependence of Mahlavu cells on the p110α isoform 
for cell survival, RNAi can be used to knock-down specific isoforms. Role of PTEN 
on the sensitivity of HCC cells to Sorafenib and PI3K/Akt inhibitor can be studied by 
knocking-down PTEN in Huh7 cells and comparing response of these cells to 
inhibitors with that of wild-type Huh7. 
  
 119 
REFERENCES 
Ackah, E., Yu, J., Zoellner, S., Iwakiri, Y., Skurk, C., Shibata, R., … Sessa, W. C. 
(2005). Akt1/protein kinase Balpha is critical for ischemic and VEGF-mediated 
angiogenesis. The Journal of Clinical Investigation, 115(8), 2119–27. 
doi:10.1172/JCI24726 
Andersen, C. L., Jensen, J. L., & Ørntoft, T. F. (2004). Normalization of Real-Time 
Quantitative Reverse Transcription-PCR Data: A Model-Based Variance 
Estimation Approach to Identify Genes Suited for Normalization, Applied to 
Bladder and Colon Cancer Data Sets. Cancer Research , 64 (15 ), 5245–5250. 
doi:10.1158/0008-5472.CAN-04-0496 
Antoniv, T. T., & Ivashkiv, L. B. (2011). Interleukin-10-induced gene expression and 
suppressive function are selectively modulated by the PI3K-Akt-GSK3 
pathway. Immunology, 132(4), 567–77. doi:10.1111/j.1365-2567.2010.03402.x 
Aravalli, R. N. (2013). Role of innate immunity in the development of hepatocellular 
carcinoma. World Journal of Gastroenterology!: WJG, 19(43), 7500–14. 
doi:10.3748/wjg.v19.i43.7500 
Aston, N. S., Watt, N., Morton, I. E., Tanner, M. S., & Evans, G. S. (2000). Copper 
toxicity affects proliferation and viability of human hepatoma cells (HepG2 
line). Human & Experimental Toxicology, 19(6), 367–76. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/10962511 
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-
McGuinn, K. M., … Tutt, A. (2010). Oral poly(ADP-ribose) polymerase 
inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent 
ovarian cancer: a proof-of-concept trial. Lancet, 376(9737), 245–51. 
doi:10.1016/S0140-6736(10)60893-8 
Augustin, H. G., Koh, G. Y., Thurston, G., & Alitalo, K. (2009). Control of vascular 
 120 
morphogenesis and homeostasis through the angiopoietin-Tie system. Nature 
Reviews. Molecular Cell Biology, 10(3), 165–77. doi:10.1038/nrm2639 
Bae, J.-J., Rho, J.-W., Lee, T.-J., Yun, S.-S., Kim, H.-J., Choi, J.-H., … Lee, T.-Y. 
(2007). Loss of heterozygosity on chromosome 10q23 and mutation of the 
phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor 
gene in Korean hepatocellular carcinoma patients. Oncology Reports, 18(4), 
1007–13. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17786367 
Bai, H., Weng, Y., Bai, S., Jiang, Y., Li, B., He, F., … Shi, Q. (2014). CCL5 secreted 
from bone marrow stromal cells stimulates the migration and invasion of Huh7 
hepatocellular carcinoma cells via the PI3K-Akt pathway. International Journal 
of Oncology, 45(1), 333–43. doi:10.3892/ijo.2014.2421 
Bai, P., & Virág, L. (2012). Role of poly(ADP-ribose) polymerases in the regulation 
of inflammatory processes. FEBS Letters, 586(21), 3771–7. 
doi:10.1016/j.febslet.2012.09.026 
Balkwill, F. (2004). Cancer and the chemokine network. Nature Reviews. Cancer, 
4(7), 540–50. doi:10.1038/nrc1388 
Bensaad, K., Tsuruta, A., Selak, M. a, Vidal, M. N. C., Nakano, K., Bartrons, R., … 
Vousden, K. H. (2006). TIGAR, a p53-inducible regulator of glycolysis and 
apoptosis. Cell, 126(1), 107–20. doi:10.1016/j.cell.2006.05.036 
Berenjeno, I. M., Guillermet-Guibert, J., Pearce, W., Gray, A., Fleming, S., & 
Vanhaesebroeck, B. (2012). Both p110α and p110β isoforms of PI3K can 
modulate the impact of loss-of-function of the PTEN tumour suppressor. The 
Biochemical Journal, 442(1), 151–9. doi:10.1042/BJ20111741 
Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. 
Nature Reviews. Cancer, 8(8), 592–603. doi:10.1038/nrc2442 
Beyoğlu, D., Imbeaud, S., Maurhofer, O., Bioulac-Sage, P., Zucman-Rossi, J., 
Dufour, J.-F., & Idle, J. R. (2013). Tissue metabolomics of hepatocellular 
carcinoma: tumor energy metabolism and the role of transcriptomic 
 121 
classification. Hepatology (Baltimore, Md.), 58(1), 229–38. 
doi:10.1002/hep.26350 
Bierie, B., & Moses, H. L. (2006). Tumour microenvironment: TGFbeta: the 
molecular Jekyll and Hyde of cancer. Nature Reviews. Cancer, 6(7), 506–20. 
doi:10.1038/nrc1926 
Bjornsti, M.-A., & Houghton, P. J. (2004). The TOR pathway: a target for cancer 
therapy. Nature Reviews. Cancer, 4(5), 335–48. doi:10.1038/nrc1362 
Boyault, S., Rickman, D. S., de Reyniès, A., Balabaud, C., Rebouissou, S., Jeannot, 
E., … Zucman-Rossi, J. (2007). Transcriptome classification of HCC is related 
to gene alterations and to new therapeutic targets. Hepatology (Baltimore, Md.), 
45(1), 42–52. doi:10.1002/hep.21467 
Brenndörfer, E. D., & Sällberg, M. (2012). Hepatitis C virus-mediated modulation of 
cellular immunity. Archivum Immunologiae et Therapiae Experimentalis, 60(5), 
315–29. doi:10.1007/s00005-012-0184-z 
Brownell, J., & Polyak, S. J. (2013). Molecular pathways: hepatitis C virus, 
CXCL10, and the inflammatory road to liver cancer. Clinical Cancer Research!: 
An Official Journal of the American Association for Cancer Research, 19(6), 
1347–52. doi:10.1158/1078-0432.CCR-12-0928 
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., … 
Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with 
inhibitors of poly(ADP-ribose) polymerase. Nature, 434(7035), 913–7. 
doi:10.1038/nature03443 
Budanov, A. V, & Karin, M. (2008). p53 target genes sestrin1 and sestrin2 connect 
genotoxic stress and mTOR signaling. Cell, 134(3), 451–60. 
doi:10.1016/j.cell.2008.06.028 
Budhu, A., Roessler, S., Zhao, X., Yu, Z., Forgues, M., Ji, J., … Wang, X. W. 
(2013). Integrated metabolite and gene expression profiles identify lipid 
biomarkers associated with progression of hepatocellular carcinoma and patient 
 122 
outcomes. Gastroenterology, 144(5), 1066–1075.e1. 
doi:10.1053/j.gastro.2013.01.054 
Buontempo, F., Ersahin, T., Missiroli, S., Senturk, S., Etro, D., Ozturk, M., … Neri, 
M. L. (2011). Inhibition of Akt signaling in hepatoma cells induces apoptotic 
cell death independent of Akt activation status. Investigational New Drugs, 
29(6), 1303–13. doi:10.1007/s10637-010-9486-3 
Caja, L., Sancho, P., Bertran, E., & Fabregat, I. (2011). Dissecting the effect of 
targeting the epidermal growth factor receptor on TGF-β-induced-apoptosis in 
human hepatocellular carcinoma cells. Journal of Hepatology, 55(2), 351–8. 
doi:10.1016/j.jhep.2010.10.041 
Caja, L., Sancho, P., Bertran, E., Iglesias-Serret, D., Gil, J., & Fabregat, I. (2009). 
Overactivation of the MEK/ERK pathway in liver tumor cells confers resistance 
to TGF-{beta}-induced cell death through impairing up-regulation of the 
NADPH oxidase NOX4. Cancer Research, 69(19), 7595–602. 
doi:10.1158/0008-5472.CAN-09-1482 
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. a, Lee, J.-S., … 
Thorgeirsson, S. S. (2006). Ubiquitous activation of Ras and Jak/Stat pathways 
in human HCC. Gastroenterology, 130(4), 1117–28. 
doi:10.1053/j.gastro.2006.01.006 
Campbell, J. S., Johnson, M. M., Bauer, R. L., Hudkins, K. L., Gilbertson, D. G., 
Riehle, K. J., … Fausto, N. (2007). Targeting stromal cells for the treatment of 
platelet-derived growth factor C-induced hepatocellular carcinogenesis. 
Differentiation; Research in Biological Diversity, 75(9), 843–52. 
doi:10.1111/j.1432-0436.2007.00235.x 
Cantor, J. R., & Sabatini, D. M. (2012). Cancer cell metabolism: one hallmark, many 
faces. Cancer Discovery, 2(10), 881–98. doi:10.1158/2159-8290.CD-12-0345 
Capece, D., Fischietti, M., Verzella, D., Gaggiano, A., Cicciarelli, G., Tessitore, A., 
… Alesse, E. (2013). The inflammatory microenvironment in hepatocellular 
carcinoma: a pivotal role for tumor-associated macrophages. BioMed Research 
 123 
International, 2013, 187204. doi:10.1155/2013/187204 
Challen, C., Guo, K., Collier, J. D., Cavanagh, D., & Bassendine, M. F. (1992). 
Infrequent point mutations in codons 12 and 61 of ras oncogenes in human 
hepatocellular carcinomas. Journal of Hepatology, 14(2-3), 342–6. Retrieved 
from http://www.ncbi.nlm.nih.gov/pubmed/1323601 
Chan, I. S., Guy, C. D., Chen, Y., Lu, J., Swiderska-Syn, M., Michelotti, G. A., … 
Diehl, A. M. (2012). Paracrine Hedgehog signaling drives metabolic changes in 
hepatocellular carcinoma. Cancer Research, 72(24), 6344–50. 
doi:10.1158/0008-5472.CAN-12-1068 
Chen, W. S., Xu, P. Z., Gottlob, K., Chen, M. L., Sokol, K., Shiyanova, T., … Hay, 
N. (2001). Growth retardation and increased apoptosis in mice with 
homozygous disruption of the Akt1 gene. Genes & Development, 15(17), 2203–
8. doi:10.1101/gad.913901 
Chen, Y., Huang, Y., Reiberger, T., Duyverman, A. M., Huang, P., Samuel, R., … 
Duda, D. G. (2014). Differential effects of sorafenib on liver versus tumor 
fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis 
and myeloid differentiation antigen-positive myeloid cell infiltration in mice. 
Hepatology (Baltimore, Md.), 59(4), 1435–47. doi:10.1002/hep.26790 
Cheng, A.-L., Guan, Z., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., … Kang, Y.-K. 
(2012). Efficacy and safety of sorafenib in patients with advanced 
hepatocellular carcinoma according to baseline status: subset analyses of the 
phase III Sorafenib Asia-Pacific trial. European Journal of Cancer (Oxford, 
England!: 1990), 48(10), 1452–65. doi:10.1016/j.ejca.2011.12.006 
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., … Guan, Z. 
(2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region 
with advanced hepatocellular carcinoma: a phase III randomised, double-blind, 
placebo-controlled trial. The Lancet Oncology, 10(1), 25–34. 
doi:10.1016/S1470-2045(08)70285-7 
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., … 
 124 
Llovet, J. M. (2008). Focal gains of VEGFA and molecular classification of 
hepatocellular carcinoma. Cancer Research, 68(16), 6779–88. 
doi:10.1158/0008-5472.CAN-08-0742 
Chin, Y. R., & Toker, A. (2009). Function of Akt/PKB signaling to cell motility, 
invasion and the tumor stroma in cancer. Cellular Signalling, 21(4), 470–6. 
doi:10.1016/j.cellsig.2008.11.015 
Chin, Y. R., & Toker, A. (2011). Akt isoform-specific signaling in breast cancer: 
uncovering an anti-migratory role for palladin. Cell Adhesion & Migration, 
5(3), 211–4. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3210203&tool=pmc
entrez&rendertype=abstract 
Chin, Y. R., Yuan, X., Balk, S. P., & Toker, A. (2014). PTEN-Deficient Tumors 
Depend on AKT2 for Maintenance and Survival. Cancer Discovery. 
doi:10.1158/2159-8290.CD-13-0873 
Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw, E. B., … 
Birnbaum, M. J. (2001). Insulin resistance and a diabetes mellitus-like 
syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science (New 
York, N.Y.), 292(5522), 1728–31. doi:10.1126/science.292.5522.1728 
Cho, H., Thorvaldsen, J. L., Chu, Q., Feng, F., & Birnbaum, M. J. (2001). 
Akt1/PKBalpha is required for normal growth but dispensable for maintenance 
of glucose homeostasis in mice. The Journal of Biological Chemistry, 276(42), 
38349–52. doi:10.1074/jbc.C100462200 
Copple, B. L. (2010). Hypoxia stimulates hepatocyte epithelial to mesenchymal 
transition by hypoxia-inducible factor and transforming growth factor-beta-
dependent mechanisms. Liver International!: Official Journal of the 
International Association for the Study of the Liver, 30(5), 669–82. 
doi:10.1111/j.1478-3231.2010.02205.x 
Dedes, K. J., Wetterskog, D., Mendes-Pereira, A. M., Natrajan, R., Lambros, M. B., 
Geyer, F. C., … Reis-Filho, J. S. (2010). PTEN deficiency in endometrioid 
 125 
endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Science 
Translational Medicine, 2(53), 53ra75. doi:10.1126/scitranslmed.3001538 
Deng, Q., Wang, Q., Zong, W.-Y., Zheng, D.-L., Wen, Y.-X., Wang, K.-S., … Han, 
Z.-G. (2010). E2F8 contributes to human hepatocellular carcinoma via 
regulating cell proliferation. Cancer Research, 70(2), 782–91. 
doi:10.1158/0008-5472.CAN-09-3082 
Dong, L., Yang, G., Pan, Y., Chen, Y., Tan, Y., Dai, R., … Wang, H. (2011). The 
oncoprotein p28GANK establishes a positive feedback loop in β-catenin 
signaling. Cell Research, 21(8), 1248–61. doi:10.1038/cr.2011.103 
Drew, Y., Mulligan, E. A., Vong, W.-T., Thomas, H. D., Kahn, S., Kyle, S., … 
Curtin, N. J. (2011). Therapeutic potential of poly(ADP-ribose) polymerase 
inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or 
BRCA2. Journal of the National Cancer Institute, 103(4), 334–46. 
doi:10.1093/jnci/djq509 
Duda, D. G., Kozin, S. V, Kirkpatrick, N. D., Xu, L., Fukumura, D., & Jain, R. K. 
(2011). CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an 
emerging sensitizer for anticancer therapies? Clinical Cancer Research!: An 
Official Journal of the American Association for Cancer Research, 17(8), 2074–
80. doi:10.1158/1078-0432.CCR-10-2636 
Dudgeon, C., Peng, R., Wang, P., Sebastiani, A., Yu, J., & Zhang, L. (2012). 
Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and 
NF-κB to suppress tumor cell growth. Oncogene, 31(46), 4848–58. 
doi:10.1038/onc.2011.644 
Dummler, B., Tschopp, O., Hynx, D., Yang, Z.-Z., Dirnhofer, S., & Hemmings, B. 
A. (2006). Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are 
viable but display impaired glucose homeostasis and growth deficiencies. 
Molecular and Cellular Biology, 26(21), 8042–51. doi:10.1128/MCB.00722-06 
Eckers, A., Reimann, K., & Klotz, L.-O. (2009). Nickel and copper ion-induced 
stress signaling in human hepatoma cells: analysis of phosphoinositide 3’-
 126 
kinase/Akt signaling. Biometals!: An International Journal on the Role of Metal 
Ions in Biology, Biochemistry, and Medicine, 22(2), 307–16. 
doi:10.1007/s10534-008-9167-2 
Eisenberg, E., & Levanon, E. Y. (2003). Human housekeeping genes are compact. 
Trends in Genetics!: TIG, 19(7), 356–62. doi:10.1016/S0168-9525(03)00137-9 
El-Serag, H. B. (2011). Hepatocellular carcinoma. The New England Journal of 
Medicine, 365(12), 1118–27. doi:10.1056/NEJMra1001683 
Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., 
… Thompson, C. B. (2004). Akt stimulates aerobic glycolysis in cancer cells. 
Cancer Research, 64(11), 3892–9. doi:10.1158/0008-5472.CAN-03-2904 
Engelman, J. a. (2009). Targeting PI3K signalling in cancer: opportunities, 
challenges and limitations. Nature Reviews. Cancer, 9(8), 550–62. 
doi:10.1038/nrc2664 
Fabregat, I., Roncero, C., & Fernández, M. (2007). Survival and apoptosis: a 
dysregulated balance in liver cancer. Liver International!: Official Journal of the 
International Association for the Study of the Liver, 27(2), 155–62. 
doi:10.1111/j.1478-3231.2006.01409.x 
Fang, M., Shen, Z., Huang, S., Zhao, L., Chen, S., Mak, T. W., & Wang, X. (2010). 
The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg 
effect, and proliferation in the PTEN pathway. Cell, 143(5), 711–24. 
doi:10.1016/j.cell.2010.10.010 
Farazi, P. A., & DePinho, R. A. (2006). Hepatocellular carcinoma pathogenesis: 
from genes to environment. Nature Reviews. Cancer, 6(9), 674–87. 
doi:10.1038/nrc1934 
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. 
B., … Ashworth, A. (2005). Targeting the DNA repair defect in BRCA mutant 
cells as a therapeutic strategy. Nature, 434(7035), 917–21. 
doi:10.1038/nature03445 
 127 
Ferlay, J., Shin, H.-R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). 
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. 
International Journal of Cancer. Journal International Du Cancer, 127(12), 
2893–917. doi:10.1002/ijc.25516 
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., … de 
Bono, J. S. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from 
BRCA mutation carriers. The New England Journal of Medicine, 361(2), 123–
34. doi:10.1056/NEJMoa0900212 
Fruman, D. A., & Rommel, C. (2014). PI3K and cancer: lessons, challenges and 
opportunities. Nature Reviews. Drug Discovery, 13(2), 140–56. 
doi:10.1038/nrd4204 
Fujimoto, A., Totoki, Y., Abe, T., Boroevich, K. a, Hosoda, F., Nguyen, H. H., … 
Nakagawa, H. (2012). Whole-genome sequencing of liver cancers identifies 
etiological influences on mutation patterns and recurrent mutations in chromatin 
regulators. Nature Genetics, 44(7), 760–4. doi:10.1038/ng.2291 
Fujiwara, Y., Hoon, D. S., Yamada, T., Umeshita, K., Gotoh, M., Sakon, M., … 
Monden, M. (2000). PTEN / MMAC1 mutation and frequent loss of 
heterozygosity identified in chromosome 10q in a subset of hepatocellular 
carcinomas. Japanese Journal of Cancer Research!: Gann, 91(3), 287–92. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10760687 
Gao, Q., Wang, X.-Y., Fan, J., Qiu, S.-J., Zhou, J., Shi, Y.-H., … Sun, J. (2008). 
Selection of reference genes for real-time PCR in human hepatocellular 
carcinoma tissues. Journal of Cancer Research and Clinical Oncology, 134(9), 
979–86. doi:10.1007/s00432-008-0369-3 
Garofalo, R. S., Orena, S. J., Rafidi, K., Torchia, A. J., Stock, J. L., Hildebrandt, A. 
L., … Coleman, K. G. (2003). Severe diabetes, age-dependent loss of adipose 
tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. The Journal 
of Clinical Investigation, 112(2), 197–208. doi:10.1172/JCI16885 
Gerber, P. A., Hippe, A., Buhren, B. A., Müller, A., & Homey, B. (2009). 
 128 
Chemokines in tumor-associated angiogenesis. Biological Chemistry, 390(12), 
1213–23. doi:10.1515/BC.2009.144 
Goldstein, J. C., Waterhouse, N. J., Juin, P., Evan, G. I., & Green, D. R. (2000). The 
coordinate release of cytochrome c during apoptosis is rapid, complete and 
kinetically invariant. Nature Cell Biology, 2(3), 156–62. doi:10.1038/35004029 
Gonzalez, E., & McGraw, T. E. (2009). The Akt kinases: isoform specificity in 
metabolism and cancer. Cell Cycle (Georgetown, Tex.), 8(16), 2502–8. 
Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2997486&tool=pmc
entrez&rendertype=abstract 
Graupera, M., Guillermet-Guibert, J., Foukas, L. C., Phng, L.-K., Cain, R. J., 
Salpekar, A., … Vanhaesebroeck, B. (2008). Angiogenesis selectively requires 
the p110alpha isoform of PI3K to control endothelial cell migration. Nature, 
453(7195), 662–6. doi:10.1038/nature06892 
Graupera, M., & Potente, M. (2013). Regulation of angiogenesis by PI3K signaling 
networks. Experimental Cell Research, 319(9), 1348–55. 
doi:10.1016/j.yexcr.2013.02.021 
Guertin, D. a, & Sabatini, D. M. (2007). Defining the role of mTOR in cancer. 
Cancer Cell, 12(1), 9–22. doi:10.1016/j.ccr.2007.05.008 
Ha, H.-L., Shin, H.-J., Feitelson, M. A., & Yu, D.-Y. (2010). Oxidative stress and 
antioxidants in hepatic pathogenesis. World Journal of Gastroenterology!: WJG, 
16(48), 6035–43. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3012582&tool=pmc
entrez&rendertype=abstract 
Haendeler, J., Hoffmann, J., Rahman, S., Zeiher, A. M., & Dimmeler, S. (2003). 
Regulation of telomerase activity and anti-apoptotic function by protein-protein 
interaction and phosphorylation. FEBS Letters, 536(1-3), 180–6. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/12586360 
 129 
Han, Z.-G. (2012). Functional genomic studies: insights into the pathogenesis of 
liver cancer. Annual review of genomics and human genetics (Vol. 13, pp. 171–
205). doi:10.1146/annurev-genom-090711-163752 
Hanahan, D., & Weinberg, R. a. (2011). Hallmarks of cancer: the next generation. 
Cell, 144(5), 646–74. doi:10.1016/j.cell.2011.02.013 
Harrold, J. M., Ramanathan, M., & Mager, D. E. (2013). Network-based approaches 
in drug discovery and early development. Clinical Pharmacology and 
Therapeutics, 94(6), 651–8. doi:10.1038/clpt.2013.176 
Hatano, E., & Brenner, D. A. (2001). Akt protects mouse hepatocytes from TNF-
alpha- and Fas-mediated apoptosis through NK-kappa B activation. American 
Journal of Physiology. Gastrointestinal and Liver Physiology, 281(6), G1357–
68. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11705740 
He, A. R., & Goldenberg, A. S. (2013). Treating hepatocellular carcinoma 
progression following first-line sorafenib: therapeutic options and clinical 
observations. Therapeutic Advances in Gastroenterology, 6(6), 447–58. 
doi:10.1177/1756283X13498540 
Honda, K., Sbisà, E., Tullo, a, Papeo, P. a, Saccone, C., Poole, S., … Habib, N. a. 
(1998). P53 Mutation Is a Poor Prognostic Indicator for Survival in Patients 
With Hepatocellular Carcinoma Undergoing Surgical Tumour Ablation. British 
Journal of Cancer, 77(5), 776–82. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2149958&tool=pmc
entrez&rendertype=abstract 
Horger, M., Lauer, U. M., Schraml, C., Berg, C. P., Koppenhöfer, U., Claussen, C. 
D., … Bitzer, M. (2009). Early MRI response monitoring of patients with 
advanced hepatocellular carcinoma under treatment with the multikinase 
inhibitor sorafenib. BMC Cancer, 9, 208. doi:10.1186/1471-2407-9-208 
Hsiao, L. L., Dangond, F., Yoshida, T., Hong, R., Jensen, R. V, Misra, J., … Gullans, 
S. R. (2001). A compendium of gene expression in normal human tissues. 
Physiological Genomics, 7(2), 97–104. 
 130 
doi:10.1152/physiolgenomics.00040.2001 
Hu, T.-H., Huang, C.-C., Lin, P.-R., Chang, H.-W., Ger, L.-P., Lin, Y.-W., … Tai, 
M.-H. (2003). Expression and prognostic role of tumor suppressor gene 
PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer, 97(8), 1929–40. 
doi:10.1002/cncr.11266 
Hu, Y., Shen, Y., Ji, B., Yin, S., Ren, X., Chen, T., … Zhang, Y. (2011). Liver-
specific gene therapy of hepatocellular carcinoma by targeting human 
telomerase reverse transcriptase with pegylated immuno-lipopolyplexes. 
European Journal of Pharmaceutics and Biopharmaceutics!: Official Journal of 
Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik e.V, 78(3), 320–5. 
doi:10.1016/j.ejpb.2010.12.036 
Hussain, S. P., Schwank, J., Staib, F., Wang, X. W., & Harris, C. C. (2007). TP53 
mutations and hepatocellular carcinoma: insights into the etiology and 
pathogenesis of liver cancer. Oncogene, 26(15), 2166–76. 
doi:10.1038/sj.onc.1210279 
Hwang, Y. H., Choi, J. Y., Kim, S., Chung, E. S., Kim, T., Koh, S. S., … Park, Y. M. 
(2004). Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and 
hepatocellular carcinoma. Hepatology Research!: The Official Journal of the 
Japan Society of Hepatology, 29(2), 113–121. doi:10.1016/j.hepres.2004.02.009 
Imose, M., Nagaki, M., Naiki, T., Osawa, Y., Brenner, D. A., Asano, T., … 
Moriwaki, H. (2003). Inhibition of nuclear factor kappaB and 
phosphatidylinositol 3-kinase/Akt is essential for massive hepatocyte apoptosis 
induced by tumor necrosis factor alpha in mice. Liver International!: Official 
Journal of the International Association for the Study of the Liver, 23(5), 386–
96. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14708901 
Isik, Z., Ersahin, T., Atalay, V., Aykanat, C., & Cetin-Atalay, R. (2012). A signal 
transduction score flow algorithm for cyclic cellular pathway analysis, which 
combines transcriptome and ChIP-seq data. Molecular bioSystems, 8(12), 3224–
31. doi:10.1039/c2mb25215e 
 131 
Jemal, A., Bray, F., & Ferlay, J. (2011). Global Cancer Statistics. CA CANCER J 
CLIN, 61(2), 69–90. doi:10.3322/caac.20107.Available 
Jia, S., Roberts, T. M., & Zhao, J. J. (2009). Should individual PI3 kinase isoforms 
be targeted in cancer? Current Opinion in Cell Biology, 21(2), 199–208. 
doi:10.1016/j.ceb.2008.12.007 
Jung, M., Drapier, J. C., Weidenbach, H., Renia, L., Oliveira, L., Wang, A., … 
Nussler, A. K. (2000). Effects of hepatocellular iron imbalance on nitric oxide 
and reactive oxygen intermediates production in a model of sepsis. Journal of 
Hepatology, 33(3), 387–94. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/11019994 
Juvekar, A., Burga, L. N., Hu, H., Lunsford, E. P., Ibrahim, Y. H., Balmañà, J., … 
Wulf, G. M. (2012). Combining a PI3K inhibitor with a PARP inhibitor 
provides an effective therapy for BRCA1-related breast cancer. Cancer 
Discovery, 2(11), 1048–63. doi:10.1158/2159-8290.CD-11-0336 
Kang, S. S., Kwon, T., Kwon, D. Y., & Do, S. I. (1999). Akt protein kinase enhances 
human telomerase activity through phosphorylation of telomerase reverse 
transcriptase subunit. The Journal of Biological Chemistry, 274(19), 13085–90. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10224060 
Kawamura, N., Nagai, H., Bando, K., Koyama, M., Matsumoto, S., Tajiri, T., … 
Emi, M. (1999). PTEN/MMAC1 mutations in hepatocellular carcinomas: 
somatic inactivation of both alleles in tumors. Japanese Journal of Cancer 
Research!: Gann, 90(4), 413–8. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/10363579 
Kedderis, G. L. (1996). Biochemical basis of hepatocellular injury. Toxicologic 
Pathology, 24(1), 77–83. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/8839284 
Kimbung, S., Biskup, E., Johansson, I., Aaltonen, K., Ottosson-Wadlund, A., 
Gruvberger-Saal, S., … Hedenfalk, I. (2012). Co-targeting of the PI3K pathway 
improves the response of BRCA1 deficient breast cancer cells to PARP1 
 132 
inhibition. Cancer Letters, 319(2), 232–41. doi:10.1016/j.canlet.2012.01.015 
Ladu, S., Calvisi, D. F., Conner, E. A., Farina, M., Factor, V. M., & Thorgeirsson, S. 
S. (2008). E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and 
COX-2 in a mouse model of human liver cancer. Gastroenterology, 135(4), 
1322–32. doi:10.1053/j.gastro.2008.07.012 
Lamouille, S., Xu, J., & Derynck, R. (2014). Molecular mechanisms of epithelial–
mesenchymal transition. Nature Reviews Molecular Cell Biology, 15(3), 178–
196. doi:10.1038/nrm3758 
Lee, J.-S., Kim, J. H., Park, Y.-Y., & Mills, G. B. (2011). Systems biology 
approaches to decoding the genome of liver cancer. Cancer Research and 
Treatment!: Official Journal of Korean Cancer Association, 43(4), 205–11. 
doi:10.4143/crt.2011.43.4.205 
Lee, T. K., Poon, R. T. P., Yuen, A. P., Ling, M. T., Kwok, W. K., Wang, X. H., … 
Fan, S. T. (2006). Twist overexpression correlates with hepatocellular 
carcinoma metastasis through induction of epithelial-mesenchymal transition. 
Clinical Cancer Research!: An Official Journal of the American Association for 
Cancer Research, 12(18), 5369–76. doi:10.1158/1078-0432.CCR-05-2722 
Levine, A. J., & Puzio-Kuter, A. M. (2010). The Control of the Metabolic Switch in 
Cancers by Oncogenes and Tumor Suppressor Genes. Science (New York, N.Y.), 
330(December 2010), 1340–1345. 
Li, W.-C., Ye, S.-L., Sun, R.-X., Liu, Y.-K., Tang, Z.-Y., Kim, Y., … Zhang, H. 
(2006). Inhibition of growth and metastasis of human hepatocellular carcinoma 
by antisense oligonucleotide targeting signal transducer and activator of 
transcription 3. Clinical Cancer Research!: An Official Journal of the American 
Association for Cancer Research, 12(23), 7140–8. doi:10.1158/1078-
0432.CCR-06-0484 
Li, X. M., Tang, Z. Y., Zhou, G., Lui, Y. K., & Ye, S. L. (1998). Significance of 
vascular endothelial growth factor mRNA expression in invasion and metastasis 
of hepatocellular carcinoma. Journal of Experimental & Clinical Cancer 
 133 
Research!: CR, 17(1), 13–7. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/9646228 
Li, Y. Y., & Jones, S. J. (2012). Drug repositioning for personalized medicine. 
Genome Medicine, 4(3), 27. doi:10.1186/gm326 
Li, Z., Dong, X., Dong, X., Wang, Z., Liu, W., Deng, N., … Wu, D. (2005). 
Regulation of PTEN by Rho small GTPases. Nature Cell Biology, 7(4), 399–
404. doi:10.1038/ncb1236 
Liang, Y., Zheng, T., Song, R., Wang, J., Yin, D., Wang, L., … Liu, L. (2013). 
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von 
Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular 
carcinoma. Hepatology (Baltimore, Md.), 57(5), 1847–57. 
doi:10.1002/hep.26224 
Liu, J., Zhu, Q., Li, J., Zhao, S., & Li, L. (2008). The retrovirus-mediated antisense 
human telomerase RNA (hTR) gene limits the growth of hepatocellular 
carcinoma growth in cell culture and animals. Digestive Diseases and Sciences, 
53(4), 1122–30. doi:10.1007/s10620-007-9980-4 
Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., … Carter, C. 
(2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor 
angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma 
model PLC/PRF/5. Cancer Research, 66(24), 11851–8. doi:10.1158/0008-
5472.CAN-06-1377 
Liu, L., Ho, R. L. K., Chen, G. G., & Lai, P. B. S. (2012). Sorafenib inhibits 
hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity 
in hepatocellular carcinoma. Clinical Cancer Research!: An Official Journal of 
the American Association for Cancer Research, 18(20), 5662–71. 
doi:10.1158/1078-0432.CCR-12-0552 
Liu, L., Zhu, X.-D., Wang, W.-Q., Shen, Y., Qin, Y., Ren, Z.-G., … Tang, Z.-Y. 
(2010). Activation of beta-catenin by hypoxia in hepatocellular carcinoma 
contributes to enhanced metastatic potential and poor prognosis. Clinical 
 134 
Cancer Research!: An Official Journal of the American Association for Cancer 
Research, 16(10), 2740–50. doi:10.1158/1078-0432.CCR-09-2610 
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009). Targeting the 
phosphoinositide 3-kinase pathway in cancer. Nature Reviews. Drug Discovery, 
8(8), 627–44. doi:10.1038/nrd2926 
Liu, Y., Fuchs, J., Li, C., & Lin, J. (2010). IL-6, a risk factor for hepatocellular 
carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human 
hepatocellular cancer cells. Cell Cycle (Georgetown, Tex.), 9(17), 3423–7. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20818158 
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., 
… Gores, G. J. (2008). Design and endpoints of clinical trials in hepatocellular 
carcinoma. Journal of the National Cancer Institute, 100(10), 698–711. 
doi:10.1093/jnci/djn134 
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., … Bruix, 
J. (2008). Sorafenib in advanced hepatocellular carcinoma. The New England 
Journal of Medicine, 359(4), 378–90. doi:10.1056/NEJMoa0708857 
Manning, B. D., & Cantley, L. C. (2007). AKT/PKB signaling: navigating 
downstream. Cell, 129(7), 1261–74. doi:10.1016/j.cell.2007.06.009 
Martin, M., Rehani, K., Jope, R. S., & Michalek, S. M. (2005). Toll-like receptor-
mediated cytokine production is differentially regulated by glycogen synthase 
kinase 3. Nature Immunology, 6(8), 777–84. doi:10.1038/ni1221 
Matsuo, N., Shiraha, H., Fujikawa, T., Takaoka, N., Ueda, N., Tanaka, S., … 
Yamamoto, K. (2009). Twist expression promotes migration and invasion in 
hepatocellular carcinoma. BMC Cancer, 9, 240. doi:10.1186/1471-2407-9-240 
Mazzocca, A., Fransvea, E., Dituri, F., Lupo, L., Antonaci, S., & Giannelli, G. 
(2010). Down-regulation of connective tissue growth factor by inhibition of 
transforming growth factor beta blocks the tumor-stroma cross-talk and tumor 
progression in hepatocellular carcinoma. Hepatology (Baltimore, Md.), 51(2), 
 135 
523–34. doi:10.1002/hep.23285 
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Bialkowska, A., Swift, S., … 
Ashworth, A. (2006). Deficiency in the repair of DNA damage by homologous 
recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. 
Cancer Research, 66(16), 8109–15. doi:10.1158/0008-5472.CAN-06-0140 
McEllin, B., Camacho, C. V, Mukherjee, B., Hahm, B., Tomimatsu, N., Bachoo, R. 
M., & Burma, S. (2010). PTEN loss compromises homologous recombination 
repair in astrocytes: implications for glioblastoma therapy with temozolomide or 
poly(ADP-ribose) polymerase inhibitors. Cancer Research, 70(13), 5457–64. 
doi:10.1158/0008-5472.CAN-09-4295 
Mendes-Pereira, A. M., Martin, S. A., Brough, R., McCarthy, A., Taylor, J. R., Kim, 
J.-S., … Ashworth, A. (2009). Synthetic lethal targeting of PTEN mutant cells 
with PARP inhibitors. EMBO Molecular Medicine, 1(6-7), 315–22. 
doi:10.1002/emmm.200900041 
Mitsuhashi, N., Shimizu, H., Ohtsuka, M., Wakabayashi, Y., Ito, H., Kimura, F., … 
Miyazaki, M. (2003). Angiopoietins and Tie-2 expression in angiogenesis and 
proliferation of human hepatocellular carcinoma. Hepatology (Baltimore, Md.), 
37(5), 1105–13. doi:10.1053/jhep.2003.50204 
Monnier, J., Boissan, M., L’Helgoualc'h, A., Lacombe, M.-L., Turlin, B., Zucman-
Rossi, J., … Samson, M. (2012). CXCR7 is up-regulated in human and murine 
hepatocellular carcinoma and is specifically expressed by endothelial cells. 
European Journal of Cancer (Oxford, England!: 1990), 48(1), 138–48. 
doi:10.1016/j.ejca.2011.06.044 
Nakagawa, H., & Shibata, T. (2013). Comprehensive genome sequencing of the liver 
cancer genome. Cancer Letters, 340(2), 234–240. 
doi:10.1016/j.canlet.2012.10.035 
Ng, I. O., Poon, R. T., Lee, J. M., Fan, S. T., Ng, M., & Tso, W. K. (2001). 
Microvessel density, vascular endothelial growth factor and its receptors Flt-1 
and Flk-1/KDR in hepatocellular carcinoma. American Journal of Clinical 
 136 
Pathology, 116(6), 838–45. doi:10.1309/FXNL-QTN1-94FH-AB3A 
Niu, R. F., Zhang, L., Xi, G. M., Wei, X. Y., Yang, Y., Shi, Y. R., & Hao, X. S. 
(2007). Up-regulation of Twist induces angiogenesis and correlates with 
metastasis in hepatocellular carcinoma. Journal of Experimental & Clinical 
Cancer Research!: CR, 26(3), 385–94. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/17987801 
Niwa, Y., Kanda, H., Shikauchi, Y., Saiura, A., Matsubara, K., Kitagawa, T., … 
Yoshikawa, H. (2005). Methylation silencing of SOCS-3 promotes cell growth 
and migration by enhancing JAK/STAT and FAK signalings in human 
hepatocellular carcinoma. Oncogene, 24(42), 6406–17. 
doi:10.1038/sj.onc.1208788 
Noh, K. H., Kang, T. H., Kim, J. H., Pai, S. I., Lin, K. Y., Hung, C.-F., … Kim, T. 
W. (2009). Activation of Akt as a mechanism for tumor immune evasion. 
Molecular Therapy!: The Journal of the American Society of Gene Therapy, 
17(3), 439–47. doi:10.1038/mt.2008.255 
Nomura, F., Yaguchi, M., Togawa, A., Miyazaki, M., Isobe, K., Miyake, M., … 
Nakai, T. (2000). Enhancement of poly-adenosine diphosphate-ribosylation in 
human hepatocellular carcinoma. Journal of Gastroenterology and Hepatology, 
15(5), 529–35. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10847440 
Oh, B.-K., Jo Chae, K., Park, C., Kim, K., Jung Lee, W., Han, K., & Nyun Park, Y. 
(2003). Telomere shortening and telomerase reactivation in dysplastic nodules 
of human hepatocarcinogenesis. Journal of Hepatology, 39(5), 786–792. 
doi:10.1016/S0168-8278(03)00395-7 
Oh, B.-K., Kim, H., Park, Y. N., Yoo, J. E., Choi, J., Kim, K.-S., … Park, C. (2008). 
High telomerase activity and long telomeres in advanced hepatocellular 
carcinomas with poor prognosis. Laboratory Investigation; a Journal of 
Technical Methods and Pathology, 88(2), 144–52. 
doi:10.1038/labinvest.3700710 
Ozcelik, D., Ozaras, R., Gurel, Z., Uzun, H., & Aydin, S. (2003). Copper-mediated 
 137 
oxidative stress in rat liver. Biological Trace Element Research, 96(1-3), 209–
15. doi:10.1385/BTER:96:1-3:209 
Pan, Y., Tan, Y., Wang, M., Zhang, J., Zhang, B., Yang, C., … Wang, H. (2013). 
Signal regulatory protein α is associated with tumor-polarized macrophages 
phenotype switch and plays a pivotal role in tumor progression. Hepatology 
(Baltimore, Md.), 58(2), 680–91. doi:10.1002/hep.26391 
Pang, R., & Poon, R. T. P. (2006). Angiogenesis and antiangiogenic therapy in 
hepatocellular carcinoma. Cancer Letters, 242(2), 151–67. 
doi:10.1016/j.canlet.2006.01.008 
Pedroza-Gonzalez, A., Verhoef, C., Ijzermans, J. N. M., Peppelenbosch, M. P., 
Kwekkeboom, J., Verheij, J., … Sprengers, D. (2013). Activated tumor-
infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with 
primary or metastatic liver cancer. Hepatology (Baltimore, Md.), 57(1), 183–94. 
doi:10.1002/hep.26013 
Perz, J. F., Armstrong, G. L., Farrington, L. a, Hutin, Y. J. F., & Bell, B. P. (2006). 
The contributions of hepatitis B virus and hepatitis C virus infections to 
cirrhosis and primary liver cancer worldwide. Journal of Hepatology, 45(4), 
529–38. doi:10.1016/j.jhep.2006.05.013 
Plentz, R. R., Caselitz, M., Bleck, J. S., Gebel, M., Flemming, P., Kubicka, S., … 
Rudolph, K. L. (2004). Hepatocellular telomere shortening correlates with 
chromosomal instability and the development of human hepatoma. Hepatology 
(Baltimore, Md.), 40(1), 80–6. doi:10.1002/hep.20271 
Poon, R. T. P., Ho, J. W. Y., Tong, C. S. W., Lau, C., Ng, I. O. L., & Fan, S.-T. 
(2004). Prognostic significance of serum vascular endothelial growth factor and 
endostatin in patients with hepatocellular carcinoma. The British Journal of 
Surgery, 91(10), 1354–60. doi:10.1002/bjs.4594 
Porta, C., De Amici, M., Quaglini, S., Paglino, C., Tagliani, F., Boncimino, A., … 
Corazza, G. R. (2008). Circulating interleukin-6 as a tumor marker for 
hepatocellular carcinoma. Annals of Oncology!: Official Journal of the 
 138 
European Society for Medical Oncology / ESMO, 19(2), 353–8. 
doi:10.1093/annonc/mdm448 
Porta, C., Paglino, C., & Mosca, A. (2014). Targeting PI3K/Akt/mTOR Signaling in 
Cancer. Frontiers in Oncology, 4, 64. doi:10.3389/fonc.2014.00064 
Potente, M., Urbich, C., Sasaki, K., Hofmann, W. K., Heeschen, C., Aicher, A., … 
Dimmeler, S. (2005). Involvement of Foxo transcription factors in angiogenesis 
and postnatal neovascularization. The Journal of Clinical Investigation, 115(9), 
2382–92. doi:10.1172/JCI23126 
Raoul, J.-L., Bruix, J., Greten, T. F., Sherman, M., Mazzaferro, V., Hilgard, P., … 
Llovet, J. M. (2012). Relationship between baseline hepatic status and outcome, 
and effect of sorafenib on liver function: SHARP trial subanalyses. Journal of 
Hepatology, 56(5), 1080–8. doi:10.1016/j.jhep.2011.12.009 
Rebouissou, S., Amessou, M., Couchy, G., Poussin, K., Imbeaud, S., Pilati, C., … 
Zucman-Rossi, J. (2009). Frequent in-frame somatic deletions activate gp130 in 
inflammatory hepatocellular tumours. Nature, 457(7226), 200–4. 
doi:10.1038/nature07475 
Rodon, J., Dienstmann, R., Serra, V., & Tabernero, J. (2013). Development of PI3K 
inhibitors: lessons learned from early clinical trials. Nature Reviews. Clinical 
Oncology, 10(3), 143–53. doi:10.1038/nrclinonc.2013.10 
Sakurai, T., He, G., Matsuzawa, A., Yu, G.-Y., Maeda, S., Hardiman, G., & Karin, 
M. (2008). Hepatocyte necrosis induced by oxidative stress and IL-1 alpha 
release mediate carcinogen-induced compensatory proliferation and liver 
tumorigenesis. Cancer Cell, 14(2), 156–65. doi:10.1016/j.ccr.2008.06.016 
Sethi, N., & Kang, Y. (2011). Unravelling the complexity of metastasis - molecular 
understanding and targeted therapies. Nature Reviews. Cancer, 11(10), 735–48. 
doi:10.1038/nrc3125 
Shen, W. H., Balajee, A. S., Wang, J., Wu, H., Eng, C., Pandolfi, P. P., & Yin, Y. 
(2007). Essential role for nuclear PTEN in maintaining chromosomal integrity. 
 139 
Cell, 128(1), 157–70. doi:10.1016/j.cell.2006.11.042 
Shen, Y.-C., Lin, Z.-Z., Hsu, C.-H., Hsu, C., Shao, Y.-Y., & Cheng, A.-L. (2013). 
Clinical Trials in Hepatocellular Carcinoma: An Update. Liver Cancer, 2(3-4), 
345–364. doi:10.1159/000343850 
Shen, Z., Huang, S., Fang, M., & Wang, X. (2011). ENTPD5, an endoplasmic 
reticulum UDPase, alleviates ER stress induced by protein overloading in AKT-
activated cancer cells. Cold Spring Harbor Symposia on Quantitative Biology, 
76, 217–23. doi:10.1101/sqb.2011.76.010876 
Shim, J. S., & Liu, J. O. (2014). Recent Advances in Drug Repositioning for the 
Discovery of New Anticancer Drugs. International Journal of Biological 
Sciences, 10(7), 654–663. doi:10.7150/ijbs.9224 
Shimamura, T., Saito, S., Morita, K., Kitamura, T., Morimoto, M., Kiba, T., … 
Sekihara, H. (2000). Detection of vascular endothelial growth factor and its 
receptor expression in human hepatocellular carcinoma biopsy specimens. 
Journal of Gastroenterology and Hepatology, 15(6), 640–6. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/10921418 
Shimizu, S., Nomura, F., Tomonaga, T., Sunaga, M., Noda, M., Ebara, M., & Saisho, 
H. (2004). Expression of poly(ADP-ribose) polymerase in human hepatocellular 
carcinoma and analysis of biopsy specimens obtained under sonographic 
guidance. Oncology Reports, 12(4), 821–5. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/15375506 
Sikand, K., Singh, J., Ebron, J. S., & Shukla, G. C. (2012). Housekeeping Gene 
Selection Advisory: Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) 
and β-Actin Are Targets of miR-644a. PLoS ONE, 7(10), e47510. Retrieved 
from http://dx.doi.org/10.1371/journal.pone.0047510 
Soldani, C., & Scovassi, A. I. (2002). Poly(ADP-ribose) polymerase-1 cleavage 
during apoptosis: an update. Apoptosis!: An International Journal on 
Programmed Cell Death, 7(4), 321–8. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/12101391 
 140 
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012). The functions and regulation of 
the PTEN tumour suppressor. Nature Reviews. Molecular Cell Biology, 13(5), 
283–96. doi:10.1038/nrm3330 
Sonntag, R., Gassler, N., Bangen, J.-M., Trautwein, C., & Liedtke, C. (2014). Pro-
apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and 
is associated with PUMA expression in vitro and in vivo. Cell Death & Disease, 
5, e1030. doi:10.1038/cddis.2013.557 
Stark, A., Brennecke, J., Bushati, N., Russell, R. B., & Cohen, S. M. (2005, 
December 16). Animal MicroRNAs Confer Robustness to Gene Expression and 
Have a Significant Impact on 32UTR Evolution. Cell. Cell Press. Retrieved 
from http://linkinghub.elsevier.com/retrieve/pii/S0092867405012729 
Sugano, Y., Matsuzaki, K., Tahashi, Y., Furukawa, F., Mori, S., Yamagata, H., … 
Inoue, K. (2003). Distortion of autocrine transforming growth factor beta signal 
accelerates malignant potential by enhancing cell growth as well as PAI-1 and 
VEGF production in human hepatocellular carcinoma cells. Oncogene, 22(15), 
2309–21. doi:10.1038/sj.onc.1206305 
Sun, R. C., & Denko, N. C. (2014). Hypoxic Regulation of Glutamine Metabolism 
through HIF1 and SIAH2 Supports Lipid Synthesis that Is Necessary for Tumor 
Growth. Cell Metabolism, 19(2), 285–92. doi:10.1016/j.cmet.2013.11.022 
Sun, X., Sui, Q., Zhang, C., Tian, Z., & Zhang, J. (2013). Targeting blockage of 
STAT3 in hepatocellular carcinoma cells augments NK cell functions via 
reverse hepatocellular carcinoma-induced immune suppression. Molecular 
Cancer Therapeutics, 12(12), 2885–96. doi:10.1158/1535-7163.MCT-12-1087 
Sun, Y., Li, Y., Luo, D., & Liao, D. J. (2012). Pseudogenes as Weaknesses of ACTB 
(Actb) and GAPDH (Gapdh) Used as Reference Genes in Reverse Transcription 
and Polymerase Chain Reactions. PLoS ONE, 7(8), e41659. Retrieved from 
http://dx.doi.org/10.1371/journal.pone.0041659 
Tacke, R. S., Tosello-Trampont, A., Nguyen, V., Mullins, D. W., & Hahn, Y. S. 
(2011). Extracellular hepatitis C virus core protein activates STAT3 in human 
 141 
monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. The 
Journal of Biological Chemistry, 286(12), 10847–55. 
doi:10.1074/jbc.M110.217653 
Takada, S., & Koike, K. (1989). Activated N-ras gene was found in human hepatoma 
tissue but only in a small fraction of the tumor cells. Oncogene, 4(2), 189–93. 
Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2538792 
Tang, X., Mo, C., Wang, Y., Wei, D., & Xiao, H. (2013). Anti-tumour strategies 
aiming to target tumour-associated macrophages. Immunology, 138(2), 93–104. 
doi:10.1111/imm.12023 
Teicher, B. A., Linehan, W. M., & Helman, L. J. (2012). Targeting cancer 
metabolism. Clinical Cancer Research!: An Official Journal of the American 
Association for Cancer Research, 18(20), 5537–45. doi:10.1158/1078-
0432.CCR-12-2587 
Thomson, A. W., Turnquist, H. R., & Raimondi, G. (2009). Immunoregulatory 
functions of mTOR inhibition. Nature Reviews. Immunology, 9(5), 324–37. 
doi:10.1038/nri2546 
Toh, S. T., Jin, Y., Liu, L., Wang, J., Babrzadeh, F., Gharizadeh, B., … Lee, C. G.-L. 
(2013). Deep sequencing of the hepatitis B virus in hepatocellular carcinoma 
patients reveals enriched integration events, structural alterations and sequence 
variations. Carcinogenesis, 34(4), 787–98. doi:10.1093/carcin/bgs406 
Totoki, Y., Tatsuno, K., Yamamoto, S., Arai, Y., Hosoda, F., Ishikawa, S., … 
Shibata, T. (2011). High-resolution characterization of a hepatocellular 
carcinoma genome. Nature Genetics, 43(5), 464–9. doi:10.1038/ng.804 
Trikha, M., Corringham, R., Klein, B., & Rossi, J.-F. (2003). Targeted anti-
interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale 
and clinical evidence. Clinical Cancer Research!: An Official Journal of the 
American Association for Cancer Research, 9(13), 4653–65. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2929399&tool=pmc
entrez&rendertype=abstract 
 142 
Tschopp, O., Yang, Z.-Z., Brodbeck, D., Dummler, B. A., Hemmings-Mieszczak, 
M., Watanabe, T., … Hemmings, B. A. (2005). Essential role of protein kinase 
B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose 
homeostasis. Development (Cambridge, England), 132(13), 2943–54. 
doi:10.1242/dev.01864 
Tsuda, H., Hirohashi, S., Shimosato, Y., Ino, Y., Yoshida, T., & Terada, M. (1989). 
Low incidence of point mutation of c-Ki-ras and N-ras oncogenes in human 
hepatocellular carcinoma. Japanese Journal of Cancer Research!: Gann, 80(3), 
196–9. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2542205 
Van Zijl, F., Mair, M., Csiszar, A., Schneller, D., Zulehner, G., Huber, H., … 
Mikulits, W. (2009). Hepatic tumor-stroma crosstalk guides epithelial to 
mesenchymal transition at the tumor edge. Oncogene, 28(45), 4022–33. 
doi:10.1038/onc.2009.253 
Van Zijl, F., Zulehner, G., Petz, M., Schneller, D., Kornauth, C., Hau, M., … 
Mikulits, W. (2009). Epithelial-mesenchymal transition in hepatocellular 
carcinoma. Future Oncology (London, England), 5(8), 1169–79. 
doi:10.2217/fon.09.91 
Vandesompele, J., De Preter, K., Pattyn, F., Poppe, B., Van Roy, N., De Paepe, A., & 
Speleman, F. (2002). Accurate normalization of real-time quantitative RT-PCR 
data by geometric averaging of multiple internal control genes. Genome 
Biology, 3(7), RESEARCH0034. Retrieved from 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=126239&tool=pmce
ntrez&rendertype=abstract 
Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010). 
The emerging mechanisms of isoform-specific PI3K signalling. Nature 
Reviews. Molecular Cell Biology, 11(5), 329–41. doi:10.1038/nrm2882 
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., … Llovet, 
J. M. (2008). Pivotal role of mTOR signaling in hepatocellular carcinoma. 
Gastroenterology, 135(6), 1972–83, 1983.e1–11. 
 143 
doi:10.1053/j.gastro.2008.08.008 
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, 
M. J., … Strasser, A. (2003). p53- and drug-induced apoptotic responses 
mediated by BH3-only proteins puma and noxa. Science (New York, N.Y.), 
302(5647), 1036–8. doi:10.1126/science.1090072 
Vogt, P. K., & Hart, J. R. (2011). PI3K and STAT3: a new alliance. Cancer 
Discovery, 1(6), 481–6. doi:10.1158/2159-8290.CD-11-0218 
WARBURG, O. (1956). On the origin of cancer cells. Science (New York, N.Y.), 
123(3191), 309–14. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/13298683 
WARRINGTON, J. A., NAIR, A., MAHADEVAPPA, M., & TSYGANSKAYA, M. 
(2000). Comparison of human adult and fetal expression and identification of 
535 housekeeping/maintenance genes. Physiological Genomics , 2 (3 ), 143–
147. Retrieved from 
http://physiolgenomics.physiology.org/content/2/3/143.abstract 
Waxman, S., & Wurmbach, E. (2007). De-regulation of common housekeeping 
genes in hepatocellular carcinoma. BMC Genomics, 8, 243. doi:10.1186/1471-
2164-8-243 
Wilhelm, S., Carter, C., Lynch, M., Lowinger, T., Dumas, J., Smith, R. a, … Kelley, 
S. (2006). Discovery and development of sorafenib: a multikinase inhibitor for 
treating cancer. Nature Reviews. Drug Discovery, 5(10), 835–44. 
doi:10.1038/nrd2130 
Williamson, C. T., Muzik, H., Turhan, A. G., Zamò, A., O’Connor, M. J., Bebb, D. 
G., & Lees-Miller, S. P. (2010). ATM deficiency sensitizes mantle cell 
lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Molecular 
Cancer Therapeutics, 9(2), 347–57. doi:10.1158/1535-7163.MCT-09-0872 
Wong, C.-M., Yam, J. W.-P., Ching, Y.-P., Yau, T.-O., Leung, T. H.-Y., Jin, D.-Y., 
& Ng, I. O.-L. (2005). Rho GTPase-activating protein deleted in liver cancer 
 144 
suppresses cell proliferation and invasion in hepatocellular carcinoma. Cancer 
Research, 65(19), 8861–8. doi:10.1158/0008-5472.CAN-05-1318 
Woo, H. G., Park, E. S., Lee, J.-S., Lee, Y.-H., Ishikawa, T., Kim, Y. J., & 
Thorgeirsson, S. S. (2009). Identification of potential driver genes in human 
liver carcinoma by genomewide screening. Cancer Research, 69(9), 4059–66. 
doi:10.1158/0008-5472.CAN-09-0164 
Wörns, M.-A., & Galle, P. R. (2014). HCC therapies-lessons learned. Nature 
Reviews. Gastroenterology & Hepatology, 11(7), 447–52. 
doi:10.1038/nrgastro.2014.10 
Wu, S.-D., Ma, Y.-S., Fang, Y., Liu, L.-L., Fu, D., & Shen, X.-Z. (2012). Role of the 
microenvironment in hepatocellular carcinoma development and progression. 
Cancer Treatment Reviews, 38(3), 218–25. doi:10.1016/j.ctrv.2011.06.010 
Wu, Z., Wang, Y., & Chen, L. (2013). Network-based drug repositioning. Molecular 
bioSystems, 9(6), 1268–81. doi:10.1039/c3mb25382a 
Xu, B., Di, J., Wang, Z., Han, X., Li, Z., Luo, X., & Zheng, Q. (2013). Quantitative 
analysis of RASSF1A promoter methylation in hepatocellular carcinoma and its 
prognostic implications. Biochemical and Biophysical Research 
Communications, 438(2), 324–8. doi:10.1016/j.bbrc.2013.07.070 
Xu, X., Sakon, M., Nagano, H., Hiraoka, N., Yamamoto, H., Hayashi, N., … 
Monden, M. (2004). Akt2 expression correlates with prognosis of human 
hepatocellular carcinoma. Oncology Reports, 11(1), 25–32. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/14654898 
Xu, X., Ye, L., Araki, K., & Ahmed, R. (2012). mTOR, linking metabolism and 
immunity. Seminars in Immunology, 24(6), 429–35. 
doi:10.1016/j.smim.2012.12.005 
Yamazaki, K., Masugi, Y., & Sakamoto, M. (2011). Molecular pathogenesis of 
hepatocellular carcinoma: altering transforming growth factor-β signaling in 
hepatocarcinogenesis. Digestive Diseases (Basel, Switzerland), 29(3), 284–8. 
 145 
doi:10.1159/000327560 
Yan, W., Fu, Y., Tian, D., Liao, J., Liu, M., Wang, B., … Luo, M. (2009). PI3 
kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic 
hepatocellular carcinoma cells. Biochemical and Biophysical Research 
Communications, 382(3), 631–6. doi:10.1016/j.bbrc.2009.03.088 
Yang, H. W., Shin, M.-G., Lee, S., Kim, J.-R., Park, W. S., Cho, K.-H., … Heo, W. 
Do. (2012). Cooperative activation of PI3K by Ras and Rho family small 
GTPases. Molecular Cell, 47(2), 281–90. doi:10.1016/j.molcel.2012.05.007 
Yang, L., Wang, K.-J., Wang, L.-S., Jegga, A. G., Qin, S.-Y., He, G., … He, L. 
(2011). Chemical-protein interactome and its application in off-target 
identification. Interdisciplinary Sciences, Computational Life Sciences, 3(1), 
22–30. doi:10.1007/s12539-011-0051-8 
Yang, M.-H., Chen, C.-L., Chau, G.-Y., Chiou, S.-H., Su, C.-W., Chou, T.-Y., … 
Wu, J.-C. (2009). Comprehensive analysis of the independent effect of twist and 
snail in promoting metastasis of hepatocellular carcinoma. Hepatology 
(Baltimore, Md.), 50(5), 1464–74. doi:10.1002/hep.23221 
Yao, Y. J., Ping, X. L., Zhang, H., Chen, F. F., Lee, P. K., Ahsan, H., … Tsou, H. C. 
(1999). PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene, 
18(20), 3181–5. doi:10.1038/sj.onc.1202659 
Yildiz, G., Arslan-Ergul, A., Bagislar, S., Konu, O., Yuzugullu, H., Gursoy-
Yuzugullu, O., … Ozturk, M. (2013). Genome-wide transcriptional 
reorganization associated with senescence-to-immortality switch during human 
hepatocellular carcinogenesis. PloS One, 8(5), e64016. 
doi:10.1371/journal.pone.0064016 
Yoshikawa, H., Matsubara, K., Qian, G. S., Jackson, P., Groopman, J. D., Manning, 
J. E., … Herman, J. G. (2001). SOCS-1, a negative regulator of the JAK/STAT 
pathway, is silenced by methylation in human hepatocellular carcinoma and 
shows growth-suppression activity. Nature Genetics, 28(1), 29–35. 
doi:10.1038/88225 
 146 
Yu, H., Pardoll, D., & Jove, R. (2009). STATs in cancer inflammation and 
immunity: a leading role for STAT3. Nature Reviews. Cancer, 9(11), 798–809. 
doi:10.1038/nrc2734 
Yu, J., & Zhang, L. (2008). PUMA, a potent killer with or without p53. Oncogene, 
27 Suppl 1, S71–83. doi:10.1038/onc.2009.45 
Zhang, L., Zhou, F., & ten Dijke, P. (2013). Signaling interplay between 
transforming growth factor-β receptor and PI3K/AKT pathways in cancer. 
Trends in Biochemical Sciences, 38(12), 612–20. doi:10.1016/j.tibs.2013.10.001 
Zhang, Q.-B., Sun, H.-C., Zhang, K.-Z., Jia, Q.-A., Bu, Y., Wang, M., … Tang, Z.-
Y. (2013). Suppression of natural killer cells by sorafenib contributes to 
prometastatic effects in hepatocellular carcinoma. PloS One, 8(2), e55945. 
doi:10.1371/journal.pone.0055945 
Zheng, L., Yang, W., Wu, F., Wang, C., Yu, L., Tang, L., … Wang, H. (2013). 
Prognostic significance of AMPK activation and therapeutic effects of 
metformin in hepatocellular carcinoma. Clinical Cancer Research!: An Official 
Journal of the American Association for Cancer Research, 19(19), 5372–80. 
doi:10.1158/1078-0432.CCR-13-0203 
Zlotnik, A., Burkhardt, A. M., & Homey, B. (2011). Homeostatic chemokine 
receptors and organ-specific metastasis. Nature Reviews. Immunology, 11(9), 
597–606. doi:10.1038/nri3049 
  
 147 
APPENDIX 
 
 
 
 
 
 
ELSEVIER LICENSE
TERMS AND CONDITIONS
Jul 21, 2014
This is a License Agreement between Tulin Ersahin ("You") and Elsevier ("Elsevier")
provided by Copyright Clearance Center ("CCC"). The license consists of your order details,
the terms and conditions provided by Elsevier, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
Supplier Elsevier Limited
The Boulevard,Langford Lane
Kidlington,Oxford,OX5 1GB,UK
Registered Company
Number
1982084
Customer name Tulin Ersahin
Customer address Bilkent University
 Ankara, 06800
License number 3433770253849
License date Jul 21, 2014
Licensed content publisher Elsevier
Licensed content publication Cell
Licensed content title Hallmarks of Cancer: The Next Generation
Licensed content author Douglas Hanahan,Robert A. Weinberg
Licensed content date 4 March 2011
Licensed content volume
number
144
Licensed content issue
number
5
Number of pages 29
Start Page 646
End Page 674
Type of Use reuse in a thesis/dissertation
Intended publisher of new
work
other
Portion figures/tables/illustrations
Number of
figures/tables/illustrations
1
Format both print and electronic
Are you the author of this
Elsevier article?
No
Will you be translating? No
NATURE PUBLISHING GROUP LICENSE
TERMS AND CONDITIONS
Jul 21, 2014
This is a License Agreement between Tulin Ersahin ("You") and Nature Publishing Group
("Nature Publishing Group") provided by Copyright Clearance Center ("CCC"). The license
consists of your order details, the terms and conditions provided by Nature Publishing
Group, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number 3433821311713
License date Jul 21, 2014
Licensed content publisher Nature Publishing Group
Licensed content publication Nature Reviews Clinical Oncology
Licensed content title Development of PI3K inhibitors: lessons learned from early clinical
trials
Licensed content author Jordi Rodon, Rodrigo Dienstmann, Violeta Serra and Josep
Tabernero
Licensed content date Feb 12, 2013
Volume number 10
Issue number 3
Type of Use reuse in a dissertation / thesis
Requestor type academic/educational
Format print and electronic
Portion figures/tables/illustrations
Number of
figures/tables/illustrations
1
High-res required no
Figures Figure 1: Signaling of PI3K and relevant drugs
Author of this NPG article no
Your reference number None
Title of your thesis /
dissertation
Systems biology approach for targeted therapy of liver cancer
Expected completion date Aug 2014
Estimated size (number of
pages)
250
Total 0.00 USD
Terms and Conditions
Terms and Conditions for Permissions
NATURE PUBLISHING GROUP LICENSE
TERMS AND CONDITIONS
Jul 21, 2014
This is a License Agreement between Tulin Ersahin ("You") and Nature Publishing Group
("Nature Publishing Group") provided by Copyright Clearance Center ("CCC"). The license
consists of your order details, the terms and conditions provided by Nature Publishing
Group, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number 3433770051467
License date Jul 21, 2014
Licensed content publisher Nature Publishing Group
Licensed content publication Nature Reviews Drug Discovery
Licensed content title Targeting the phosphoinositide 3-kinase pathway in cancer
Licensed content author Pixu Liu, Hailing Cheng, Thomas M. Roberts and Jean J. Zhao
Licensed content date Aug 1, 2009
Volume number 8
Issue number 8
Type of Use reuse in a dissertation / thesis
Requestor type academic/educational
Format print and electronic
Portion figures/tables/illustrations
Number of
figures/tables/illustrations
3
High-res required no
Figures Figure 1: The class i Pi3K signalling pathway Figure 3: Targeting the
Pi3K pathway in cancer Figure 5: Function and therapeutic targeting
of p110 isoforms
Author of this NPG article no
Your reference number None
Title of your thesis /
dissertation
Systems biology approach for targeted therapy of liver cancer
Expected completion date Aug 2014
Estimated size (number of
pages)
250
Total 0.00 USD
Terms and Conditions
Terms and Conditions for Permissions
ELSEVIER LICENSE
TERMS AND CONDITIONS
Jul 21, 2014
This is a License Agreement between Tulin Ersahin ("You") and Elsevier ("Elsevier")
provided by Copyright Clearance Center ("CCC"). The license consists of your order details,
the terms and conditions provided by Elsevier, and the payment terms and conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
Supplier Elsevier Limited
The Boulevard,Langford Lane
Kidlington,Oxford,OX5 1GB,UK
Registered Company
Number
1982084
Customer name Tulin Ersahin
Customer address Bilkent University
 Ankara, 06800
License number 3433810817720
License date Jul 21, 2014
Licensed content publisher Elsevier
Licensed content publication Cellular Signalling
Licensed content title Function of Akt/PKB signaling to cell motility, invasion and the tumor
stroma in cancer
Licensed content author Y. Rebecca Chin,Alex Toker
Licensed content date April 2009
Licensed content volume
number
21
Licensed content issue
number
4
Number of pages 7
Start Page 470
End Page 476
Type of Use reuse in a thesis/dissertation
Portion figures/tables/illustrations
Number of
figures/tables/illustrations
1
Format both print and electronic
Are you the author of this
Elsevier article?
No
Will you be translating? No
Title of your Systems biology approach for targeted therapy of liver cancer
Decision Letter (mcb.200400024/pub2)
From: emcbmm@wiley.com
To: rengul@bilkent.edu.tr, vatalay@metu.edu.tr
CC:
Subject: Encyclopedia of Molecular Cell Biology and Molecular Medicine - Manuscript ID mcb.200400024/pub2 hasbeen accepted
Body: Dear Dr. Cetin-Atalay, 
It is a pleasure to accept your manuscript entitled "Molecular Biology of Liver Cancer" in its current form
for publication in Encyclopedia of Molecular Cell Biology and Molecular Medicine. 
Thank you for your excellent contribution. 
Sincerely, 
Sarah Mellor 
Managing Editor 
Wiley-VCH 
emcbmm@wiley.com 
on behalf of 
Dr Bob Meyers 
Reviewer: 1 
Comments to the Author 
Reviewing report for mcb.200400024/pub2 from T. Ersahin et alii. 
In this paper Ersahin and coworkers propose a full panoramic view of the molecular pathways altered in
hepatocellular carcinoma (HCC) one of the most deadly tumor in humans. 
Their work takes as a guideline the catalog of cancer hallmarks proposed by Hanahan and Weinberg. The
authors performed, thus, a search for altered pathways relevant to each class of hallmarks. The work is a
genuine sum of work without equivalent in the literature. It is easy to read and may provide a sound basis
for basic or translational researchers willing to conduct analyses on HCC tissues or cell lines. 
In this brilliant and consistent contribution, a single aspect was worrying. Epigenetic aspects (section 5)
cover 15 lines of the manuscript. Surprisingly, the authors consider that “epigenome of HCC is highly
affected. DNA methylation changes appear to predominate HCC epigenome” (last paragraph of
conclusion). 
Considering this statement, is it possible to get a table similar to that produced for miRNA but filled with
the principal relevant targets of DNA methylation in HCC ? 
I have, in addition, only few minor remarks to make after examination of this remarkable manuscript 
1. Introduction 
Why are all references mentioned in this section without a proper numerotation ? This should be corrected
in the final version of the text. 
The authors mention that endogenous toxic metabolites participate to liver injury. Could they provide the
name of such compounds as an illustration of their statement ? For metal ions mentioning Fe, Cu or As
will be useful to be mentioned as well for outsiders to the field. 
2.1 Genome instability and mutations 
-hTert is cited as the most heavily mutated gene in HCC. Although, it may be perfectly true, it may
appear as an elementary cautiousness to be less affirmative in this matter. There is only one publication
describing Htert mutations and HCC is intrinsically heterogeneous as emphasized later on by the authors
themselves. 
-beta-catenin mutations in HCV-associated tumors on non-cirrhotic livers: The “non-cirrhotic” situation is
particularly infrequent with HCV. The authors mentioned a puzzling number of 8 references attached to
this particular situation. Could they focus more precisely on the report describing what they describe ? 
-RB gene is mentioned as mutated in 15% of cases. The few reports that mentioned these mutations are
old. Furthermore, RB was never found mutated in recently performed exome analyses. I consider that the
authors should be less affirmative concerning RB. 
-CDKN2A: what is the meaning of “quite frequently” ? Please, give a range. 
2.6 Replicative immortality 
ROS accumulation : “accumulation” sounds as a rather inappropriate term for the ROS that are
notoriously unstable compounds. “Sustained production” is maybe more faithful to the reality. In addition,
ROS are toxic compounds that kill the cells instead of conferring immortality. It is, thus, an abusive
shortcut to consider their abundant presence as beneficial
 
Encyclopedia of Molecular Cell Biology and Molecular Medicine
! 1!
Molecular Biology of Liver Cancer 
 
Tulin Ersahin1, Mehmet Ozturk2, Rengul Cetin-Atalay1,3  
1Department of Molecular Biology and Genetics, Bilkent University, Ankara, 06800, Turkey 
2Dokuz Eylul University, Advanced Biomedical Research Center, 035340, Izmir, Turkey.  
3Corresponding author 
 
1. Introduction 
2. Molecular Hallmarks of Hepatocellular Carcinoma 
2.1. Genomic instability and Mutations  
2.2. Sustaining Proliferative Signaling  
2.3. Evading Growth Suppressors  
2.4. Resisting Cell Death  
2.5. Enabling Replicative Immortality  
2.6. Inducing Angiogenesis  
2.7. Activating Invasion and Metastasis  
2.8. Reprogramming Energy Metabolism  
2.9. Tumor-promoting inflammation  
2.10. Evading Immune Destruction  
3. Genome-wide changes in Hepatocellular Carcinoma 
4. MicroRNA Profiling in Hepatocellular Carcinoma 
5. Epigenetic Mechanisms  
6. Concluding Remarks 
References 
 
Keywords 
HBV 
A small DNA virus that infects hepatocytes in the liver, causing acute or chronic hepatitis. 
HCV 
A small RNA virus that infects hepatocytes in the liver, causing acute or chronic hepatitis. 
Genome-wide expression 
An experimental approach for the identification of disease-specific gene expression 
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profiles. 
Gene signatures 
Expression pattern of a set of genes associated with a clinical subtype of a disease. 
PI3K/AKT pathway 
A signaling pathway involved in cell survival that is hyper-activated in various cancers, 
including liver cancer. 
MAPK/ERK pathway 
Kinase protein cascade involved in cell survival that is up-regulated in various cancers, 
including liver cancer. 
P53 
A tumor suppressor protein that is inactivated by mutation in cancers, including liver 
cancer. 
hTERT 
Human telomerase reverse transcriptase that is inactivated by mutation in cancers, 
including liver cancer. 
 
 
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related 
mortality worldwide. Recent advances in the molecular profiling of HCC emphasize its intra-
tumoral heterogeneity and reveal how cellular pathways are altered in favor of tumor 
progression. Malignant transformation of primary liver cancer is achieved through the 
acquisition of cancer hallmark capabilities that promote uncontrolled proliferation hepatocytes. 
Here, we review the characteristics and acquired capabilities of human primary liver cancer 
based on the HCC-specific genetic and epigenetic alterations. 
1. Introduction 
Primary liver cancer is the fifth most frequently diagnosed cancer in men, and the 
seventh in women. However, due to its aggressive behavior and resistance to conventional 
therapies, liver cancer is the second most frequent cause of cancer death in men, and the 
sixth in women [1]. 748,300 new liver cancer cases and 695,900 cancer deaths were reported 
worldwide in 2008 [2]. Hepatocellular carcinoma (HCC) is the major histological subtype of 
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primary liver cancers, accounting for about 80% of the total liver cancer cases worldwide [3].  
The major risk factors for HCC are hepatitis B virus (HBV), hepatitis C virus (HCV) 
infections, alcohol, and aflatoxin B1 exposure. Development of HCC is a multistep process, 
where hepatic injury first leads to chronic liver disease and then continuous inflammation 
results in cycles of cell death and hepatocyte regeneration. The subsequent expansion of 
dysplastic nodules along with telomerase reactivation, and increased genomic instability is 
followed by malignant transformation [4]. Integration of HBV DNA into the host genome is 
frequent in HCC. On the other hand, RNA virus HCV leads to malignant transformation 
through oxidative stress and pro-inflammatory response induced by viral proteins [5–7]. In 
addition, exposure to exogenous (Aflatoxins) or endogenous (toxic metabolites such as 
steroids and cholesterol and metal ions such as copper, iron, nickel) hepatotoxic factors leads 
to liver injury and provokes an increase in the proliferating fraction of hepatocytes [8–12]. 
Therefore, chronic liver regeneration may itself be a source of spontaneous gene mutations 
leading to HCC [13]. 
The current classification system (Barcelona Clinic Liver Cancer - BCLC), considers 
HCC in five stages: very early, early, intermediate, advanced, and end-stage according to 
tumor size, nodule number, vascular invasion, metastasis and liver function [14]. Treatment 
strategy is determined based on the stage of the patient. Patients with very early and early 
HCC are treated with resection, liver transplantation or partial hepatectomy and patients with 
intermediate HCC are treated with chemoembolization [15]. However, patients are often 
diagnosed at advanced stage, where these treatments cannot be applied. Chemotherapy is 
the only treatment option for patients with advanced stage HCC. Yet, patients with the same 
BCLC stage can still have variable responses, due to high genomic heterogeneity of HCC [16, 
17]. Therefore, a molecular level classification is necessary for effective diagnosis and 
personalized treatment options. Genome-wide expression analysis, exome sequencing and 
microRNA profiling techniques are being used for efficient molecular classification of HCCs. 
Sorafenib (Nexavar, BAY43-9006), a multi-kinase inhibitor, is the only FDA-approved 
molecular-targeted agent for the treatment of patients with advanced HCC [18–20]. Sorafenib 
inhibits Raf, VEGFR, and PDGFR kinases, and thereby suppresses cell proliferation and 
angiogenesis. In the phase III randomized controlled trials, Sorafenib showed an overall 
survival benefit of three months [15, 21]. 
 Primary liver cancer is a major public health problem, which requires in-depth 
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molecular analysis in order to discover optimal targeted therapeutics. Due to the presence of 
genomic variations, custom-designed therapies based on our understanding of the molecular 
biology of liver cancer will be indispensable for the treatment of HCC in the future. 
2. Molecular Hallmarks of Hepatocellular Carcinoma 
Malignant transformation requires the cancer cells to acquire several growth-promoting 
characteristics to become tumorigenic and eventually malignant. Hepatocellular cancers drive 
from initially quiescent hepatocytes, whose growth is tightly controlled. The appearance of 
tumor in this highly controlled microenvironment suggests that initial HCC cells acquire 
phenotypic hallmarks of cancer described by Hanahan and Weinberg. Six core and two 
emerging cancer hallmark capabilities have been suggested: sustaining proliferative signaling, 
evading growth suppressors, resisting cell death, enabling replicative immortality, inducing 
angiogenesis, and activating invasion and metastasis, along with deregulating cellular 
energetics, and avoiding immune destruction [22]. Acquisition of these capabilities is 
facilitated by two enabling characteristics: genome instability and tumor-promoting 
inflammation during stepwise progression of HCC. 
2.1. Genome instability and Mutations 
Tumorigenesis is a multistep process that initiates from dysplastic lesions which 
accumulates somatically acquired mutations and genomic instability [23]. Genomic instability, 
including chromosomal rearrangements and point mutations, is an enabling characteristic of 
multistep tumorigenesis and underlies the acquisition of hallmark capabilities [22].  
HCC harbors chromosomal gains at 1q, 5, 6p, 7, 8q, 17q and 20 and losses at 1p, 4q, 
6q, 8p, 13q, 16, 17p and 21 [24, 25]. The gain of 1q and the loss of 1p and 17p are 
associated with early stages of HCC, while the gain of 6p, 5q and 8q and loss of 4q and 8p 
are associated with advanced stage HCC [26, 27]. Moreover, integration of HBV DNA within 
or upstream of the TERT (telomerase reverse transcriptase) gene in the host genome was 
observed in patients with HBV-related HCCs [28, 29]. DNA-damaging reactive oxygen 
species can also contribute to genomic instability [30, 31].  
The TERT gene is frequently mutated in HCC, allowing cells to gain replicative 
immortality. TERT promoter mutations in 44% of 61 HCC patients were shown to associate 
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with early stages of HCC independent of viral-infection, sex, age and ethnicity [32]. These 
mutations are associated with early stages of HCC and are independent of viral-infection, sex, 
age and ethnicity. TP53 is the second most frequently mutated tumor suppressor gene in 
HCC and is associated with poor prognosis [33]. Mutation rates are 50% and 20% in HCCs 
with or without aflatoxin exposure, respectively [34]. A hot spot mutation at codon 249 
(R249S) is specific to AFB1 exposure in 36 % tumors from Africa and 32% of tumors from 
China [35, 36]. Aberrant activation of Wnt/β-catenin signaling pathway, which plays a key role 
in hepatocarcinogenesis, is achieved by activating mutations of β-catenin (CTNNB1) and 
inactivating mutations or LOH of AXIN1 [24, 37–39]. Although mutations of retinoblastoma 
gene (RB1) are rare, RB is frequently inactivated in HCC through the loss of heterozygosity 
(LOH) of 13q, proteosomal degradation or aberrant cyclin-dependent kinase activity [40–42]. 
The cyclin-dependent kinase inhibitor 2A gene (p16), which acts as a tumor suppressor 
downstream of p53 and Rb is inactivated frequently in HCC [43, 44]. 
Mutations in the downstream elements of receptor tyrosine kinase (RTK) signaling are 
also observed in HCC. The inactivating mutations of the tumor suppressor gene Phosphatase 
and tensin homolog (PTEN), which is a negative regulator of PI3K/Akt survival pathway, are 
observed in HCC, but not very frequently [45–49]. Ras proto-oncogenes (H-ras, K-Ras, N-ras) 
are also rarely mutated and activated in HCC [43, 50–52]. Runt-related transcription factor 
(RUNX) family genes induce a senescence-like growth arrest in response to oncogenic Ras. 
Expression of one of the members of this family, RUNX3, is decreased in more then 50% of 
HCC cases [53, 54]. Its down-regulation is associated with escape from apoptosis and 
sustained growth [55, 56]. Recently, its role in mediating angiogenesis and of epithelial-
mesenchymal transition was also shown [57]. Thus, the loss of RUNX expression may explain 
the rarity of Ras mutations in these cancers. 
Less frequent inactivating tumor suppressing mutations of P14, IGFR2, KLF6, HNF1α, 
SMAD2, SMAD4 and LKB1/STK11, and less frequent activating oncogenic mutations of 
EGFR, Erb2, and PIK3CA have also been reported in HCC [58, 59]. Molecular alterations of 
critical genes and their contribution to the acquisition of hallmark capabilities are presented in 
Table 1. 
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Table 1. Molecular Alterations of Critical Genes in HCC 
Cellular 
Process 
Molecule Alteration in HCC Acquired Capability 
Growth factor 
signaling 
EGF / EGFR Up-regulation 
Sustaining proliferative signaling 
HGF / MET Up-regulation 
IGF / IGFR Overexpression Resisting cell death 
VEGF / VEGFR Up-regulation 
Inducing angiogenesis PDGF / PDGFR Up-regulation 
FGF / FGFR Up-regulation 
Cell Cycle 
Regulation 
TP53 
Inactivating mutation / 
LOH 
Sustaining proliferative signaling 
Evading growth suppressors 
RB1 
Inactivating mutation / 
LOH 
c-myc Overexpression 
p16 (CDKN2A) 
Inactivating mutation / 
Hypermethylation 
Cyclin D1 Overexpression 
IRF2 Inactivating mutation 
Ras/RAF 
pathway 
RAS Activating mutation Sustaining proliferative signaling 
Evading growth suppressors 
Inducing angiogenesis 
Activating invasion and 
metastasis 
RPS6KA3 Inactivating mutation 
PI3K/AKT 
pathway 
PI3K-alpha 
(PIK3CA) 
Activating mutation 
Sustaining proliferative signaling 
Evading growth suppressors 
Inducing angiogenesis 
Activating Invasion and 
Metastasis  
Reprogramming energy 
metabolism 
PTEN 
Inactivating mutation / 
LOH 
AKT Constitutive activation 
mTORC1 Up-regulation 
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JAK/Stat 
pathway 
Stat Constitutive activation 
Tumor-promoting inflammation 
SOCS1,SOCS3 Down-regulation 
NF-κB 
pathway 
NF-κB Constitutive activation 
Sustaining proliferative signaling 
Resisting cell death 
Tumor-promoting inflammation 
Wnt/훽-catenin 
pathway 
β-catenin 
(CTNNB1) 
Activating mutation / 
Overexpression 
Sustaining proliferative signaling 
Tumor-promoting inflammation AXIN1, AXIN2 
Inactivating mutation / 
LOH 
APC Inactivating mutation 
Hedgehog 
pathway 
SHH Overexpression 
Reprogramming energy 
metabolism 
SMO Overexpression 
HHIP LOH, hypermethylation 
Histone 
modification 
DNMT1, 3A, 3B Up-regulation 
Sustaining proliferative signaling 
Evading growth suppressors 
EZH2 Overexpression 
ARID1, ARID2 Inactivating mutation 
Apoptosis 
Fas Down-regulation 
Resisting cell death FasL Up-regulation 
DR5 Down-regulation 
Angiogenesis 
Angiopoietin Up-regulation 
Inducing angiogenesis 
Tie-2 Up-regulation 
Immunity Glypican-3 Up-regulation Evading immune destruction 
 
2.2. Sustaining Proliferative Signaling 
Constitutive activation of survival pathways, inactivation of tumor suppressors TP53, 
Rb, and p16, overexpression of c-myc and Cyclin D1, epigenetic silencing of p16INK4 and 
overexpression of E2F family members promote cell cycle progression and sustained 
proliferation of HCC cells.  
Growth factors and their corresponding activated tyrosine kinase receptors such as 
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EGF-EGFR, IGF-IGFR, and HGF-MET transmit the proliferation signal through 
Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways. Constitutive activation of these pathways 
are maintained through the overexpression of MET and EGFR and the inactivation or down-
regulation of the negative regulators PTEN and RASSF1A of PI3K/AKT/mTOR and 
Ras/Raf/MEK/ERK pathways respectively. Identification of potential driver genes in human 
liver carcinoma by genome-wide screening revealed genes with specific signaling pathways 
such as PI3K/Akt/mTOR, AMP-activated protein kinase (AMPK), and EGFR [60]. Cell 
proliferation in HCV-positive HCC is also associated with Myc and AKT activation [61]. 
Moreover, it is known that overexpression of E2F family members, which are responsible for 
the transcription of genes involved in cell cycle and proliferation, inhibits c-Myc-driven 
apoptosis through PI3K/AKT/mTOR pathway [62, 63].  
Additionally, large-scale analysis with high number of HCC samples revealed 
proliferation gene signatures. Chen et al., in 2002, showed high expression of a “proliferation 
cluster” comprised of genes required for cell cycle progression in 102 primary HCC tumor 
samples and 10 HCC cell lines [64]. Ribosomal protein genes were highly expressed as 
expected in cells with unlimited cell growth. Up-regulated genes were related to DNA 
replication and G2/M progression. In another study from 91 human primary HCC, a 
proliferation gene signature (containing PCNA, Bub3, MCM2, MCM6, MCM7, cyclinA2, 
cyclinB1, CKS2 and CDK4) was able to distinguish two groups of HCC patients with distinct 
prognosis [65].  
2.3. Evading Growth Suppressors 
Inactivation of pRB, p53 and p16, and overexpression of c-myc and cyclin D1 confer 
growth advantages in HCC. Activation of the MYC transcription signature is strongly 
associated with the malignant conversion of pre-neoplastic liver nodules and inactivation of 
MYC in invasive HCCs lead to sustained tumor regression as well as proliferation arrest, 
differentiation, and apoptosis of malignant cells [66, 67].  
HCV Core protein induces promoter hypermethylation and down-regulation of p16 
expression and subsequently induces Rb phosphorylation, leading to the activation of E2F1, 
that in turn stimulates cell growth [68]. This mechanism is also exploited to overcome stress-
induced premature senescence in the presence of HCV-induced oxidative stress [69]. 
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Furthermore, HCV Core protein up-regulates DNA methyltransferases 1 and 3b and induces 
promoter hypermethylation of retinoic acid receptor-β2 (RAR-β2). This mechanism leads to 
escape from RB/E2F-related growth arrest induced by all-trans retinoic acid [70]. 
Up-regulation of the oncoprotein gankyrin enhances the transcriptional activity of β-
catenin, which in turn transcriptionally activates gankyrin by a positive feedback loop [71]. 
Gankyrin is highly expressed in HCC and its overexpression mediates the degradation of the 
tumor suppressor proteins Rb and p53 and thereby accelerates cell cycle progression. 
Growth arrest and DNA damage 45G (GADD45G) is commonly down-regulated in 
oncogene-transformed HCC [72]. Ectopic expression of GADD45G induces senescence in 
HCC through repression of Jak/Stat3 pathway, independently of p53, p16INK4a, and Rb. 
Expression of constitutively activated Stat3 or human telomerase reverse transcriptase 
(hTERT) reverts GADD45G-induced senescence.  
Transforming growth factor-beta (TGF-β) signaling has a growth suppressive role in 
the early stages of HCC. Resistance to TGF-β signaling-mediated growth inhibition is a 
frequent event during malignant transformation of hepatocytes. In the advanced stages of 
HCC, TGF-β is secreted by the stromal cells in tumor microenvironment and therefore 
induces apoptosis in hepatocytes. However, the down-regulation of the receptors of TGF-β 
and up-regulation of the EGFR and MEK/ERK pathways confers resistance to TGF-β-induced 
cell death in liver tumor cells [73–79]. 
2.4. Resisting Cell Death 
Presence of elevated levels of growth factors such as IGF, up-regulation of anti-
apoptotic pathways such as NF-κB pathway, down-regulation of death receptors such as DR5 
and Fas, mutations in the tumor suppressor genes such as p53, contribute to evasion of 
apoptosis in many cancers including liver cancer. The IGF/IGFR signaling pathway that is 
constitutively activated in 20% of HCC via IGF2 or IGFR1 overexpression, regulates 
proliferation, motility, invasion and inhibition of apoptosis. This is correlated with stage, 
metastasis and survival of HCC [80–84]. The IGF pathway activates cell survival pathways 
PI3K/AKT and RAF/MEK/ERK and provides a mechanism to evade apoptosis [80].  
Mutations in the tumor suppressor gene p53 cause the loss of apoptotic response. 
Large scale gene expression analysis showed that cell cycle-related genes (CCNG2, 
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BZAP45) and cell proliferation-related genes (SSR1, ANXA2, S100A10, and PTMA) were 
overexpressed in mutant-p53 tumors compared to wild type-p53 tumors in HCV-related HCC 
[85]. 
Tumor Necrosis Factor (TNF) activates the anti-apoptotic NF-κB pathway, the pro-
apoptotic caspase–cascade, and JNK kinases in HCC. Inhibition of NF-κB by NEMO results 
in the up-regulation of the death receptor DR5, whose ligand (TRAIL) is predominantly 
expressed by natural killer (NK) cells and is essentially involved in liver injury in NEMO-
deficient hepatocytes [86]. Furthermore, Caspase-8 is frequently inactivated in HCC and 
therefore interferes with the pro-apoptotic caspase–cascade [87].  Down-regulation of Fas 
expression, up-regulation of its ligand (FasL) expression in hepatocytes, and elevation of 
serum soluble Fas levels were also identified as critical players of evasion from immune 
surveillance, and hepatic carcinogenesis [88]. 
2.5. Enabling Replicative Immortality 
It is known that reactivation of telomerase maintains the telomere length and replicative 
immortality during cirrhosis and therefore leads to HCC progression [89, 90]. Not only 
telomere dysfunction, but also oncogene activation, persistent DNA damage and ROS-
induced oxidative stress can cause permanent cell cycle arrest, known as senescence [31, 
91]. Bypass of senescence is a characteristic of liver cancer cells to gain replicative 
immortality. 
TGF-beta, Ras, Raf, Mos, Mek, Myc, E2F, Stat5, Cyclin E and PTEN are key players 
of oncogene-induced senescence [92]. Re-activation of telomerase and inactivation of p53, 
p15, p16, p21 may play critical roles in the bypass of senescence and maintaining immortality 
[91]. Indeed, expression of human hTERT was able to revert GADD455 - induced 
senescence in HCC [72].  Up-regulation of hTERT expression by low-dose cisplatin 
contributed to cell death resistance in a HCC cell line and this resistance was reverted by 
inhibition of hTERT [93]. Two independent mutations were identified within the core promoter 
of TERT. These mutations increased transcriptional activity from the TERT promoter by two- 
to four- fold and were shown to occur frequently in HCC [94]. Recurrent integration of HBV 
into the promoter of the TERT gene was correlated with increased TERT expression in HBV-
related HCC patient samples [95]. Furthermore, a recent study showed that HCCs expressing 
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"stemness"-related proteins (K19, EpCAM, CD133) have increased telomere length, 
increased expression of hTERT and shelterin complex proteins (TRF1, TRF2, TIN2, POT1, 
TPP1, RAP1), and increased chromosomal instability compared to HCCs without these 
markers [96]. Hence, high telomerase activity and long telomeres in HCCs are associated 
with aggressive behaviour and poor prognosis [95, 97]. We reported recently that there is a 
major shift from senescence-associated gene expression to immortality-associated gene 
expression during transition from dysplasia to early HCC lesions. Moreover, a senescence 
bypass signature was able to differentiate HCC from cirrhosis [98]. Therefore, targeting 
senescence in liver cancer treatment can be considered as an alternative mechanism in 
addition to classical chemotherapeutic agents [99]. 
2.6. Inducing Angiogenesis 
Angiogenesis and neo-vascularization involves interactions between tumor cells, 
vascular endothelial cells and their supporting pericytes in order to supply oxygen and 
nutrients to the growing tumor [30]. In HCC, the balance between pro-angiogenic and anti-
angiogenic factors is disrupted due to excess secretion of angiogenic factors by endothelial 
cells and pericytes in the tumor microenvironment [100]. Angiogenic factors including vascular 
endothelial growth factor (VEGF), fibroblast growth factors (FGF), platelet-derived growth 
factor (PDGF) and angiopoietin-2, Tie-2 are up-regulated in HCC. This process induces 
angiogenic signaling through activation of the RAF/MEK/ERK, PI3K/AKT/mTOR, JAK/Stat 
and HGF/MET pathways [101–106]. 
VEGF and its receptors VEGFR-1 and VEGFR-2 are over-expressed in HCC, and are 
associated with aggressiveness and poor prognosis [107–111]. The HBV x antigen also up-
regulates VEGFR-3 [112]. VEGF acts synergistically with FGF, whose overexpression is 
correlated with HCC angiogenesis [113, 114]. 
Hypoxia, which occurs during fibrosis, cirrhosis and malignant transformation, 
enhances proliferation, angiogenesis, metastasis, chemoresistance, and radioresistance of 
HCC [100]. Hypoxia induced factor 1 alpha (HIF-1α) promotes hepatocyte epithelial-
mesenchymal transition (EMT) through PI3K/Akt, TGF-β and β-catenin signaling and this is 
associated with enhanced metastatic potential and poor prognosis in HCC [115–117]. Bone 
morphogenetic protein 4 (BMP-4) is also induced in hypoxic conditions and promotes 
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vasculogenesis and tumor progression in HCC [118]. 
2.7. Activating Invasion and Metastasis 
Cell detachment is an early step of tumor invasion, requiring alterations of the adhesive 
properties of cancer cells in general. Therefore, epithelial-mesenchymal transition (EMT) is 
critical for activating invasion and metastasis of HCC. Up-regulation and activation of Twist, 
Snail, Slug, Zeb1/2, and Vimentin, and down-regulation of E-cadherin and hepatocyte nuclear 
factor (HNF)-4α frequently occur during EMT and correlate with poor prognosis in liver cancer 
[119–122]. Furthermore, p53 regulates EMT through miR-200 family members and miR-192, 
which targets Zeb1 and Zeb2 [123]. HBx expression was shown to induce EMT by activating 
the PI3K/Akt/GSK-3β pathway, which stabilizes Snail and mediates integrin α6β1 signaling, 
thus facilitating tumor invasion and metastasis during HCC progression [124, 125]. In HCV-
positive HCC patients, expression of a four gene signature, including E-cadherin, inhibitor of 
DNA binding 2 (ID2), MMP9, and transcription factor 3 (TCF3), is correlated with poor 
prognosis [126].  
Osteopontin is over-expressed in metastatic HBV-related HCC and invasion and 
metastasis are effectively blocked by an osteopontin-specific antibody both in vitro and in vivo 
[127]. This observation suggests that osteopontin can be considered as a diagnostic marker 
and a potential therapeutic target for HBV-related metastatic HCC [128, 129]. Tumor 
suppressor DLC1 and cytoskeletal protein RhoA are also involved in the prevention of 
dissemination and metastasis of human HCC cells in nude mice [130, 131]. Additionally, intra-
tumoral hypoxia triggers invasion and metastasis of HCC through oncogenic HGF/MET 
signaling pathway [132]. A Met-regulated gene expression signature defines an aggressive 
subtype of HCC with increased vascular invasion rate, microvessel density and decreased 
mean survival time of HCC patients [103].  
2.8. Reprogramming Energy Metabolism 
Cancer cells reprogram their energy metabolism so that they can use glucose to 
supply energy through aerobic glycolysis and glutamine to provide intermediates of the 
tricarboxylic acid (TCA) cycle [133]. In addition, autophagy enables fast growing cells to break 
down cellular organelles, resulting in recycled catabolites that can be used for biosynthesis 
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and energy metabolism [22]. mTOR, an evolutionarily conserved serine/threonine kinase 
located downstream in the PI3K/AKT pathway, also works as a nutrition sensor to monitor 
cellular metabolism [134]. In the presence of sufficient energy and nutrients, active mTOR 
promotes translation and biosynthesis, hence suppresses autophagy. In the absence of 
sufficient energy and nutrients, mTOR with down-regulated activity leads to the reduction of 
biosynthesis and promotes autophagy [135]. PI3K/AKT pathway also stimulates glucose 
uptake and metabolism for continued growth and survival of cancer cells [136].  
On the other hand, glutamine uptake and metabolism is under the control of c-myc 
[137]. Elevated energy consumption and addiction to mitochondrial glutaminolysis is 
dependent on the AMPK-related kinase 5 (ARK5) through oncogenic c-myc expression in 
HCC cells. ARK5 limits protein synthesis via inhibition of mTORC1 and maintains a high 
respiratory capacity required for efficient glutamine metabolism [138]. Therefore, targeting 
cellular energy homeostasis is a promising therapeutic strategy for HCC cells with higher c-
myc expression. AMP-activated protein kinase (AMPK), which is activated in response to 
reduced energy levels, promotes ATP production by increasing catabolism and conserves 
ATP by switching off biosynthetic pathways. AMPK was found to be dysfunctional in patients 
with HCC, and low p-AMPK levels correlated with aggressiveness and poor prognosis [139]. 
Moreover, AMPK is also activated by the p53 targets, Sestrin1 and Sestrin2 [140]. p53 
stimulates oxidative phosphorylation and reduces the rate of glycolysis through the 
upregulation of TP53-induced glycolysis and apoptosis regulator (TIGAR) [141]. Therefore, 
energy metabolism is shifted from mitochondrial respiration towards glycolysis by the loss of 
p53 in cancer cells. 
During HCC development metabolic remodeling from mitochondrial oxidation to 
glycolysis was assessed by a combined transcriptomics and metabolomics study in 6 sub-
groups of HCC tissues defined by Boyault et al. [142]. HCC has lower levels of glucose and 
other metabolites (glycerol 3-phosphate, glycerol 2-phosphate, malate, alanine, and myo-
inositol) involved in energy production compared to healthy liver. Moreover, concentrations of 
certain saturated lipids are reduced in a sub-group of HCC cells associated with high serum 
alpha-fetoprotein (AFP) levels. This is consistent with the previous observations on the up-
regulation of lipid catabolism accompanied by elevated AFP expression. Another study 
identified 28 metabolites and 169 genes involved in energy metabolism associated with 
aggressive HCC [143]. Metabolic activities in HCC microenvironment are also promoted by 
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Hedgehog signaling activation by malignant hepatocytes. Hedgehog ligands produced by 
these cells stimulate glycolysis in the neighboring myofibroblasts, resulting in the release of 
myofibroblast-derived lactate, which is used as an energy source by the malignant 
hepatocytes [144].  
Mutations that activate oncogenes (such as c-myc, HIF-1α, and PI3K/AKT) or 
inactivate tumor suppressors (such as p53, PTEN, TSC2 and LKB1) have been shown to 
contribute to metabolic alterations in various types of cancer [145]. Oncogene-altered energy 
metabolism presents a new class of target molecules for tumor therapy. Indeed, activating 
oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor (Dichloroacetate) 
overcame sorafenib resistance of HCC and combination of Sorafenib and Dichloroacetate 
resulted in elevated tumor regression compared to Sorafenib alone [146]. Therefore, tumor 
bioenergetics can be further exploited for HCC therapy.  
2.9. Tumor-promoting inflammation 
Tissue microenvironment plays a critical role in HCC formation and development [100]. 
HCC microenvironment is composed of cancer-associated fibroblasts (CAFs), invading 
inflammatory cells, endothelial cells (ECs), pericytes adjacent to the ECs, hepatic stellate 
cells (HSCs), macrophages (Kupffer cells), dendritic cells, and stem/progenitor cells. 
Extracellular matrix (ECM) components including collagen, fibronectin, laminin, 
glycosaminoglycans, and proteoglycans provide a support of microenvironment for these cells 
[100, 147]. All of these components of the microenvironment interact with each other and 
produce growth factors, cytokines, chemokines and free radicals that contribute to liver 
fibrosis, therefore tumor initiation and progression. Overexpression of highly negatively 
charged extracellular matrix protein osteopontin is associated with large tumor size, advanced 
tumor stage, capsular infiltration, vascular invasion, lymph node invasion, intrahepatic 
metastasis, early recurrence and poor prognosis of HCC [148–154]. Furthermore, plasma 
osteopontin levels were significantly higher in HCC patients and therefore, can be considered 
for early HCC marker together with AFP [151, 155, 156].  
During HBV- or HCV- infection-associated chronic liver disease, hepatocyte injury 
leads to inflammatory cell infiltration, where host immune cells destroy virus-infected 
hepatocytes [157, 158]. Continuous inflammation results in a cycle of hepatocyte death and 
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proliferation leading to an increased genomic instability and mutations [4]. When stimulated 
with pro-inflammatory cytokines (IL-1β, TNF-α, and PDGF), Kupffer cells and HSCs produce 
osteopontin that plays an important role in inflammation, growth, invasion, metastasis, 
angiogenesis and inhibition of apoptosis [159–162]. TNF-α, produced by Kupffer cells and 
other immune cells promotes tumor progression mainly through NF-κB and Akt pathways 
[159]. 
Kupffer cells express and release pro-inflammatory cytokine interleukin-6 (IL-6). IL-6 is 
one of the major mediators of inflammation and activates STAT3 pathway to mediate its 
signal through the gp130 protein. IL-6 protects liver cells against apoptosis via STAT3 
pathway following viral infection or chemical ingestion [163, 164]. This mechanism is also 
exploited during tumor promotion [165]. Constitutively activated Stat3 protein maintains NF-κB 
activity in tumors by preventing nuclear export of NF-κB complex through RelA acetylation 
[166]). RelA, in turn, maintains persistent activation of STAT3 and IL-6 in HCC 
microenvironment [167]. Therefore, conditional knock-out of STAT3 expression impairs liver 
regeneration, but tissue-specific knock-out of hepatic STAT3 effects glucose homeostasis and 
induction of insulin resistance [168, 169]. 
Oncogenic β-catenin also triggers an inflammatory response, including activation of the 
NF-κB pathway in hepatocytes, which promotes aggressiveness of HCC in mice [170]. 
Elevated IL-6 levels and constitutively activated STAT3 has been frequently detected in HCC 
patients and in cell lines [171–176]. In addition, the Jak-Stat inhibitors SOCS1 and SOCS3 
are downregulated in HCC via promoter hypermethylation [177] . Moreover, somatic gain-of-
function mutations in the IL6ST gene (gp130), have been identified in inflammatory 
hepatocellular adenomas [178]. IL-6/STAT3 further activates several interleukins and growth 
factors. 
A low-grade inflammatory response is induced upon lipid accumulation in obesity, 
which in turn increases IL-6 and TNF expression by adipose tissue and Kupffer cells [179, 
180]. IL-6 and TNF signaling promotes proliferation of damaged hepatocytes via activation of 
JAK/STAT and AKT/ERK, respectively [159, 181]. 
A unique 17 gene immune response signature of the liver microenvironment could 
predict venous metastases, recurrence, and prognosis in HCC [182]. A global Th1- to Th2-like 
cytokine shift is associated with HCC metastasis, which is promoted through a shift toward 
anti-inflammatory/immune-suppressive responses.  
! 16!
2.10. Evading Immune Destruction 
Liver cancer develops usually on top of chronic inflammation during fibrosis and 
cirrhosis. Even though tumor cells exploit inflammation in favor of their growth as mentioned 
above, they still need to escape from immune destruction. HCC cells evade immune 
destruction by expressing immunosuppressive molecules such as PD-L1 and indolamine 2,3-
dioxygenase (IDO), and secreting cytokines and chemokines such as IL6, IL10, TGF-β, and 
VEGF [183]. The resulting immunosuppressive microenvironment is supported by the 
induction of regulatory Dendritic cells (DCregs), regulatory T cells (Tregs) and tumor-
associated macrophages (TAMs) and suppression of DCs, effector T cells and natural killer 
(NK) cells.  
Macrophages are the major infiltrating leukocytes and are involved in both innate and 
adaptive immune responses [184]. During HBV- or HCV- infection, fibrotic and cirrhotic liver 
causes inflammatory cell infiltration due to necrosis of hepatocytes. Therefore, the status of 
TAMs and other immune cells in the tumor microenvironment is closely associated with 
suppression of anti-tumor immunity and progression of HCC. Polarizing inflammatory 
responses towards the preferential recruitment of Th2 type cells and Tregs rather than Th1 
type cells promotes tumor immune evasion. While M2-type 'alternatively activated' 
macrophages promote tumor progression, M1-type 'classically activated' macrophages can 
exert anti-tumor activity by killing tumor cells. Therefore, shifting the macrophage balance 
from tumor promotion by innate immunity-driven inflammation towards tumor surveillance by 
adaptive immune responses can be an effective therapeutic strategy [185]. 
Dendritic cells (DCs), which are important for chronic liver inflammation, express and 
present antigens to infiltrating cytotoxic T lymphocytes (CTLs). Dendritic cells express 
Glypican 3 (GPC3), whose up-regulation is associated with poor prognosis in HCC [186]. 
Indeed, tumor-induced regulatory Dendritic cells with hyper-activate Stat3 can facilitate tumor 
immune evasion independent of Stat3 hyper-activation status in tumors [187]. Additionally, 
CTL-mediated immune response can be impaired by Kupffer cells through programmed death 
ligand 1(PD-L1), and regulatory DCs (CD14+ CTLA4+) through CTLA4-dependent IL-10 and 
IDO production, enabling immune evasion [188, 189]. 
Cytokine production by natural killer (NK) cells in chronic HCV infection is shifted 
toward secretion of Th2 type cytokines promoting an environment, which is more permissive 
for HCV [190]. In chronic HCV patients, NK cells have reduced cytotoxicity and IFN-γ 
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production, and secrete IL-10 and TGF-β resulting in the induction of Th2 cells and Tregs, 
maintaining immune evasion. Furthermore, many immune system-related genes, including 
SATB1, TNFRSF5, CTLA4, GITR, SIRP!, PD-L1!and ICOS have altered expression in HCC 
[85, 191, 192]. 
It has been shown that the only FDA-approved chemotherapeutic agent Sorafenib also 
suppresses proliferation and activation of natural killer (NK) cells in addition to malignant 
hepatocytes. Consequently, reduced cytotoxicity of NK cells handicaps HCC patients during 
treatment by rendering the host more susceptive to tumor growth and metastasis [193]. 
Therefore, immunotherapeutic approaches activating NK cells can enhance the efficacy of 
Sorafenib. 
In light of above described cellular mechanisms, hallmarks of cancer are represented 
in parallel with the altered genes involved in the development of the multistep progression of 
liver cancer in Figure 1. This overall picture demonstrates that genome instability and 
mutations along with sustaining proliferative signaling having the highest number of altered 
genes, are the most studied hallmarks in HCC. Yet, the new emerging capabilities of tumor 
cells should be further studied in this disease in order to identify novel genes associated with 
HCC malignancy. 
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Figure 1. Molecular Hallmarks of Hepatocellular Carcinoma. Molecular alterations 
promote the hallmark capabilities through either activation/expression/up-regulation are in red 
or inactivation/loss/down-regulation are in green. (Modified from Hanahan and Weinberg with 
permission [22]). 
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3. Genome-wide changes in Hepatocellular Carcinoma 
During the last decade, several high-throughput analyses on HCC samples have been 
published. Microarray, whole-genome sequencing and exome sequencing studies will 
enlighten the intra-tumoral heterogeneity of HCCs from various etiologies and histological 
pathologies. These large-scale studies revealed novel HCC-related pathways or gene 
signatures that can distinguish subgroups of HCC based on etiology, molecular background 
and histopathology. These signatures also predict survival, metastasis and recurrence. Major 
findings of recent high-throughput analyses on HCC are presented in Table 2. Some of the 
novel important genes associated with HCC are also included in the table along with their 
respective study. 
 
 
 
Table 2: Major findings of recent high-throughput analyses on HCC 
Classification of HCC based on altered gene expression Reference 
Highly expressed “proliferation cluster” genes in HCC  [64] 
“proliferation cluster” genes predict survival by 406 gene signature [65] 
HCC classified into two groups based on IFN-regulated and apoptosis-relevant genes  [194] 
Identify 240 gene signature for low- to high- grade dyplastic nodules and HCC [195] 
6 subgroups of HCC related to genetic alterations 
G1: IGFR1 activation, AKT activation, developmental imprinting 
G2: PIK3CA and TP53 mutations, AKT activation 
G3: TP53 mutation and overexpression of cell-cycle genes 
G4: a heterogeneous subgroup 
G5: !-catenin mutations, Wnt/!-catenin activation 
G6: G5 with satellite nodules, having higher activation of the Wnt pathway and low E- 
cadherin expression 
[43] 
4 neoplastic stages of HCV-positive HCC: 
control vs. cirrhosis: 8 gene signature 
[196] 
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cirrhosis vs. dysplasia: 24 gene signature 
dysplasia vs. early HCC: 93 gene signature 
early vs. advanced HCC: 9 gene signature 
Subclasses of HCC with different genetic backgrounds  
c-Myc induced, 6p/1q-amplified, 17q-amplified 
[197] 
5 classes of HCV-positive HCC:  
CTNNB1 class: !-catenin mutations 
Proliferation class: IGF1R activation and RPS6 phosphorylation 
IFN-related class: a novel class defined by polysomy of chromosome 7 
[111] 
3 molecular subclasses of HCC: 
S1: Wnt/!-catenin activation 
S2: proliferation with Myc and AKT activation and IFN repression 
S3: tumor size, differentiation, and serum AFP levels 
[61] 
Cirrhosis vs. HCC 
Immortality and senescent signature: 15 immortality gene 
[98] 
Classification of HCC based on chromosomal imbalance Reference 
Early vs. advanced stages of HCC [198] 
3 HBV-positive HCC subgroups predict survival [199] 
Classification of HCC based on different etiologies Reference 
Invasiveness gene signatures of HBV- or HCV- associated HCC [200] 
HBV- or HCV- positivity: 
HBV-positive HCC: 31 genes relating to signal transduction, transcription, metastasis   
HCV-positive HCC: 52 genes related to detoxification and immune response 
[201] 
HBV-positive HCC vs. non-tumor liver tissues 
44 gene signature 
[202] 
Early vs. late stages of HBV-positive HCC: 
65 gene signature 
[203] 
Susceptibility to HBV-positive HCC 
1p36.22 locus, and KIF1B-, UBE4B-, PGD-related pathways 
[204] 
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Susceptibility to HCV-positive HCC 
common variants within the DEPDC5 locus on chromosome 22 
[205] 
HCV-positive HCC 
Strong association of a locus in the 5' flanking region of MICA, which leads to activation of 
natural killer cells and CD8+ T cells 
[206] 
Molecular profile of specific gene alterations Reference 
HCV-positive HCC with mutant-p53 vs. wild-type-p53 
Overexpressed: cell cycle- and cell proliferation-related genes  
Underexpressed: immune system-related genes 
[85] 
Myc signature in cirrhosis vs. nodules vs. HCC  [66] 
Met knock-out signature: HGF/Met activation associated with poor survival [103] 
RB knock-out signature: increased proliferation and RB/E2F activity [207] 
TGF-ß knock-out signature: invasive phenotype and increased tumor recurrence [208] 
Identification of genetic alterations Reference 
Somatic substitutions in HCV-positive HCC : T>C / A>G and C>T / G>A 11,731 mutations, 
including TP53, AXIN1, ADAM22, JAK2, KHDRBS2, NEK8 and TRRAP  
[209] 
Frequent mutations in HCV-associated HCC, including CTNNB1, TP53, ARID2, DMXL1 
and NLP1 
ARID2 as a tumor suppressor gene in HCV-associated HCC 
[210] 
Cirrhotic vs. non-cirrhotic HCC: G>T and C>A transversions are more frequent in tumors 
from non-cirrhotic liver 
new recurrent alterations in ARID1A, RPS6KA3, NFE2L2 and IRF2 
[24] 
Identification of epigenetic alterations Reference 
Predict survival: aberrant DNA methylation signature at promoter sites [211] 
High frequency chromatin regulating gene mutation 
Mutation in ARID2  
[29] 
Identification of potential tumor driver mutations Reference 
50 potential genes with specific signaling pathways (mTOR, AMPK, and EGFR) [60] 
! 22!
3 tumor mutations (CCNG1, P62, and an indel/fusion gene) from 
sequencing of 3 HCC nodules from 1 HBV-positive HCC patient 
[212] 
13 potential tumor suppressor genes, including XPO4 [213] 
Prediction of metastasis from gene signatures Reference 
153 gene signature in HBV-positive HCC 
Osteopontin overexpression 
[127] 
17 gene stromal tissue signature to predict metastasis  [182] 
HBV-positive HCC patients with portal vein tumor thromboses 
Transversions: C:G > A:T and T:A > A:T  
mutation in ARID1A 
[214] 
Prediction of recurrence from gene signatures Reference 
12 gene signature [215] 
early intrahepatic recurrence  [216] 
57 gene signature [217] 
early recurrence in HBV-positive HCC 
CD24  
[218] 
late recurrence from stromal tissues [219] 
Molecular profile of poorly-differentiated cells Reference 
Hepatoblast-like subclass with AP1 activation 
associated with poor prognosis 
[220] 
Progenitor-like class with EPCAM and AFP in HBV-positive HCC  
EPCAM-/AFP+ are associated with poor prognosis 
[221] 
 
4. microRNA Profiling of Hepatocellular Carcinoma 
Recent findings highlight the importance of microRNAs in mediating the acquired 
capabilities of HCC. Comprehensive analysis of microRNA expression patterns revealed 
differential expression of miRNAs in metastatic HCC and non-metastatic HCC compared to 
healthy liver (Table 3). Hence, miRNAs can be utilized as prognostic markers in HCC patients 
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with various clinical phenotypes. miR-26a, whose expression is reduced in HCC, inhibits 
angiogenesis by down-regulating VEGFA through PIK3C2α/Akt/HIF-1α and suppresses 
growth and metastasis through IL-6/Stat3 signaling [222, 223]. miRNA replacement therapy, 
where miR-26a is administrated in a mouse model of HCC, inhibits cancer cell proliferation 
and induces apoptosis [224]. Delivery of downregulated miRNAs that are highly expressed 
and therefore tolerated in normal liver inhibits tumorigenicity without toxicity. Therefore, this 
approach can be a valuable strategy for miRNA-mediated HCC therapies. 
 
 
Table 3: Alterations in microRNAs and their mechanisms of promoting HCC progression 
microRNA Mechanism Alteration in HCC Reference 
miR-101 Targets EZH2 and inhibits HCC progression Down-regulation [225] 
miR-122  
Sensitize HCC cells to chemotherapeutic drugs by 
downregulating MDR related genes 
Down-regulation [226] 
miR-124 
- Targets PIK3CA, suppresses PI3K/AKT pathway 
- Suppresses the HCC growth through targeting 
STAT3. 
- Transient inhibition of HNF4α initiates HCC 
through a microRNA-inflammatory feedback loop 
of miR-124, IL6R, STAT3, miR-24, and miR-629. 
Down-regulation [227–229]  
miR-139 
Promotes cell proliferation and invasion through 
the WNT/TCF-4 pathway 
Down-regulation [230] 
miR-140-5p 
Suppresses cell proliferation and metastasis by 
targeting TGFBR1 and FGF9 
Down-regulation [231] 
miR-148a 
- Suppresses EMT and metastasis by targeting 
Met/Snail.  
- Reduces HPIP, represses AKT and ERK and 
inhibits mTOR through AKT/ERK/FOXO4/ATF5 
Down-regulation [232, 233] 
miR-155 
Targets APC, promotes hepatocyte proliferation 
and tumorigenesis by activating Wnt signaling 
Overexpression [234] 
miR-17  
Inhibits cell migration and invasion via suppression 
of MMP-3 and Akt 
Down-regulation [235] 
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miR-195 
Blocks G1/S transition by repressing Rb/E2F 
signaling 
Down-regulation [236] 
miR-199a/b-3p 
Suppress HCC growth through targeting PAK4 and 
inhibiting PAK4/Raf/MEK/ERK pathway  
Down-regulation [237] 
miR-21 
Suppresses PTEN, hSulf-1, PDCD4 and RECK 
and activates EMT via AKT and ERK pathways 
Overexpression [238, 239] 
miR-214 
Contributes to angiogenesis through activation of 
HDGF paracrine pathway 
Down-regulation [240] 
miR-216a/217 
Activates the PI3K/Akt and TGF-β pathways by 
targeting PTEN and SMAD7 
Overexpression [241] 
miR-221  
Accelerates hepatocyte proliferation during liver 
regeneration 
Overexpression [242] 
miR-222 
Promotes metastasis through activating AKT 
signaling and targeting PPP2R2A 
Overexpression [243] 
miR-224 
Activates AKT signaling pathway by targeting 
PPP2R1B 
Overexpression [244] 
miR-26a 
Inhibits angiogenesis by down-Regulating VEGFA 
through PIK3C2α/Akt/HIF-1α  
Suppress HCC growth and metastasis through IL-
6-Stat3 signaling 
Down-regulation [222, 223] 
miR-27a 
Reverses drug resistance (MDR) by inhibiting the 
FZD7/β-catenin pathway 
Down-regulation [245] 
miR-375 Inhibits autophagy by reducingATG7 expression Down-regulation [246] 
miR-503  
Blocks G1/S transition by repressing Rb/E2F 
signaling 
Down-regulation 
[247] 
miR-519d 
Targets CDKN1A/p21, PTEN, AKT3 and TIMP2. 
Promotes cell proliferation, invasion and impairs 
apoptosis  
Overexpression [248] 
miR-520b 
Contributes to escape from growth suppression by 
targeting MEKK2 and cyclin D1 through JNK and 
Rb 
Down-regulation [249] 
miR-612 Suppresses EMT through Akt2 Down-regulation [250] 
miR-675 Increases proliferation and inhibits invasiveness by Overexpression [251] 
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downregulating RB and Twist1 
miR-7  
Inhibits HCC cell growth and metastasis by 
targeting PI3K/AKT pathway 
Down-regulation [252] 
 
5. Epigenetic Mechanisms 
Epigenetic regulation of gene expression involves DNA methylation, post-translational 
histone modifications and changes in expression profiles of chromatin-modifying enzymes, 
which are highly deregulated in cancers, including HCC [253]. 
Epigenetic alterations in HCC include global DNA hypomethylation, gene-specific DNA 
hypermethylation of Rb, E-cadherin, RASSF1A and p16, gene-specific DNA hypomethylation 
of Vimentin, uPA and CD147, upregulation of DNA methyltransferases DNMT1, DNMT3A, 
and DNMT3B, and altered histone modification patterns of H3K9, and H3K27 through 
deregulation of histone modifying enzymes HDAC1/2/3, SIRT1, EZH2 and ARID2 [24, 29, 210, 
254–260]. 
The histone methyltransferase EZH2 is overexpressed in HCC and contributes to the 
epigenetic silencing of target genes that regulate cancer cell growth and survival. Sorafenib 
was shown to down-regulate EZH2 protein level through accelerating its proteasome-
mediated degradation in hepatoma cells, and thereby altering the HCC epigenome by 
reducing H3K27 trimethylation [261]. Overexpression of EZH2 reverses sorafenib-induced cell 
cycle arrest, and apoptosis. This epigenetics-based study revealed a novel combinational 
therapy approach, where inhibition of EZH2 can be used to increase sensitivity of HCC cells 
to chemotherapeutic agents. 
All hallmarks of HCC are under the control of epigenetic mechanisms. In return, altered 
metabolism in HCC cells can determine the availability of metabolites that are necessary for 
the functioning of epigenetic modifiers and thereby regulate the cancer epigenome [262]. 
Aberrant activity of epigenetic regulators and gene-specific methylation alterations in HCC are 
given in Tables 4 and 5. 
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Table 4: Epigenetic deregulations in HCC 
DNA methyltransferases Alteration in HCC References 
DNMT1, DNMT3A, DNMT3B up-regulated [256, 263–266] 
Histone deacetylases Alteration in HCC References 
HDAC-1, HDAC-2, HDAC-3 up-regulated [267, 268] 
SIRT1 up-regulated [269, 270] 
SIRT2 up-regulated [271] 
SIRT3 down-regulated [272] 
SIRT6 down-regulated [273, 274] 
Histone methyltransferases Alteration in HCC References 
EZH2  up-regulated [275, 276] 
SUV39H1 up-regulated [277] 
SMYD3 up-regulated [278] 
MMSET (NSD2) up-regulated [279] 
 
Table 5: Hypermethylated and hypomethylated genes in HCC 
Hypermethylated 
genes 
Description Role in HCC References 
RASSF1A Ras Association Domain Family 
Member 1 
Ras signaling pathway   
[280–285] 
RASSF5 
(NORE1B) 
Ras association domain family 
member 5  
Ras signaling pathway [281] 
DAB2IP DAB2 (mitogen-responsive 
phosphoprotein) interacting 
protein 
Ras GTPase-activating 
protein 
[283–285] 
PTEN phosphatase and tensin 
homolog 
PI3K/Akt/mTOR pathway [280, 286] 
TP53 tumor protein p53 survival, cell death, 
proliferation, growth 
[287] 
RB1 retinoblastoma 1  cell cycle, proliferation, [288] 
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growth 
CDKN2A (p16) cyclin-dependent kinase 
inhibitor 2A 
cell cycle, proliferation, 
growth 
[283–285, 
289–293] 
CDKN2B (p15) cyclin-dependent kinase 
inhibitor 2B  
cell cycle, proliferation, 
growth 
[290, 294] 
CDKL2 cyclin-dependent kinase-like 2 cell cycle, proliferation, 
growth 
[283–285] 
DACH1 dachshund family transcription 
factor 1  
proliferation, growth [295] 
BMP4 Bone Morphogenetic Protein 4 growth, metabolism, 
angiogenesis 
[283–285] 
BMP6 bone morphogenetic protein 6 growth, metabolism, 
angiogenesis 
[296] 
SOCS1 suppressor of cytokine signaling 
1  
Jak/Stat pathway [176, 297, 
298] 
SOCS3 suppressor of cytokine signaling 
3 
Jak/Stat pathway [174] 
SYK spleen tyrosine kinase Immune response [299] 
MAT1A methionine adenosyltransferase 
I, alpha (liver-specific) 
metabolism [300–302] 
GLS2 glutaminase 2 (liver, 
mitochondrial) 
metabolism [303] 
GSTP1 glutathione S-transferase pi 1  metabolism [282, 304, 
305] 
NQO1 NAD(P)H dehydrogenase, 
quinone 1  
metabolism [306] 
COX-1, COX- 2 Cyclooxygenases metabolism [307] 
NKX6-2 NK6 homeobox 2 metabolism [283–285] 
CDH1 cadherin 1, type 1, E-cadherin  invasion, metastasis [308] 
SFRPs Secreted frizzled-related 
proteins 
Wnt/β-catenin pathway [309–312] 
DACT2 dishevelled-binding antagonist 
of beta-catenin 2  
Wnt/β-catenin pathway [313, 314] 
PRDM2 (RIZ1) PR domain containing 2, with epigenetic regulation [315, 316] 
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ZNF domain  
PRDM5 PR domain containing 5  epigenetic regulation [317] 
CHD5 chromodomain helicase DNA 
binding protein 5 
chromatin remodeling  [318] 
DNM3 dynamin 3 microtubule dynamics,  
vesicular transport 
[283–285] 
Hypomethylated 
genes 
Description Role in HCC References 
MET met proto-oncogene  growth, invasion, metastasis [319] 
AKT3 v-akt murine thymoma viral 
oncogene homolog 3 
PI3K/Akt/mTOR pathway [283–285] 
CD147 basigin (Ok blood group) invasion, metastasis [257] 
VIM Vimentin invasion, metastasis [260] 
TFF3 Frequent trefoil factor 3 inflammation, immune 
response 
[320] 
CCL20 chemokine (C-C motif) ligand 20 inflammation, immune 
response 
[283–285] 
CD1B T-Cell Surface Glycoprotein 
CD1b 
inflammation, immune 
response 
[283–285] 
CD1E T-Cell Surface Glycoprotein 
CD1e 
inflammation, immune 
response 
[283–285] 
CD300E immune Receptor Expressed 
On Myeloid Cells 2 
inflammation, immune 
response 
[283–285] 
MNDA myeloid cell nuclear 
differentiation antigen 
inflammation, immune 
response 
[283–285] 
MAT2A methionine adenosyltransferase 
2, alpha 
metabolism [302, 321] 
CYP11B1 cytochrome P450, family 11, 
subfamily B, polypeptide 1 
drug metabolism [283–285] 
LINE-1 long interspersed nuclear 
element 1 
proliferation [322] 
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6. Concluding Remarks 
Hepatocellular carcinoma is one of the leading causes of cancer-related death. This 
cancer is mostly a viral infection-associated disease and its etiology is quite well known. Late 
diagnosis and the paucity of efficient therapeutic interventions are the major reasons why this 
cancer remains one of the most deadly cancers, worldwide. During the last decade, most of 
the research on liver cancer focused on molecular classification methods and the finding of 
novel therapeutic targets and targeted agents. High throughput analysis of genomic state and 
genome-wide expression analysis were the most frequently used approaches for molecular 
classification. The primary purpose of molecular classification studies is to reduce the 
heterogeneity of HCC in terms of therapeutic response and patient survival. These studies 
allowed the discovery of different molecular subtypes of liver cancer by using so called “gene 
signatures”. A gene signature is the expression pattern of a set of genes associated with a 
clinical subtype of a disease. With this regards, several gene signatures and associated 
molecular types of HCC have been described. Figure 2 represents heterogeneity of liver 
cancer in parallel to multi-step evolution of this cancer. During progression of HCC, various 
cellular mechanisms and their underlying genetic, epigenetic and proteomic alterations enable 
acquisition of malignant behavior. These findings demonstrated that indeed HCC is a 
heterogeneous disease that can be subdivided into more or less homogenous subclasses. 
Unfortunately, these findings did not help much to the clinical follow-up of HCC patients, 
mostly because gene signatures are composed of large sets of genes, not readily adaptable 
to routine use. 
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Figure 2. Multistep evolution of primary liver cancer. Development of HCC is a multistep 
process, where injured hepatocytes promote chronic inflammation leading to hepatocyte 
death and regeneration cycles during cirrhosis and enduring liver disease. The subsequent 
expansion of dysplastic nodules, telomerase reactivation, increased genomic instability, 
inactivation of tumor suppressors, activation of oncogenes and increase in growth factor 
signaling initiates HCC. Chromosomal instability and somatic mutations that favor the 
uncontrolled growth of HCC cells accumulate as the cancer advances. The acquisition of 
malignant phenotype is supported by tumor-promoting inflammation, capability to evade 
immune destruction and metabolic alterations that allow continued growth and survival of 
cancer cells. Onset of invasive, metastatic and angiogenetic capabilities promotes 
progression of carcinoma to the highly malignant metastatic state associated with stemness 
markers. Molecular alterations throughout the malignant transformation of HCC are regulated 
both in genetic and epigenetic levels.  
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The outputs of the efforts for finding novel targets for HCC treatment are so far less 
than satisfactory. There are several reasons for this. Firstly the number of mutant but 
targetable genes is limited. Secondly, the pathogenesis of HCC may be related to cellular 
signaling pathways rather than specific genes. Probably, some of the HCC-promoting 
signaling pathways are activated by mechanisms other than gene mutations. Changes in 
gene expression or protein networks (such as overall expression, stability, post-translational 
modifications) may be more critical for HCC pathology than gene mutations. The number of 
genes with dysregulated expression in HCC is extremely high. Consequently, a large set of 
signaling pathways appear to be deregulated in this cancer.  The paucity of gene mutations 
together with such a high number of genes with expression changes strongly suggests that 
the epigenome of HCC is highly affected. DNA methylation changes appear to predominate 
HCC epigenome. In addition, a few published data on histone methylation patterns suggests 
that there are profound changes in the organization of HCC nucleosomes and chromatin. 
Future studies aiming to decipher the status of HCC epigenome and its effect on HCC 
proteome may lead to a better understanding of this unusual cancer and may then lead to the 
discovery of novel therapeutic targets.  
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Summary The serine/threonine kinase Akt, a downstream
effector of phosphatidylinositol 3-kinase (PI3K), is in-
volved in cell survival and anti-apoptotic signaling. Akt
has been shown to be constitutively expressed in a variety
of human tumors including hepatocellular carcinoma
(HCC). In this report we analyzed the status of Akt
pathway in three HCC cell lines, and tested cytotoxic
effects of Akt pathway inhibitors LY294002, Wortmannin
and Inhibitor VIII. In Mahlavu human hepatoma cells Akt
was constitutively activated, as demonstrated by its Ser473
phosphorylation, downstream hyperphosphorylation of
BAD on Ser136, and by a specific cell-free kinase assay.
In contrast, Huh7 and HepG2 did not show hyperactivation
when tested by the same criteria. Akt enzyme hyper-
activation in Mahlavu was associated with a loss of PTEN
protein expression. Akt signaling was inhibited by the
upstream kinase inhibitors, LY294002, Wortmannin, as
well as by the specific Akt Inhibitor VIII in all three
hepatoma cell lines. Cytotoxicity assays with Akt inhibitors
in the same cell lines indicated that they were all sensitive,
but with different IC50 values as assayed by RT-CES. We
also demonstrated that the cytotoxic effect was through
apoptotic cell death. Our findings provide evidence for its
constitutive activation in one HCC cell line, and that HCC
cell lines, independent of their Akt activation status respond
to Akt inhibitors by apoptotic cell death. Thus, Akt
inhibition may be considered as an attractive therapeutic
intervention in liver cancer.
Keywords Akt . PI3K . PTEN . HCC . LY294002 .
Inhibitor VIII .Wortmannin . RTCES
Introduction
Hepatocellular carcinoma (HCC) is one of the most common
cancers worldwide occurs in patients with chronic viral
hepatitis and cirrhosis at a high rate (3–5% annually) and is
a major cause of morbidity and mortality in patients with
advanced liver disease [1]. In healthy individuals, liver is a
quiescent organ and adult hepatocytes are nondividing cells
under normal physiological conditions. However, chronic
liver injury due to viral diseases, exposure to chemicals and
other environmental or host factors results in extensive cell
death and consequently hepatocyte proliferation [2]. Chronic
cell death in liver leads to a state where continuous
hepatocyte regeneration is observed as a result of the
inflammatory response. Continuous cycles of liver cell death
and proliferation induce many cell signaling pathways
including cell survival pathways such as Akt [3, 4].
Knowledge on the signaling pathways and the alterations
involved in HCC is extending, however their role in
molecular targeted therapy still remains to be described.
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The most promising molecular targets in the generation of
new chemotherapy agents are the protein kinases, including
those in the PI3K/Akt pathway. The Akt pathway is involved
in many cancers, as well as HCC development, through its
activation by EGF or IGF signaling or the constitutive
activation of Akt proteins or the inactivation of PTEN tumor
suppressor [5–8]. The serine/threonine kinase Akt is a well-
characterized downstream target of PI3K and resides within
the cytoplasm in an inactive state, but binding of PtdIns
(3,4,5)P3 to its pleckstrin homology (PH) domain recruits
Akt to the plasma membrane and enables its activation by
phosphorylation on the C-terminal hydrophobic tail [9].
Once activated, signaling through Akt can be propagated to a
diverse array of substrates. Activated Akt is known to inhibit
apoptosis through its ability to phosphorylate several targets,
including BAD, FoxO transcription factors, Raf-1 and
caspase-9, which are critical for cell survival [9]. Moreover,
the tumor suppressor protein PTEN prevents Akt activation
by acting as a lipid phosphatase on the PI3K product PtdIns
(3,4,5)P3. Akt pathway hyper-activation has been reported
due to the loss of tumor suppressor protein PTEN function
through mutations, deletions, or epigenetic silencing [10, 11].
The PTEN gene is the second most frequently modified
tumor suppressor gene, and is related to many cancers
including brain, bladder, breast, prostate, endometrial and
liver cancer [10–12].
In primary liver carcinoma, one of the major pathogenic
mechanisms resides in the activated intracellular signal
transduction caused by oncogenes and the tumor suppressor
gene dysfunction that stimulates cell-cycle progression and
enhance cell survival [13]. Despite this much information, the
behavior and relevance of the Akt pathway in HCC and its
therapeutic potential remain to be further elucidated. Since
liver cancer usually develops on the background of chronic
liver disease, conventional anticancer therapies are not
effective. Moreover, the chemotherapeutics currently in use
are non-selective cytotoxic drugs that can lead to systemic
side effects in HCC patients with compromised liver function.
Recently, Sorafenib, a multikinase inhibitor acting through
VEGFR and PDGFR of the Raf kinase pathway, was
approved for hepatocellular carcinoma treatment [4]. The
Sorafenib Hepatocellular Carcinoma Assessment Random-
ized Protocol (SHARP) three-year clinical trial included 602
advanced-stage HCC patients (ClinicalTrials.gov number,
NCT00105443) [4]. The average survival rate for the group
taking Sorafenib was 10.7 months, and that for the group
taking the placebo was 7.9 months. For the Sorafenib group a
one-year survival rate of 44% was observed, whereas it was
33% for the placebo group. FDA- and EU- approved
chemotherapeutic Sorafenib thus prolongs median survival
and the time to progression by nearly three months in patients
with advanced hepatocellular carcinoma. Therefore FDA and
EU approved chemotherapeutic Sorafenib prolongs median
survival and the time to progression by nearly 3 months in
patients with advanced hepatocellular carcinoma. Therefore,
there is a need for new liver cancer specific drugs based on
the molecular mechanisms involved in liver carcinogenesis.
In this study, we investigated the Akt activation status in
HCC cell lines the differential effects of three Akt pathway
inhibitors and the extent of the inhibition of Akt signaling
as a major molecular mechanism in determining inhibitor-
induced apoptosis in these cells. The Akt pathway can be
blocked by cell line specific doses of pathway inhibitors.
Therefore, our findings suggested that PI3K/Akt could
represent an attractive target mitigating in liver cancer.
Materials and methods
Materials
DMEM (cat.12-614F), FCS (cat.DE 14-801F), antibiotics
(cat.DE 17-602E), glutamine and non essential amino acids
(cat.BE 13-114E) were from Lonza (Milan). Calnexin, β-
actin antibody, and Sulforhodamine B (SRB) (cat.86183-
5 g) were from Sigma (St. Louis, MO). Lumi-Light
detection kit (cat.12 015 196001) was from Roche M.B.
(Germany). Akt Inhibitor VIII (cat.124018), Wortmannin
(cat. BML-ST415-0005) and LY294002 (cat.440202) were
from Calbiochem (La Jolla, CA). The DMSO concentration
for drug solubilization was always less than 1% in the cell
culture medium.
The Akt Antibody (cat.610861) was from BD Transduc-
tion Laboratories (Franklin Lakes, NJ) and anti-p-473Ser
Akt (cat.587F11), anti-BAD (cat.185D10), anti-p-BAD
(cat.#9292), recGSK3α/β fusion protein (cat.#9237 L),
anti-p-GSK3α/β (cat.#9331 L), anti-PTEN and anti-PARP
(cat.46D11) antibodies were from Cell Signaling (Danvers,
MA). The immunoprecipitation matrix (cat.sc-45042) was
from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell culture
Hepatoma cells (Huh7, HepG2, Mahlavu) were cultured at
37°C, 5% CO2 in standard medium (2 mML-Glutamine,
0.1 mM NEA, 1xPS in DMEM) with 10% FCS.
Western blotting analysis
Proteins, from cells grown to 60–70% confluence, were
separated on 10% SDS-PAGE, transferred onto nitrocellu-
lose membranes and visualized as described previously [14].
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Akt kinase activity assay
Total homogenates from cells were resuspended in 50 mM
Tris-HCl pH 7.4, 1 mM EDTA, 1 mM EGTA, 150 mM
NaCl, 1% Triton X-100, 0.1% SDS plus phosphatase and
proteases inhibitors. IP was performed according to the
manufacturer’s instruction. Akt IP was resuspended in
20 mM HEPES pH 7.4, 10 mM MgCl2 and 10 mM MnCl2.
The reaction was started by incubating 10 μl IP, 100 μM
ATP and 1 μg recGSK3α/β for 40 min at RT, and then
stopped by 1 M Tris-HCl pH 6.8, 8% SDS, 40% glycerol,
20% β-ME. GSK3α/β phosphorylation was detected by
western blotting.
NCI-60 Sulforhodamine B (SRB) cytotoxicity assay
The cytotoxicities of LY294002, Akt Inhibitor VIII and
Wortmannin were tested as previously described [15].
Hepatoma cells (5000) were inoculated into 96 well
plates,100 μl/well. Next day, inhibitors with the indicated
concentrations were applied in a total of 200 μl of
medium. After 72 h of treatment, cells were fixed by cold
10% (w/v) TCA and then the wells were washed and
dried. One hundred μl of 0.4% SRB dye was applied to
each well and incubated at RT for 10 min then removed
and wells were dried. SRB dye was solubilized in 200 μl
10 mM Tris-Base and the absorbance was measured at
515 nm.
Real-time cell growth surveillance by cell electronic
sensing
Hepatoma cells (2000cell/well in 150 μl) were inoculat-
ed into 96 E-Plates (Roche) containing 50 μl medium/
well. Proliferation was monitored in real-time cell
electronic sensing RT-CES (xCELLigence-Roche Ap-
plied Science), and the cell index (CI) was measured
every 30 min for 24 h [16]. Next day, 100 μl medium
was discarded and 50 μl fresh medium was added to each
well. Inhibitors with indicated concentrations were ap-
plied to150 μl of medium. CI values were taken every
10 min for 4 h to visualize the fast drug response and then
every 30 min to visualize the long-term drug response.
Impedance measurements are displayed as Cell Index (CI)
values and the effect of the inhibitors on cell growth is
calculated as CIDRUG/CIDMSO. When the cells adhered to
electrodes on the bottom of the wells, CI values increased
in parallel to the cell growth due to the insulating
properties of the cell membrane. As the number of cells
covering the electrodes increases the electrical impedance
(Z) increased (Z0=0 --->Z=Zcell).
Fluorescence microscopy
Cells were seeded at 3×104 cells/cm2 on coverslips,
allowed to grow for 24 h, as indicated in the figure
legends, then washed twice with PBS and fixed with 4%
paraformaldehyde. Subsequently, cells were washed once
more with PBS and stained with 0.5 mg/ml DAPI.
Preparations were dehydrated with increasing concentra-
tions of ethanol and embedded in glycerol containing the
antifading agent to be analyzed with Zeiss Axiophot
epifluorescence microscope coupled with a Photometric
Cool Snap CCD camera for image acquisition. The
percentage of apoptotic cells was determined by counting
fragmented nuclei in a minimum of 4 fields containing at
least 150 cells. These experiments were performed in
triplicate. As a positive control for apoptosis, cells were
treated with 100 ng/ml Doxorubicine.
RT-PCR
Total RNA was isolated with NucleoSpin RNA II Kit (MN,
Germany). cDNAs synthesized from 4 μg RNA with
RevertAid kit (MBI Fermentas, Lithuania) were amplified
by PCR with the primers (PTEN: intron-3-F_5´-AAAGATT
CAGGCAATGTTTGTT-3´, intron-4-R_5´-TCTCACTCGA
TAATCTGGATGAC-3´, exon-4-F_5´-GACATTATGA
C A C C G C C A A A - 3 ´ , e x o n - 5 - R _ 5 ´ - T T C G
TCCCTTTCCAGCTTTA-3´, exon-7-F_5´-CGACGGGAA
GACAAGTTCAT- 3 ´ , e x o n - 8 - R _ 5 ´ AGGTTT
CCTCTGGTCCTGGT-3´, and GAPDH: F-5´-GGCTGA
GAACGGGAAGCTTGTCAT-3´ and R-5´CAGCCTTCTC
CATGGTGGTGAAGA-3´).
Results
Akt hyperphosphorylation in Mahlavu HCC cells
Hyperactivation of Akt was previously reported in HCC
[17]. Therefore, we sought first to analyze the Akt levels
and its serine-473 phosphorylation in hepatoma cells. Akt
total amount seems comparable albeit a slight higher
expression could be observed in Mahlavu cells when
compared to Huh7 and HepG2 cells (Fig. 1a). In addition,
significant Akt phosphorylation was detectable in Mah-
lavu cells, whereas only a slight Akt phosphorylation was
detectable in HepG2 and Huh7 cells under native
conditions.
Therefore, our initial observation suggested that the poorly
differentiated Mahlavu cell line might have hyperactivated
Akt signaling in comparison to the well-differentiated HCC
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cell lines; Huh7 and HepG2 [18]. To further assess whether
Akt hyperphosphorylation in Mahlavu cells is related to the
hyperactivation of its kinase enzymatic activity, we per-
formed a kinase assay on the fusion protein GSK3
containing Akt target-phosphorylation residues. The results
of this assay (Fig. 1b) showed the presence of a very low
intrinsic activity in Huh7 cells, an intermediate activity in
HepG2 cells but a very high kinase activity in Mahlavu cells.
As a control for equal loading, samples of immunoprecipi-
tated total Akt for the kinase assay were used. These data
correlate very well with those obtained by western blot data
on p-Akt (Fig. 1a).
We sought to further verify Akt pathway activation on a
native target of Akt. To this end, we analyzed the
phosphorylation status of BAD, a well-known protein
downstream of Akt, whose phosphorylation prevents cells
from undergoing apoptosis and confers them a proliferative
advantage. The p-BAD antibody used in our study was
specific to the Ser136 target of Akt kinase. In this way we
excluded the possibility of BAD being phosphorylated by
other kinases such as Erk-p90RSK kinase, which targets
Ser122 [19]. pSer136-BAD was absent in Huh7 cells, and
barely detectable in HepG2 cells, whereas a high level of
pSer136-BAD was detected in Mahlavu cells (Fig. 1c).
Interestingly, total BAD protein levels were not equal in the
cell lines analyzed although each lane contained 20 μg of total
cell lysate, in particular Mahlavu showed lower BAD protein
levels than HepG2 (Fig. 1c). However, we observed an
intense phosphorylation by endogenous BAD in this cell
line, which might explain the faint pSer136-BAD band in
HepG2.
Determination of IC50 values for the HCC cells with SRB
cytotoxicity assay
After the analysis of the hyperphosphorylation state of the
Akt protein in well differentiated Huh7, HepG2 cells and
poorly differentiated Mahlavu cells under native conditions,
we decided to see the effect of PI3K inhibitors (LY294002,
Wortmannin) and the specific Akt inhibitor (Inhibitor VIII)
on this signaling pathway. Akt Inhibitor VIII selectively
prevents Akt1 and Akt2 activity through pleckstrin homol-
ogy (PH) domain [20, 21].
Initially we assessed their cytotoxicity by NCI-60
conventional Sulforhodamine B assay that was performed
in quadruplicate and for 5 different concentrations follow-
ing the NCI’s drug screening protocol. The inhibitory effect
of each drug of treatment was plotted (Fig. 2). IC50 values
were calculated from these graphs for 24, 48, and 72 h
(Fig. 2). IC50 values of LY294002 were 3.65 μM,
25.03 μM and 7.19 μM for 24 h and 3.75 μM, 5.82 μM
and 8.71 μM for 72 h in Huh7, HepG2 and Mahlavu cell
lines, respectively. For Wortmannin IC50 values in Huh7,
HepG2 and Mahlavu cell lines were 26.07 μM, 29.23 μM
and 20.19 μM for 24 h and 17.78 μM, 11.27 μM and
36.88 μM for 72 h, respectively. For 24 h, the IC50 values
of Inhibitor VIII were 4.42 μM and 17.16 μM for Huh7
and HepG2, while there was not a significant inhibition
observed in Mahlavu with NCI-60 assay. For 72 h, the IC50
values of Inhibitor VIII were 5.27 μM, 4.48 μM and
9.04 μM for Huh7, HepG2 and Mahlavu cells, respectively.
Real-time, dynamic monitoring of cell growth in HCC cells
treated with the inhibitors
In order to further analyze if the growth inhibition of HCC
cells is permanent or temporary, we used a novel cell
surveillance system to monitor real-time, dynamic changes
in cell growth based on the electrical impedance measure-
ment technique. The RT-CES system allowed us to monitor
the effects of LY294002, Wortmannin, and Inhibitor VIII
on the hepatoma cells by a label-free and a real-time native
approach. The proliferation and cytotoxicity of the inhib-
itors were followed by real-time through electronic cell
sensors, integrated in the bottom of the 96 E-Plates in
triplicates with 5 different concentrations (40 μM, 20 μM,
10 μM, 5 μM, 2.5 μM) (Fig. 3). When normalized to
a MVHepG2Huh7
Akt tot
p-Akt tot
β-actin
b Huh7 HepG2 MV
p-GSK3
Akt 
pSer136-Bad
Huh7 HepG2 MV
Bad tot
c
Fig. 1 Akt activity analysis in HCC cell lines. a Western blot analysis
of untreated Huh7, HepG2, and Mahlavu cell lines, detected with anti
Akt antibody or anti-p-Akt antibody. b Kinase assay on the fusion
protein of GSK3α/β added to the reaction mixture as an exogenous
substrate. As a control for equal loading, samples of immunoprecipi-
tated Akt for the kinase assay were used. c Western blot analysis of
untreated HCC cell lines was performed with anti-total BAD antibody
or anti-p-BAD antibody. 20 μg of proteins were loaded for each lane.
Data given here are representative of three independent experiments.
SDS are less than 10%. The Mahlavu cell line displays high a Akt
phosphorylation level and the highest enzymatic activity tested on
both exogenous (GSK3α/β) and endogenous (BAD) substrate
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DMSO treated cell proliferation curves the cell growth plots
demonstrated the concentration- and time-dependent cyto-
toxic effect of the inhibitors. In addition to provide also a
visual demonstration of the effects of these drugs on these
cells we treated cells with inhibitors and show their
morphological changes by light microscope images at 24
and 48 hours in parallel with the RT-CES experiments with
IC50 of 24 hours concentrations (Fig. 3b).
High dose treatment of LY294002 (40 μM) suppressed
cell growth permanently after 8 h and continuing up to 84 h
in Huh7 and Mahlavu cell lines. Lower doses (5 μM,
2.5 μM) of LY294002 had a minor effect on cell growth for
up to 48 h but then the cells resumed growth, especially in
the case of the Mahlavu cell line. With Inhibitor VIII
treatment, cells responded similarly as to LY294002
exposure although Inhibitor VIII appeared more effective
at short exposure times. Wortmannin treatment was effec-
tive in inhibiting cell growth only for about 24 h and then
the cells gradually resumed normal growth. This real-time
dynamic continuous analysis of cell growth and toxicity
was essential to determine the optimal time points for
performing biochemical endpoint assays. The continuous,
dynamic analysis of cell growth of LY294002, Wortmannin
and Akt Inhibitor VIII treated Huh7 and Mahlavu cells
supported the time- and concentration-dependent effects of
the three inhibitors on HCC cells as shown in Fig. 2.
We also analyzed Akt enzyme activity in the presence of
inhibitors. The IC50 values of 72 h for LY294002,
Wortmannin and Akt Inhibitor VIII were used to assess
the effects of drug treatments on Akt kinase activity in
HCC cell lines by a specific kinase assay using the fusion
protein fusion protein of GSK3α/β as substrate similarly to
that of Fig. 1b. Our results demonstrated the inhibitory
effect of the three drugs on the kinase activity of the Akt
protein, when compared to the kinase assay under native
conditions. In all cases no Akt phosphorylation activity was
Fig. 2 Inhibitory effects of LY294002, Wortmannin and Akt Inhibitor
VIII on HCC cell growth. % inhibition of cell growth after a 24, b 48,
c 72 and d 96 hours of treatment with the inhibitors. Sulforhodamine
B (SRB) colorimetric assay was performed in quadruplets with 5
different concentrations (50 μM, 15 μM, 10 μM, 5 μM, 1 μM)
represented with error bars (Supplementary Figs. 1–3). The growth
inhibitory effect for shorter exposure is relevant also for low
concentrations. At longer exposure times growth inhibition requires
higher drug concentrations. IC50 values were calculated based on the
logarithmic regression line fitted on the % inhibition vs. log
(concentration) graph, Huh7 ( ), HepG2 ( ), Mahlavu ( )
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detected on the fusion protein of GSK3α/β (data not
shown). These data indicate a very low Akt activity in each
cell line, evidence of a significant inhibition of the pathway
by these inhibitory molecules in HCC cells.
Cytotoxic effect of drugs on HCC cells through apoptosis
It is a well-documented fact that the Akt pathway has an
important anti-apoptotic role in different cells [22, 23].
Morphological changes specific to apoptosis can be
observed quite early after apoptotic stimuli [24, 25]. In
order to see the morphological changes in Huh7, HepG2
and Mahlavu cells after treatment with each drug, cells
were treated with inhibitors for 24 and 48 h. Each drug was
used at its IC50 value obtained after 24 h of treatment.
Apoptotic cells usually exhibit extensive DNA cleavage
during the early stages of this controlled cell death
mechanism. Cleavage may produce double-stranded, low
molecular weight DNA fragments as well as single-
stranded high molecular weight DNA fragments that
manifests themselves as condensed aberrant nuclei, as
shown by DAPI (Fig. 4) and the Hoechst 33258 stain (data
not shown). This observation demonstrated that those cells
displayed the type of cell death that is specific to apoptosis.
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Fig. 3 Cell growth of LY294002, Wortmannin and Akt Inhibitor VIII
treated Huh7 and Mahlavu cells. a Cell growth is assessed with the
xCELLigence system that measures electrical impedance across
micro-electrodes integrated on the bottom of tissue culture E-96
plates. Impedance measurements are displayed as Cell Index (CI)
values, providing real-time quantitative information on cell growth.
The effect of the inhibitors on cell growth is calculated as CIDRUG/
CIDMSO. The cell growth assay was performed in triplicates with 5
different concentrations 40 μM, 20 μM, 10 μM, 5 μM, and 2.5 μM.
Huh7-LY294002 ( ), Huh7-Akt Inhibitor VIII ( ), Huh7-
Wortmannin ( ), Mahlavu-LY294002 ( ), Mahlavu-Akt In-
hibitor VIII ( ), Mahlavu-Wortmannin ( ). b Analysis of
apoptosis associated morphological changes with light microscopy.
Huh7 and Mahlavu cells were treated with the indicated inhibitors at 24
and 48 hours. Huh7 cells : LY294002 (4 μM), Wortmannin (26 μM),
Akt Inhibitor VIII (4.5 μM) ; Mahlavu cells : LY294002 (7 μM),
Wortmannin (20 μM), Akt Inhibitor VIII (10 μM). 20X pictures were
taken with OLYMPUS CKX41 microscope with DP72 camera
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The pro-apoptotic effect of the drugs was assessed by
counting aberrant nuclei in DAPI stained cells. The
morphological features of apoptosis, i.e. condensation of
chromatin and fragmentation of the nucleus, were exam-
ined. Control cells showed rounded and homogeneous
nuclei, whereas drug treated-cells showed condensed and
fragmented nuclei (Fig. 5a). The percentage of apoptosis
ranged from 32% to 25% in Huh7, from 32% to 27% in
HepG2 and from 35% to 28% in Mahlavu, (Fig. 4b).
In order to further clarify the type of cell death
mechanism and the morphological changes that we observe
in Figs. 3b, 4a, in the presence of the inhibitors as
apoptosis, we performed Poly ADP-ribosyl polymerase
(PARP) cleavage analysis by western blot. Huh7, HepG2
and Mahlavu cells were treated with each drug at the
24hours-IC50. PARP is typically cleaved from 113 kDa to
89 and 24 kDa fragments by caspase-3 during apoptosis.
Although cleaved PARP is also detected during necrosis,
the cleaved product’s molecular size is different (50 kDa).
As shown in Fig. 5, the cleaved band (89 kDa) is due to
apoptosis, not necrosis [26]. Our observations clearly
demonstrated that Akt pathway inhibitors had an
apoptosis-dependent cytotoxic effect on HCC cell lines.
Comparative analysis of PTEN in HCC cells
With the aim of identifying differential responses of HCC
cells to Akt pathway inhibitors, we further investigated
PTEN, another pathway related molecule. PTEN protein
expression in HCC cell lines exhibited differential expres-
HepG2
Huh7
b
MV
untreated DMSO Doxo LY294002 Wort Inh VIIIa
Fig. 4 DAPI staining showing the aberrant nuclear DNA due to the
apoptotic cells with condensed nuclei (white arrows) in the presence
of inhibitors with IC50 concentrations. a The pro-apoptotic effect of
Akt pathway inhibitors on the morphology of the nuclear chromatin in
HCC cells. Cells were treated for 24 h with the IC50 values (Huh7 :
LY294002 (4 μM), Wortmannin (26 μM), Akt Inhibitor VIII
(4.5 μM); HepG2 : LY294002 (25 μM), Wortmannin (29 μM), Akt
Inhibitor VIII (18 μM); Mahlavu : LY294002 (7 μM), Wortmannin
(20 μM), Akt Inhibitor VIII (10 μM)), then fixed and stained with
DAPI. No changes were induced by DMSO. All samples treated with
the positive control, Doxorubicine (100 ng/ml) showed evident
apoptotic nuclei. Well markable, even if less present, are apoptotic nuclei
after apoptosis induction with each drug. The results were from one
experiment representative of three experiments. Bar=10 μm b Apoptotic
cells were quantified by counting a minimum of 4 fields containing at
least 150 cells. The results are presented as the mean of three
independent experiments. Doxorubicine, an inhibitor of enzyme top-
oisomerase II progression by intercalation of DNA, induced a marked
percentage of apoptosis. The three inhibitors used in this study within
each cell line, gave similar results. SD was less then 10%
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sion patterns, ranging from marked expression in the Huh7
and HepG2 cell lines, to the absence of PTEN expression in
Mahlavu cell line. The absence of PTEN protein expression
was in correlation with the hyperphosphorylation of Akt,
higher kinase activity on exogenous GSK3α/β fusion
protein and on endogenous BAD protein in Mahlavu cell
line. In correlation with the absence of PTEN protein
expression, the Mahlavu cell line had mRNA expression
with a partial deletion in the PTEN gene in exon 4 (Fig. 6),
which may explain the lack of protein that results in the
hyperactivation of the Akt protein in this cell line.
Discussion
In this study, we have shown hyperactivation of the Akt
protein in hepatoma cell lines and apoptosis induction in
time- and dose- dependent manners after treatment with
three specific inhibitors of the PI3K/Akt pathway. The
PI3K/Akt signaling pathway plays a significant role in
carcinogenesis and drug resistance in different types of
cancer including HCC, making Akt a potential target for
cancer treatment [28, 29].
Tumors with activated PI3K/Akt signaling have been
shown to become more aggressive, and Akt pathway
activation has been identified as a significant risk factor
for early disease recurrence and poor prognosis in HCC
patients [30, 31]. Activated Akt correlates also with local
metastasis of tumor cells from the primary liver cancer into
the circulatory system and the survival of the circulating
cells without cell-substratum interaction [32], showing the
significance of this hyperactivated pathway not only in liver
tumor aggressiveness but also in tumor diffusion and
survival in different environments. Therefore we initially
examined total Akt protein and native p-Akt levels in HCC
cell lines. Mahlavu cells were previously reported to be
poorly differentiated when compared to the well-
differentiated “hepatocyte-like” Huh7 and HepG2 cells
[18]. Although the cell lines included in this study showed
similar total Akt protein expression (Fig. 1a), only Mahlavu
cells displayed hyperphosphorylated Akt protein (Fig. 1a),
which was determined by anti-p473Ser-Akt antibodies,
because Ser473 Akt phosphorylation is a requirement for
full Akt enzyme activity [33]. In Mahlavu cells, in parallel to
the hyperphosphorylation of Akt, we also observed a lack of
PTEN protein expression (Fig. 6) and increased phosphor-
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Fig. 5 Investigation of apoptotic cell death in the presence of Akt
pathway inhibitors. Apoptosis activation was detected by means of
PARP cleavage. The antibodies used recognize both the intact form
(113 KDa) and the cleaved one (89 KDa). In each lane 20 μg proteins
were loaded. . Almost no cleavage is observable in control and
DMSO-treated samples. An evident PARP cleavage is induced by the
three inhibitors used. Each cell line induced similar PARP cleavage.
Data were representative of three independent experiments
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Fig. 6 Differential expression
of the PTEN gene in human
HCC cell lines. a Whole-cell
lysates (40 μg) were analyzed
by Western blotting using anti-
PTEN antibody. Mahlavu cell
line has no PTEN expression. b
PCR analysis of PTEN gene in
HCC cell lines. Figure describes
the loss of PTEN gene fragment.
The gene fragment that is
lacking is located within exon
4 and 5
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ylation of the downstream protein Bad on Ser136 and of the
exogenous GSK3 substrate (Fig. 1b and c).
The activation of PI3K/Akt signaling frequently related
to PTEN mutation has also been observed in nearly 50% of
HCC [34], suggesting the importance of this pathway, since
tumors with hyperactive Akt due to PTEN loss depend on
hyperactivated Akt signaling for growth and survival [10].
Indeed, our results support the observations that a PTEN
deficient cell line Mahlavu has hyperactivated Akt protein.
Moreover Mahlavu has the higher IC50 values for
Wortmannin than well differentiated Huh7 and HepG2 cell
lines.
The great majority of protein kinase inhibitors that have
been developed, bind at or near the ATP binding site [35].
These compounds were recommended for use in a
concentration range of 0,1 to 100 μM to assess the roles
of particular protein kinases. Depending on concentration,
kinase inhibitors may act as multi-kinase inhibitors.
Therefore in our study we analyzed the PI3K/Akt signaling
inhibitors with concentrations between 40 μM–2.5 μM
(Figs. 2 and 3) in order to identify their specific IC50
values on hepatoma cell lines. We think that with the
concentration we used LY294002 and Wortmannin exhibit
their cytotoxic activity through binding to the proximity of
the active sites of their target kinases. Structural analysis of
the p110γ isoform of PI3K in the presence of LY294002
demonstrated that this inhibitor binds to the active site. Cell
death induced by LY294002 is through GSK3β activity,
which is also demonstrated in the presence of lithium, a
known inhibitor of GSK3β [36, 37]. Consistent with the
structural similarity between the PI3K and mTOR kinase
domains, LY294002 and Wortmannin act on both of these
kinases with similar IC50 values [38]. Both PI3K and
mTORC2 are the upstream proteins of the Akt pathway.
Therefore, we focused also on the downstream analysis of
Akt protein activation/inhibition regardless of the direct
targets of LY294002 and Wortmannin in HCC cells. To
stress the importance of Akt pathway signaling inhibition as
a potential therapeutic target in liver cancer, we analyzed
the effects of the selective Akt inhibitor, Akt Inhibitor VIII
on HCC cells [20, 21].
We applied two different cytotoxicity assays, conven-
tional NCI-60 method and novel RT-CES system. Both
assays resulted in similar IC50 values for 24, 48, and 72 h
for the specific PI3K/Akt signaling inhibitors LY294002,
Wortmannin, and Akt inhibitor VIII, although it is possible
to calculate IC50 for each time point with RT-CES. As
expected, we were able to demonstrate that all three
inhibitors had cytotoxic activity. At 24 h all three cells
had comparable IC50s but with longer treatment times
Mahlavu cells displayed higher IC50s when compared to
Huh7 and HepG2 cells. RT-CES analysis demonstrated that
normal cell growth has a cell index (CI) of around 1.2
(Fig. 3a). 20 μM inhibitor treatment did not influence the
cell proliferation during the initial 10–16 h. The cytotoxic
effect of the inhibitors became established toward the end
of the 24 h (Fig. 3a, 40–10 μM) as it can be observed by
the CI of 0.5. Between 36 h and to 60 h RT-CES data
demonstrated whether they inhibit cell proliferation irre-
versibly or whether cells can survive afterwards. In the case
of LY294002 and Akt inhibitor VIII, CI approached to 0.2
at the 60th hour meaning almost no cells attached to the
bottom of the cell culture plates to form colonies. We
confirmed this data in parallel experiments by direct light
microscopy visualization of the cells at 24 and 48 h
(Fig. 3b). Cells treated with Wortmannin displayed a
similar growth curve with CI during first 24 h to that of
LY294002 and Akt inhibitor VIII did. However starting
from 36 h both Huh7 and Mahlavu cells continued to
proliferate and expanded to cover the bottom of the E-
plate parallel to the DMSO treated control cells even with
very high (40 μM) concentrations. We confirmed again by
microscopy that the cells presented a healthy morphology
(Fig. 3b).
Continuous very low Cell Index data (0.2–0.3) with
LY294002 and Akt inhibitor VIII treatments on the
hepatoma cells were the indications of apoptotic cell death.
In addition direct light microscopy visualization of the cell
morphology showed that all the inhibitors induced apoptosis
on hepatoma cells. From the above evidence the nature of
the cell death exhibited in the presence of the PI3K/Akt
signaling inhibitors LY294002, Wortmannin, and Akt inhib-
itor VIII was characterized as apoptosis (Figs. 4 and 5).
The three drugs, generated a PARP cleavage process on
the HCC cell lines after being administered (Fig. 5). As
shown above, the drugs appear to have similar apoptotic
effects in all the cell lines tested. In addition, since PI3K-Class
IIIs control autophagic proteolysis, we examined the possi-
bility that the cytotoxic effect of these inhibitors might be
through autophagy [27]. After 48 h of incubation with the
three inhibitors we performed western blot analysis of
autophagy related proteins BECN1 and p62 but did not
observe any alterations that could be attributed to autophagy
(data not shown).
This study suggests that targeting the PI3K/Akt signaling
pathway provides a promising strategy for designing
molecular targeted therapy in the case of solid tumors,
especially HCC. Our data also suggest that PI3K/Akt
activation status serve as a biomarker for identifying
candidate patients for treatment with inhibitors of PI3K
and/or of its downstream targets. However, it should be
noted that drug transporters or IAPs (Inhibitors of Apopto-
sis Proteins) could contribute to the therapeutic resistance.
Likewise, transcription factors, such as NF-κB, can up-
regulate transporters like MRP2 to induce multidrug
resistance in HCC [39]. Furthermore, we have previously
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shown that during liver tumorigenesis HCC cells develop a
“survivor phenotype” independent of the cause of onco-
genic transformation under oxidative stress conditions [40].
It may also be important to raise questions about the
stability of the drugs for longer treatments. We performed
experiments, by monitoring cell growth real time, that
demonstrated that when drug concentration increases,
growth inhibition lasts longer. This observation could be
due to a lower a decay rate of active drug molecule
concentration. Our results obtained by the three PI3K/Akt
pathway inhibitors used clearly demonstrated that the Akt
pathway can still be a target when Akt and BAD are
hyperphosphorylated and the PTEN protein is impaired, as
we show in the Mahlavu cell line. In treatment, chemo-
therapeutic agents are usually given in a protocol with
repeating dosages to target resistant cell populations.
Tumors with hyperactive Akt due to PTEN loss depend
on Akt signaling for growth and survival [10]. Activated
Akt pathway confers resistance to cancer therapy, making
Akt a promising target for cancer treatment [34]. Increasing
knowledge in the molecular mechanisms underlying hep-
atocarcinogenesis and the advent of molecular targeted
therapies provide a promising treatment approach for HCC
patients. Novel therapeutic targets, molecular oncogenic
mechanisms and signaling cascades responsible for tumor
growth should be investigated together with potential
chemotherapeutic agents to improve clinical efficacy.
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Abstract
Transcriptome experiments are performed to assess protein abundance through mRNA expression analysis. Expression
levels of genes vary depending on the experimental conditions and the cell response. Transcriptome data must be diverse
and yet comparable in reference to stably expressed genes, even if they are generated from different experiments on the
same biological context from various laboratories. In this study, expression patterns of 9090 microarray samples grouped
into 381 NCBI-GEO datasets were investigated to identify novel candidate reference genes using randomizations and
Receiver Operating Characteristic (ROC) curves. The analysis demonstrated that cell type specific reference gene sets display
less variability than a united set for all tissues. Therefore, constitutively and stably expressed, origin specific novel reference
gene sets were identified based on their coefficient of variation and percentage of occurrence in all GEO datasets, which
were classified using Medical Subject Headings (MeSH). A large number of MeSH grouped reference gene lists are presented
as novel tissue specific reference gene lists. The most commonly observed 17 genes in these sets were compared for their
expression in 8 hepatocellular, 5 breast and 3 colon carcinoma cells by RT-qPCR to verify tissue specificity. Indeed,
commonly used housekeeping genes GAPDH, Actin and EEF2 had tissue specific variations, whereas several ribosomal genes
were among the most stably expressed genes in vitro. Our results confirm that two or more reference genes should be used
in combination for differential expression analysis of large-scale data obtained from microarray or next generation
sequencing studies. Therefore context dependent reference gene sets, as presented in this study, are required for
normalization of expression data from diverse technological backgrounds.
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Introduction
During the last decade, there has been remarkable progress in
the identification of human cells’ transcriptome blueprint through
small or large-scale quantitative gene expression studies. Since the
gene expression is the major determinant of the protein
abundance in the cell, transcriptome analysis experiments have
been widely applied to reveal the molecular mechanisms of various
cellular conditions. Depending on the cell fate, expression levels of
genes vary. Although it seems straightforward to assess these
variations through Real Time quantitative PCR or microarrays,
there is a continuing and confusing debate on what basis these
variations should be considered as deviations from normal
physiology. Therefore, there is a need for compilation and
comprehensive analysis of a gene of interest across several
experiments from different sources. A gene’s expression data must
be scaled in a comparable platform. Various normalization
methods are available to scale these data within the same
experiment, yet it becomes problematic to compare arrays of
different sources without using references.
Although most genes show variable expression depending on
cellular context, tissue of origin or treatment conditions, some
genes are constitutively expressed in all cells in all conditions.
These constitutively expressed genes are required for the
maintenance of the basal cellular functions such as metabolism,
gene expression, protein synthesis and cell signaling [1,2]. These
genes, called housekeeping genes, are generally assumed to have
expression levels unaffected by tissue of origin or experimental
condition. Therefore, they are widely used as reference genes for
normalization of expression data. However, recent studies
indicated that several widely used housekeeping genes have
altered expressions under different experimental conditions [3–
10]. Most of these studies focused on finding appropriate genes for
normalization in individual cancer types. Yet, even the most
commonly used reference genes (ACTB, GAPDH, TBP) were
differentially expressed in different pathological stages of hepato-
cellular carcinoma [7,11]. These findings bring forward the need
to process high-throughput data in order to determine a global list
of constitutively and invariably expressed genes that can be used as
reference genes [12–14]. For example, Hruz T. et al. measured the
standard deviation of gene expression across large sets of
Affymetrix arrays of human, mouse and Arabidopsis from the
Genevestigator database and developed an online tool, Ref-Genes,
that can be used to search for genes with minimal standard
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e93341
deviation across a chosen set of arrays [15,16]. They concluded
that no genes are universally stable, but a subset of stable genes
with minimal variance exists for each biological context that can
be used for the normalization of RT-qPCR data.
Although publicly available microarray or next generation
sequencing (NGS) experiments were used to generate lists of
candidate reference genes, novel statistical approaches for testing
accuracy of a reference gene are still needed. Herein, we aimed to
confirm the reliability of available housekeeping gene sets using
randomization as well as to determine other invariably expressed
gene sets based on Receiver Operating Characteristic (ROC)
curves for classifiers under large number of experimental
conditions and across a wide panel of tissue types.
Our method provides reference gene lists for global and cell-
type specific normalization of transcriptome data. Gene lists are
scored based on their expression stability, and classified according
to the Medical Subject Headings (MeSH) associated with the
transcriptome study that was published and indexed by National
Library of Medicine. Gene lists are provided in the supporting
dataset (Supporting Information S1). RT-qPCR assessment of
selected reference genes is also provided for various tissue-specific
cancer cell lines in vitro.
Results and Discussion
Development of a methodology to identify consistently
stable genes
Housekeeping/reference genes should exhibit relatively con-
stant expression levels when compared to non-housekeeping genes.
To identify the consistency of the so-called housekeeping genes
across large-scale experiment sets, the gene expression data were
downloaded from the NCBI Gene Expression Omnibus (NCBI-
GEO) database [17], and all spot data were extracted along with
their associated metadata from the platform files. The data set
approximately contained 142 million oligonucleotide microarray
spots from 9090 microarray samples, which were grouped into 381
GEO datasets. Percentile-ranking method was applied indepen-
dently on the global mean normalized data within each sample in
each GEO dataset. This process provided a rank value for each
gene within a sample. Therefore, the rank measure was
Figure 1. Screenshot of the first 40 lines from reference gene lists. Complete set of MeSH classified reference gene lists from 9090 array
samples are given in hyperlinked Supporting Information S1 spreadsheet.
doi:10.1371/journal.pone.0093341.g001
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comparable across experiments and platforms, allowing the
analysis of the behavior of a gene globally across GEO datasets.
Using ranks of genes is a standard method as also employed in
Quantile Normalization, which is a common microarray normal-
ization technique [18].
The average changes in the rank of each gene in each GEO
dataset (GDS) was computed based on the ratio of the standard
deviation to the mean and termed as its coefficient of variation
value (CV) (see Methods). CV, as a standardized measure of
sample variability, help suggest candidate reference genes whose
expression is stable and unaffected by the experimental condition
since it has been successfully applied in identification of reference
genes in multiple studies with varying thresholds [19–22]. Most
genes had coefficient of variation values only for a subset of the
available GDSs. Therefore, for each gene Gi and a predefined CV
threshold t, the ratio of GEO datasets, where CV is less than t,
Ratiot(Gi), is calculated as the measure of stable expression.
Ratiot(Gi) is the ratio of GEO datasets, in which a gene exhibits a
coefficient of variation less than t. The Ratiot(Gi) value, by itself, is
not a sufficient measure to identify statistically significant reference
genes. A gene that has a small enough CV value can get a perfect
ratio even if it is observed in only a single GEO dataset. Therefore,
a new parameter, PO(Gi), calculated as the percentage of datasets
that each gene has been observed in at least once, was used to
adjust Ratiot(Gi) parameter (Methods). Ratiot(Gi) in the context of
PO(Gi) allowed for accurate normalization of a large set of
microarray data, since it takes into account the information about
the differences in probe/clone composition of the arrays. We
assessed the utility of these measures by implementing a simple
threshold based classifier and computing the sensitivity and
specificity of this classifier using a published reference gene set
as the ground truth (Methods). Two sets of reference genes were
generated. First list contains reference gene lists with a CV
threshold of 0.12 and with various sensitivity values while the
second list is built with sensitivity of 0.5 for a range of CV
threshold values. Figure 1 shows the first 40 genes from 342
reference genes with a CV of at most 0.12, sensitivity equal or over
0.5, specificity of 0.97 and minimum percentage of occurrence of
0.75 in all 9090 array samples from 381 GEO datasets (See
Reference Gene Lists in Supporting Information S1 for the
complete list). The high specificity shows that the CV measure
coupled with percentage of occurrence is an accurate measure for
identification of reference gene sets.
Figure 2. Graph of ratio of the number of sets in which a gene has a coefficient of variation (CV) less than a threshold (t), to the
number of sets in which the gene is observed. Graphs were plotted for CV value thresholds t = 0.5 t = 0.1, t = 0.05 and t = 0.01. Percentage of
occurrence (PO) is at least 50% of the total sets. The y-axis indicates the number of genes having a ratio greater than the ratio value at the
corresponding x-axis. This function is described in the methods section, as x-axis being r and y-axis being fPO(r). The black curve represents
housekeeping genes while curves with grey colors show 5 random sets of genes excluding the housekeeping genes. Random sets of genes have the
same mean rank distribution as of those housekeeping genes.
doi:10.1371/journal.pone.0093341.g002
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Housekeeping/Reference genes should exhibit relatively con-
stant expression levels and their average rank change should be
lower than that of remaining genes. Hence, we assumed that the
candidate reference genes should have lower CV and higher
Ratiot(Gi) than that of randomly selected genes. In order to
compare the expression behaviors of reference genes to that of
random genes, we first analyzed the largest previously reported
housekeeping datasets [1,23]. There was high variation between
genes in the first dataset, in parallel with the authors’ observations.
Therefore, the dataset provided by Eisenberg et al. was used in our
analysis. The 566 housekeeping genes in this dataset were
compared to five different randomly selected sets of non-
housekeeping genes having the same mean rank distribution as
that of the housekeeping gene set.
Normalized gene expression values were analyzed for the CV
thresholds t=0.5, t=0.1, t=0.05, and t=0.01 and minimum
percentage of occurrences PO=75%, 50%, 25% and 5%. When
coefficient of variation, CV, was less than 0.5 (t=0.5), percentile-
ranked GEO datasets showed high Ratiot values for nearly all of
the analyzed genes (housekeeping or not), for all PO values. At
lower CV thresholds, t=0.1, t=0.05 and t=0.01, housekeeping
genes had significantly higher Ratiot values than those of random
gene sets for all PO values. The randomization approach allowed
us to test an optimum range of t and PO values that can
discriminate between reference and non-reference genes. Graphs
of Ratiot at PO=50% with four different CV thresholds (Figure 2)
and graphs of Ratiot at CV t=0.05 with four different PO
thresholds were plotted (Figure 3). These graphs showed that
measures could accurately distinguish previously identified refer-
ence genes from the randomly selected ones.
The difference in the ratio distribution of housekeeping genes
compared to that of the randomly selected non-housekeeping gene
sets was statistically significant, as shown by Kolmogorov-Simirnov
tests (Table S1 in Supporting Information S2, p,0.0001). The
random gene sets, excluding the housekeeping genes, did not show
any significant ratio distribution difference, as shown by using
Bonferroni adjusted Kolmogorov-Simirnov tests (Table S2 in
Supporting Information S2). These observations proved that the
expression of the tested housekeeping genes was less variable
across different experiment sets compared to that of randomly
selected gene sets.
In addition, we assessed the sensitivity and specificity of a simple
threshold based classifier using the CV threshold using the
published housekeeping gene set as the ground truth. The receiver
operator characteristic (ROC) curve in Figure 4 shows that more
than half of the published reference genes can be identified with a
Figure 3. Graph of ratio of the number of sets in which gene has coefficient of variation less than 0.05 to the number of sets in
which the gene is observed. Gene is observed at least a-) 75%, b-) 50%, c-) 25% and d-) 5% of the total sets. The y axis indicates the number of
genes having a ratio greater than ratio value at the corresponding x axis. The curve with red color represents housekeeping genes while curves with
other colors shows 5 random sets of genes excluding the housekeeping genes. Random sets of genes have the same mean rank distribution as of
those housekeeping genes.
doi:10.1371/journal.pone.0093341.g003
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specificity of 0.97. Similar analyses performed on datasets grouped
by MeSH are available in Supporting Information S3.
Identification of novel reference genes
Our primary goal in this study was to define a novel reference
gene set that can be used for both global and cell type-specific
normalization of expression experiments. For this purpose, a
classifier that can be used to identify novel reference genes was
built. Based on our analysis with the known 566-housekeeping
gene set, coefficient of variation (CV) measure was set as the
variable for building the classifier while minimum percentage of
occurrence (PO) and Ratiot values were fixed at 75% and 0.90
respectively. The accuracy of this classifier in predicting reference
genes was assessed in comparison with the previously reported 566
housekeeping gene set [23]. Among the candidate reference genes
that were identified by our classifier at each CV threshold, the
known 566 housekeeping genes were regarded as true positives
(TP) and the other genes were regarded as false positives (FP) to
plot a receiver-operating characteristic (ROC) curve. In the
supporting gene lists, the sensitivity was set to 0.5, implying that
half of the identified reference genes are the known housekeeping
genes. The ROC curve of our classifier for CV values ranging
from 0.01 to 10 showed its effectiveness in finding true positives
(sensitivity) (Figure 4). Curves for the overall (Figure 4A) and
specific reference gene sets are available in the supporting
hyperlinked dataset (Supporting Information S3).
According to a classic ROC curve, a good classifier should
capture most of the known housekeeping genes while providing a
relatively small number of false positives. However, in this
particular case, the false positives could be the newly identified
candidate reference genes. Therefore, their CV and Ratiot values
should still be considered for their potential as a reference gene.
CV, Ratio and Percentile Rank values are provided for each gene
in the supporting hyperlinked dataset. The global reference genes
were given in this list under the category of All with CV of 0.12,
sensitivity equal or over 0.5, specificity of 0.97 and minimum
percentage of occurrence of 0.75 (Figure 2A and Supporting
Information S1).
In order to determine origin- and cell type-specific reference
genes, the GEO sets were classified according to the Medical
Subject Headings (MeSH) associated with their experimental data,
published and indexed by National Library of Medicine. Of the
381 GEO datasets analyzed in this study, 341 were associated with
272 different medical publications and 264 of these publications
Figure 4. Receiver Operator Characteristic (ROC) curve of the simple threshold based classifier. The receiver operator characteristic
(ROC) curve of a simple threshold classifier over all datasets and some MeSH categories. The housekeeping gene set by Eisenberg et al. [22] is used as
the ground truth. The simple threshold classifier classifies all the genes with CV values below a threshold as housekeeping genes. By using different
CV thresholds the stringency of the classifier can be varied and the ROC curve can be plotted accordingly. Sensitivity is the ratio of correctly classified
ground truth genes over all ground truth genes and specificity is the ratio of correctly identified non-housekeeping genes over all non-housekeeping
genes. Complete set of MeSH classified RO-curves are given in hyperlinked Supporting Information S3 spreadsheet.
doi:10.1371/journal.pone.0093341.g004
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were associated with a total of 5754 MeSH terms [24]. These gene
sets were grouped into three anatomy (tissues, cells, hemic and
immune systems), and one disease (neoplasms) based MeSH
categories (Table 1). GDS identification numbers associated with
each MeSH are given in Supporting Information S1. Two lists of
reference gene sets based on CV and sensitivity, were provided for
each MeSH category. First list was constructed based on a fixed
threshold for CV,0.12 and the second on a fixed threshold of
sensitivity.0.50. Both gene sets had a fixed PO threshold of 75%.
The reference gene lists, which include CV, PO, specificity and
sensitivity values for each MeSH category, are provided as
supporting hyperlinked dataset (Supporting Information S1).
Experimental validation of selected reference genes in
different cancer cells
Among the large panel of identified reference genes, 17 genes
were selected for experimental validation (Table 2). Expression
levels of these reference genes (AARS, ACTB, CFL1, EEF2,
GAPDH, GSTO1, H2AFZ, HBXIP, RPL30, RPL41, RPL7, RPN2,
RPS10, RPS17, RPS3A, SOD1, TPT1) were assessed by RT-qPCR
in 16 different cell lines consisting of 8 Hepatocellular Carcinoma
(HCC) (HepG2, FOCUS, Mahlavu, Hep3B, Hep3B-TR, Huh7,
SkHep1, and PLC), 5 Breast Cancer (MDA-MB453, HCC1937,
BT20, T47D and CAMA-I), and 3 Colon Cancer (HCT116,
HT29, and SW620) cell lines. Housekeeping/reference genes are
expected to have high expression and low variability in expression
levels between cells. Therefore, in RT-qPCR amplification, they
should have low threshold cycle (Cq ,30) and low standard
deviation. All of the tested reference genes met this requirement
for Cq values and standard deviations (Figure 5). The best
candidate reference genes appeared at the center of the graphs for
each group (Figure 5 A–C). In order to emphasize the stability of
these genes, a well-expressed non-housekeeping gene, RECK, was
included into the CV analysis. It was not included in the analysis
with NormFinder and geNorm due to its high variability (CV
around 1.0). Genes were ranked by their stability based on their
CV. Comparison of the expression values by analysis of variance
(ANOVA) identified RPL30 as the most stable gene with lowest
variance within and between the Liver, Breast and Colon
Carcinoma cell line groups, followed by RPL41, RPS10 and
CFL1. The variance within each of these three groups was low for
RPS3A, RPS17, RPL7, ACTB, H2AFZ, and HBXIP reference gene
expression. However, the variance between the three groups was
relatively high. This implied that these reference genes are more
suitable for normalization of cell lines from single tissue-origin
than cell lines with different tissue-origins. GSTO1, TPT1, RPN2,
SOD1 showed the highest variability.
Real-time quantitative PCR gene expression stability was
further determined using geNorm and NormFinder software
[3,25]. GeNorm is a pairwise comparison-based model. For each
gene, it calculates an expression stability value based on the
average pairwise variation between all tested genes. The genes are
ranked according to their expression stability through stepwise
exclusion of the least stable gene (highest stability value).
NormFinder is a model-based approach that estimates the
variation between sample subgroups, such as liver, breast and
colon cancer cell lines, as well as the overall expression variation of
the tested genes. Unlike geNorm, the resulting stability value and
the stability rank order changes in NormFinder depending on the
input genes. Therefore, geNorm and NormFinder stability analysis
Table 1. MeSH groups and number of NCBI-GEO data sets in each group.
MeSH Tree Number MeSH Heading Number of Sets
ALL ALL 381
A10 Tissues 77
A10.272 Epithelium 16
A10.690 Muscles 46
A11 Cells 223
A11.118 Blood Cells 47
A11.148 Bone Marrow Cells 14
A11.251 Cells. Cultured 157
A11.284 Cellular Structures 40
A11.329 Connective Tissue Cells 34
A11.436 Epithelial Cells 48
A11.627 Myeloid Cells 17
A11.733 Phagocytes 14
A11.872 Stem Cells 22
A15 Hemic and Immune Systems 74
A15.145 Blood 51
A15.378 Hematopoietic System 14
A15.382 Immune System 60
C04 Neoplasms 108
C04.557 Neoplasms by Histologic Type 68
C04.588 Neoplasms by Site 68
C04.697 Neoplastic Processes 16
doi:10.1371/journal.pone.0093341.t001
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was performed with and without the least stable genes EEF2,
GSTO1, RPN2 and TPT1, which have a standard deviation value
above the mean standard deviation (stdev = 1.42). The selected
reference genes were ranked according to their overall stability
values across 16 different cell lines, determined by geNorm and
NormFinder (Table 3, Figure 6, Table S3 in Supporting
Information S2). The ranking of these genes was similar for both
methods. Ribosomal protein genes RPS10, RPL41, RPL30, and
RPS3A were the most stable genes among all 16 cell lines
according to geNorm and NormFinder respectively (Table 3,
Tables S3–S4 in Supporting Information S2). Two traditional
reference genes, ACTB and GAPDH, were less stable than the
ribosomal genes and ranked lower in the stability rank list. CFL1
and HBXIP were the most stable genes after the ribosomal protein
genes in general (Figure 7A and Table 3). While the commonly
used reference gene GAPDH was one of the stable genes within
liver cancer cell lines, it was among the least stable genes within
breast and colon cancer cell lines. It had a high variance in terms
of stability value and expression value between the three types of
carcinoma cell lines investigated. This implied that GAPDH could
be used as a reference gene when comparing liver cancer cell lines,
but not breast and colon cancer cell lines. ACTB was more stable
than GAPDH in Breast and Colon Carcinoma cell lines and had a
stability value similar to GAPDH in HCC cell lines. Moreover,
even though reference genes were known to avoid regulation by
miRNAs, recent findings showed that GAPDH and ACTB are
direct targets of miR-644a [26,27]. Besides, several pseudogenes of
GAPDH and ACTB were revealed, making them less reliable to be
used as reference genes [28].
Stability within liver, breast and colon cancer cell lines was also
analyzed separately. The ribosomal genes RPL30, RPL41, RPL7,
RPS10, and RPS3A were stable within each cell line group
(Figure 7B–D, Table 3, Tables S3, S4 in Supporting Information
S2). HBXIP, CFL1, and GAPDH were among the most stable genes
together with the ribosomal protein genes in 8 HCC cell lines
analyzed. HBXIP was the third most stable gene in breast cancer
cell lines according to geNorm, but ninth according to
NormFinder ranking. H2AFZ and HBXIP were ranked among
the most stable genes together with RPS10, RPL41, and RPS3A in
colon cancer cell lines. The difference in the gene stability ranking
order between the two softwares is due to the different
methodologies. geNorm is based on the comparison of expression
similarity of the tested genes. This may cause exclusion of a
candidate reference gene with a relatively stable expression in
early steps of the ranking procedure, if all other genes in the list
have similar expression profiles. Another disadvantage of this
approach may be a bias towards co-regulated genes, since these
genes will have similar expression profiles and hence may be
ranked top in the stability list, regardless of their expression
stability. NormFinder does not have such a bias, since expression
stability of each gene is determined independent of the rest of the
genes. However, since NormFinder ranking is based on the
variation between groups, when comparing groups like liver,
breast, and colon carcinoma cell lines, if the variation within group
Figure 5. Graphs of coefficient of variations and relative expression levels of 17 reference genes in RT-qPCR. Coefficient of Variation
(CV) was calculated based on the relative expression (efficiency2DCq) of each housekeeping gene in (A) Liver, (B) Breast, (C) Colon and (D) All cancer
cell lines.
doi:10.1371/journal.pone.0093341.g005
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is high, then the variation between groups may considered as
lower, leading to false positive results.
In order to determine the optimal number of reference genes for
accurate normalization, pairwise variation Vn/n+1 analysis was
performed using the geNorm software. Taking 0.15 as a cut-off
value as proposed, the use of RPL41 and RPS10 together as
reference genes were enough for accurate normalization (V2/3
value = 0.134) when comparing Liver, Breast and Colon Carci-
noma cell lines. An even more accurate normalization can be
achieved if RPL7 and RPS3A are also included as reference genes.
(V3/4 value = 0.091 and V4/5 value = 0.067).
Conclusions
Even the most frequently used reference genes are subject to
differential regulation under specific treatments or between
different cell lines or tissues. Therefore, new reference gene sets
should be determined instead of using traditional housekeeping/
reference genes that are themselves prone to differential regula-
tion. The use of two or more housekeeping genes for normaliza-
tion can improve the reliability of normalization [5,9,29]. The
largest meta-analysis for reference gene identification up-to-date
compiled 1431 samples from 104 microarray data sets classified
into 4 physiological states with 13 organ/tissue types and identified
reference gene candidates mostly associated with transcription,
RNA processing and translation [30]. Hruz et al. 2011 also
performed a large scale meta-analysis across multiple species and
sources using Genevestigator database [16]. They have used ranks
of standard deviations using mouse Affymetrix datasets to support
context specificity of reference gene sets. Our study also is
comprehensive containing 142 million oligonucleotide microarray
spots from 9090 microarray samples, grouped into 381 GEO
datasets from multiple platforms. We also provide a novel
methodology based on randomizations and ROC that allows
testing the specificity and sensitivity of classifying a gene as
reference or non-reference. Previously, a meta-analysis of 13,629
human gene array samples from GEO database identified
candidate housekeeping genes, including RPS13, RPL27, RPS20
and OAZ1. For each gene the coefficient of variation (CV) of its
expression and the maximum fold change was calculated to
identify genes with the minor variation in expression [19].
Recently, Eisenberg et. al. published an updated new housekeeping
gene list based on analysis of RNA-seq data [31]. However, MeSH
classification used in the present study has not been applied to
reference gene set combinations previously. In this study, we
Figure 6. Stability analysis of reference genes in RT-qPCR based on CV, geNorm and NormFinder. Genes ranked by stability based on (A)
CV, (B) geNorm and (C) NormFinder tools. White, light gray, dark gray and black bars represent Liver, Breast, Colon and All Cancer Cell lines
respectively.
doi:10.1371/journal.pone.0093341.g006
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determined novel reference gene sets that can be used for both
global and MeSH category-based normalization of gene expres-
sion data. Furthermore, we validated stability of known and novel
reference genes obtained from meta-analysis with cancer cell line
qPCR studies.
Our reference gene lists were dominated by the ribosomal
protein genes and genes that are involved in maintenance of basal
cellular activities such as translation and metabolism. Especially,
RPL30 and RPL41 are good reference genes for comparing all cell
lines regardless of their origin. Previously, 451 housekeeping genes
that were expressed in all of the 19 distinct normal human tissue
types studied, were shown to have variable expression levels
among different tissues and ribosomal genes, which were among
the most stable genes, were suggested as reference genes suitable
for normalization purposes [1]. A more recent study however
suggested that ribosomal protein genes, which display stable
expression in meta-analysis, indeed exhibit variation in mRNA
expression in a tissue-dependent manner [32]. These findings once
more emphasize that finding a common reference gene, ribosomal
or not, is not possible. The genes located at the top the reference
gene set lists display the highest confidence based on CV and PO
values therefore those genes are less likely to be wrong. However
every computational analysis might have false positive results for
this reason, users should select their reference gene of interest and
experimentally validate the stability of the expression of that
reference gene under their experimental conditions. Furthermore
more than 2 reference genes per experiment would be a better
measure for precision. Computational calculations present a road
map to guide the experimentalists. The data sets we used to build
MeSH dependent reference gene lists originated from various
sources which aimed to identify differentially expressed gene sets
under specific experimental conditions in order to minimize the
homogeneity between and within data sets. Data set IDs are given
together with reference gene lists in Supporting Information S1.
Meta-analysis and consequent classification of tissue- or cell type-
origin specificity of housekeeping genes appears to be the best
approach to determine the most appropriate reference genes
among the large number of known housekeeping genes. Further-
more identification of housekeeping genes enables normalization
of transcriptome data not only for microarrays but also for RNA-
seq experiments [33,34]. RNA-seq technology is advantageous for
detecting genes that are expressed in low levels. Hence, similar
studies with RNA-seq data may increase the reliability of
housekeeping genes when large number of NGS data are available
[14] and can be used to identify a universal reference gene set. The
tissue specific reference gene lists presented in this study, provide
housekeeping genes that can be exploited as references in
differential expression analysis of data from variety of transcrip-
tome and RT-qPCR experiments.
Methods
In order to normalize expression values, percentile ranking have
been applied. For each gene Gi in a sample ei, a single rank value,
r(Gi.ej) was computed (Equation 1). For a gene that was covered by
multiple probesets in a sample, the average gene probeset rank
value was used [23].
r(Gi,ej)~
GkjGk[G ^ ex Gk,ej
! "
ƒex Gi,ej
! "# $%% %%
Gj j |100 ð1Þ
where ex(g,e) is a function, which gives the mean normalized
expression value of gene g in sample e and G is the set of all genes.
Computation of coefficient of variation value for each gene in
each GEO dataset and identification of candidate reference genes
Let G= {G1.....Gm} be the set of genes and S = {e1.....en} be a
GEO dataset of n samples. For gene Gi in experiment ej, a single
rank value, r(Gi.ej), was computed. Given a set S with n
experiments, we had at most n rank values for a gene. The
average amount of change in the rank of gene Gi, in set S was then
computed by the Coefficient of Variation CV(S.Gi) as given below
in Equation 2.
CV (S,Gi)~
s(S,Gi)
m(S,Gi)
ð2Þ
Figure 7. Stability analysis of reference genes in tissue-specific cell lines in RT-qPCR. Stability analysis in (A) Liver, (B) Breast, (C) Colon and
(D) All cancer cell lines. NormFinder and geNorm results were represented in dark gray and light gray respectively.
doi:10.1371/journal.pone.0093341.g007
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where
m(S,Gi)~
Pn
j~1
r(Gi,ej)
n
,Vej[S ð3Þ
and
s(S,Gi)~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1
n
Xn
j~1
r(Gi,ej){m(S,Gi)
" #2vuut ,Vej[S ð4Þ
In this analysis, we computed a coefficient of variation value for
each gene Gi in each GEO dataset S.
Next, we identified candidate reference genes with coefficient of
variation values below a predefined threshold, t, observed in as
many experiments as possible. In order to account for platform
related differences, for each gene Gi and threshold t, we computed
a ratio. Ratiot(Gi) as follows:
Ratiot(Gi)~
CV S,Gið Þ CV S,Gið Þƒtjf gj j
CV S,Gið Þ CV S,Gið Þw0jf gj j ð5Þ
Calculation of percentage of occurrence
Let fPO(r) be the function that gives the number of genes with
Ratiot greater than a given r and occur in at least in PO% of the
datasets (Equation 6).
fPO rð Þ~ Gi Ratiot Gið Þvrjf gj j ð6Þ
We plotted and compared the graph of fPO(r), varying r from 0
to 1, for housekeeping genes and randomly selected non-
housekeeping genes.
Calculation of specificity and sensitivity
We use the housekeeping gene set published by Eisenberg et al.
[22] as the ground truth set of housekeeping genes. All the
remaining genes are assumed to be non-housekeeping genes for
the specificity and sensitivity analysis. The simple threshold
classifier we use simply classifies all genes with a CV value below
than a given threshold in at least Ratiot of the datasets as
housekeeping genes. All these analyses are performed at a fixed
percentage of occurrence of 75% and with a fixed Ratiot of 0.9.
The ground truth genes that are identified as housekeeping genes
by this classifier are true positives (TP) whereas, the ground truth
genes that are identified as non-housekeeping genes are false
negatives (FN). Similarly, genes not in the ground truth set but
identified as housekeeping genes are false positive genes (FP) and
genes not in the ground truth set identified as non-housekeeping
genes by the classifier are true negatives (TN). Using these
definitions, sensitivity is given by TP/(TP+FN) and specificity is
computed as TN/(TN+FP).
Cell Lines
Cell lines were obtained from the following sources and
validated by STR analysis: HepG2 (ATCC HB-8065), FOCUS
[35], Mahlavu[36], Hep3B (ATCC HB-8064), Hep3B-TR [37],
Huh7 (JCRB JCRB0403), SkHep1 (ATCC HTB- 52), PLC
(ATCC CRL-8024), MDA-MB-453 (ATCC HTB-131),
HCC1937 (ATCC CRL-2336), BT-20 (ATCC HTB-19), T47D
(ATCC HTB-133), CAMA- 1 (ATCC HTB-21), HCT116 (ATCC
CCL-247), HT29 (ATCC HTB-38), SW620 (ATCC CCL-227).
RNA extraction
RNA was extracted from 8 Hepatocellular Carcinoma cell lines
(HepG2, FOCUS, Mahlavu, Hep3B, Hep3B-TR, Huh7, SkHep1,
PLC), 5 Breast Carcinoma cell lines (MDA-MB453, HCC1937,
BT20, T470, CAMA I) and 3 Colon Carcinoma cell lines
(HCT116, HT29, SW620) with NucleoSpin Total RNA Isolation
Kit and the concentration and purity of total RNA from each cell
line was measured by using a NanoDrop Spectrophotometer
(NanoDrop Technologies). Reverse transcription was performed
using RevertAid First Strand cDNA Synthesis Kit (Fermentas)
from 2 mg RNA with oligodT primer.
Real-time quantitative PCR and stability analysis
Primers for 17 selected housekeeping genes were designed using
the Primer3 software (Table S5 in Supporting Information S2). A
cDNA dilution series for each primer set in triplicate was analyzed
to calculate efficiencies of the primers using the linear regression
slope of the dilution series with the equation Efficiency =
10(21/slope)-1. Real-time quantitative PCR assays were performed
in duplicate for each candidate gene using 1 ml of 1:100 diluted
cDNA template with DyNAmo SYBR Green qPCR Kit
(Finnzymes) on BioRad iCycler Real-Time qPCR System. The
following program was used: Initial denaturation at 95uC 15 min
amplification for 45 cycles (95uC 15 s followed by 57uC 30 s and
72uC 30 s), and final extension at 72uC 10 min. Melting curve
analysis was done for each run, in addition to agarose gel
electrophoresis, to confirm the amplicon size and presence of a
single gene-specific peak free from any primer-dimer or genomic
DNA amplification.
BioRad iCycler was programmed to set the Cq threshold on a
fixed level. Cq values generated by BioRad iCycler system were
transformed into quantities (relative expression values) according
to Vandesompele et al. [25]. Relative expression values were
calculated with the equation: Relative Expression = Efficien-
cy2DCq. Coefficient of Variation (CV) was calculated as the ratio
of standard deviation to the mean relative expression. geNorm and
NormFinder software were used for stability analysis.
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